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Anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer 
(NSCLC) most commonly arises through Echinoderm microtubule-associated 
protein like 4 (EML4)-ALK chromosomal fusion and is associated with younger 
aged patients with non-smoking or light smoking history. Patients harbouring 
EML4-ALK fusion oncoprotein are highly sensitive to ALK-tyrosine kinase 
inhibitors (TKIs). Crizotinib, a first generation ALK-TKI, was approved by the 
Food and Drug Administration (FDA) for the treatment of ALK-positive NSCLC 
patients. Crizotinib has demonstrated superior efficacy compared to standard 
platinum-based chemotherapy with longer progression-free survival and a 
higher objective response rate. However, the clinical benefit of crizotinib (and 
other ALK inhibitors) is limited due to the development of acquired resistance 
typically within a year of therapy. Mechanism of resistance includes copy 
number gain, secondary mutations in ALK, or activation of bypass signalling 
pathways Thus, this study investigated the possibility of improving the efficacy 
of ALK inhibition, and overcoming resistance, by employing the combined effect 
of ALK inhibitor, crizotinib and MEK inhibitor, selumetinib in both crizotinib 
naïve (H3122) and crizotinib resistant (CR-H3122) ALK-positive non-small cell 
lung cancer cells. 
The combination of crizotinib and selumetinib significantly decreased the 
cell viability of both H3122 and CR-H3122 cells. The mechanism behind this 
synergistic effect of combination treatment was due to the marked suppression 
of RAS/MAPK signalling pathway that led to a decrease in cell proliferation and 
increase in apoptosis. Cell cycle analysis showed that the combination treatment 
significantly increased the percentage of cells in the G1 phase by ≥ 8 % compared 
to either single drug treatment. And this was mediated by an increase in 
expression of p27 (≥ 1.2-fold) and a decrease in cyclin D1 expression (≥ 80%) by 
the combination treatment compared to either of single drug treatment. 
Similarly, there was a significant increase in the percentage of apoptotic cells (≥ 




The drug combination elicited greater than 3-fold increase in expression of Bim 
compared to crizotinib alone that in turn upregulated the expression of cleaved 
caspase and cleaved PARP. 
Furthermore, the efficacy of combination treatment in xenograft model of 
ALK-positive NSCLC was investigated. Results showed that crizotinib (25 
mg/kg) and selumetinib (25 mg/kg) decreased the tumour volume by 52 % and 
59 %, respectively compared to vehicle control. Interestingly, their combination 
further markedly reduced tumour volume compared to both crizotinib and 
selumetinib monotherapy. Moreover, the preclinical toxicity study on Balb/c 
mice demonstrated that both the single and combined treatment of crizotinib and 
selumetinib were non-toxic at the dose of 25 mg/kg with values of alanine 
transaminase (ALT) (< 80 U/L) and creatinine ( < 2 mg/dL) within the normal 
range. Also, the combination treatment did not modulate the activity of the two 
drugs major metabolizing enzyme CYP3A. 
In summary, the finding in this thesis supports the hypothesis that marked 
inhibition of tumour growth can be obtained by the combination of ALK 
inhibitor with MEK inhibitor and thus can be a potential strategy in the treatment 
of ALK-positive NSCLC. This study further raises the possibility of gaining the 
benefit of combination treatment by the use of a sufficient dose of MEK inhibitor 
alone in crizotinib resistant NSCLC. In addition to this, the study identifies Bim, 
PARP and cyclin dependent kinase (CDK) as the druggable target for possible 
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VEGF vascular endothelial growth factor 
VEGFR vascular endothelial growth factor receptor 
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1.1. Lung cancer 
1.1.1. Epidemiology 
The incidence and mortality from lung cancer have risen over the last 
century. Lung cancer has revolutionised from a rare and obscure disease to the 
most common cancer (Rubin, 1991). In 1912, Alder reported 374 cases of primary 
lung cancer that constituted only 0.5% of total cancer cases (Alder, 1912). In 2012, 
lung cancer was reported to be the most prevalent cancer worldwide, accounting 
for 13% (1.8 million new cases) of total cancer cases. There were approximately 
1.6 million lung cancer deaths (19.4% of total deaths) making it the most lethal 
type of cancer globally (Ferlay et al., 2015). In United States, 228,150 new cases 
of lung cancer (116,440 in men and 111,710 in women) and 142,670 deaths from 
lung cancer (76,650 in men and 66,020 in women) are expected to occur in 2019 
(Siegel et al., 2019). In New Zealand, lung cancer is the leading cause of cancer 
mortality with higher deaths than breast, prostate and melanoma combined. 
Ministry of Health, New Zealand has reported 2037 new cases and 1659 deaths 
from lung cancer in 2013. Additionally, the incidence and mortality from lung 
cancer are higher in Maori compared to non-Maori populations (Lung 
Foundation NZ, 2020). 
1.1.2. Etiology and risk factors 
The principal risk factor for lung cancer is smoking and the use of tobacco 
products accounts for up to 90% of lung cancer cases (de Groot et al., 2018; Hecht, 
1999). Other contributing factors include occupational and environmental 
exposures such as asbestos, silica, chromium, nickel, radon gas, arsenic, ionising 
radiation, polycyclic aromatic hydrocarbons and air pollutions (Alberg et al., 
2002; De Matteis et al., 2008). History of lung diseases such as chronic obstructive 
pulmonary disease COPD, chronic bronchitis, pneumonia and family history of 
lung cancer is associated with increased risk of lung cancer (Brenner et al., 2011; 
Cote et al., 2012). Genetic and epigenetic alteration can also increase the 
susceptibility to lung cancer. Inherited cancer syndromes due to rare germline 
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mutation in p53, retinoblastoma, reduction in DNA repair capacity due to germ 
line alteration in nucleotide excision repair genes: ERCC1, single-nucleotide 
polymorphism (SNP) variation at 15q24-15q25, loss of heterozygosity at 
chromosomal region 3p21.3 (RASSF1A), 3p14.2 (FHIT), 9p21 (p16) and 17p13 
(p53) and germ line mutation in receptor tyrosine kinases (RTKs) such as 
epidermal growth factor receptor (EGFR) are associated with higher lung cancer 
susceptibility (Bell et al., 2005; Hung et al., 2008; Hwang et al., 2003; Sanders et 
al., 1989; Spitz et al., 2003; Yu et al., 2008). 
1.1.3. Diagnosis and staging  
Lung cancer is a highly invasive and rapidly metastasising cancer. (Herbst, 
Heymach, & Lippman, 2008). The outcome of lung cancer depends on the stage 
of diagnosis. While the early diagnosis of the diseases results in longer survival, 
the majority of lung cancers are diagnosed at an advanced stage (70-80% at stage 
III-IV) leading to poor prognosis and survival (Nesbitt et al., 1995; Walters et al., 
2013). Five-year survival rate for lung cancer (all stages combined) is around 19% 
(Siegel et al., 2019). The late diagnosis of lung cancer is due to the nonspecific 
nature of symptoms. Diagnostic approaches including chest X-ray, low dose 
computed tomography (LDCT), positron emission tomography (PET) imaging 
and histological examination of tumour biopsies are commonly used (Gridelli et 
al., 2015). LDCT demonstrated greater benefit with 20% reduction in lung cancer 
mortality while chest x-ray with or without sputum had no benefit in reduction 
of mortality (Humphrey et al., 2004; National Lung Screening Trial Research et 
al., 2011). Furthermore, accurate clinical staging of lung cancer is important in 
determining the optimal treatment strategy. Clinical staging of lung cancer is 
based on the TNM system by International Association for Study of Lung Cancer 
(IASLC) where T describes size and extension of primary tumour, N describes 
the regional lymph node involvement and M describes distant metastasis. The 
updated 8th edition of TNM classification and staging of lung cancer was 
implemented from 2018 and details are presented in Table 1.1 (Goldstraw et al., 
2016; Lim et al., 2018).  
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Table 1.1 The 8th Edition of TNM classification and staging of Lung cancer 
Adapted from (Goldstraw et al., 2016). Permission obtained from Elsevier.  
8th T/M 
Descriptor 
N0 N1 N2 N3 
T1a IA1 IIB IIIA IIIB 
T1b IA2 IIB IIIA IIIB 
T1c IA3 IIB IIIA IIIB 
T2a IB IIB IIIA IIIB 
T2b IIA IIB IIIA IIIB 
T3 IIB IIIA IIIB IIIC 
T4 IIIA IIIA IIIB IIIC 
M1a IVA IVA IVA IVA 
M1b IVA IVA IVA IVA 
M1c IVB IVB IVB IVB 
Abbreviations: T, primary tumour; N, Regional lymph nodes; M, distant metastasis; T1a, Tumour ≤ 1 cm; 
T1b, Tumour > 1-2 cm; T1c, Tumour > 2- 3 cm; T2a, Tumour> 3 – 4 cm; T2b, Tumour > 4 – 5 cm; T3, Tumour 
>5-7 cm; T4, Tumour > 7 cm; M1a, pleural or pericardial nodule(s) or separate tumour nodule(s) in a 
contralateral lobe or malignant pleural or pericardial effusion; M1b, Single extrathoracic metastasis; M1c, 
Multiple extrathoracic metastases in one or more organs; N0, No regional node metastasis; N1, Metastasis 
in ipsilateral pulmonary or hilar nodes; N2, Metastasis in ipsilateral mediastinal or subcarinal nodes; N3, 
Metastasis in contralateral mediastinal, hilar, or supraclavicular nodes 
1.1.4. Histopathology and classification 
Lung cancer is a heterogeneous disease with diverse histological and 
molecular subtypes. Lung cancer is broadly classified into small-cell lung cancer 
(SCLC) and non-small-cell lung cancer (NSCLC) (Herbst et al., 2008). SCLC is a 
highly aggressive cancer accounting for 15% of total lung cancer cases. SCLC is 
characterised by high mitotic index, higher vascularisation, early metastasis, 
mutation in tumour suppressor genes and oncogenes (Bunn et al., 2016; Gazdar 
et al., 2017; George et al., 2015). It is predominantly associated with smoking and 
derived from neuroendocrine cells or neuroendocrine progenitors in the lung 
(Karachaliou et al., 2016; Park et al., 2011).  
NSCLC occurs in the remaining 85% of all lung cancer cases. Based on 
histology, NSCLC is further divided into adenocarcinoma (AC), squamous-cell 
carcinoma (SCC), and large-cell carcinoma (LCC) (Herbst et al., 2008; Travis et 
al., 2015; Travis et al., 2013). Adenocarcinoma is the most common NSCLC that 
accounts for approximately 40% of all lung cancers. AC arises from alveolar or 
bronchiolar epithelial cells and is often located in peripheral airways. It has 
glandular differentiation and expresses biomarkers such as thyroid transcription 
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factor 1 (TTF1), napsin A, and keratin 7 (Duma et al., 2019; Langer et al., 2010; 
Noguchi et al., 1995). It is commonly observed in young (<40 years old), female, 
non-smokers (Sun S, 2007). Squamous-cell carcinoma accounts for around 30% 
of lung cancers. SCC is localised in the central part of the lung, near the main 
airway and is related to smoking (Duma et al., 2019; Kenfield et al., 2008). SCC 
has squamous differentiation and expresses biomarkers such as p40, cytokeratin 
5 (CK5), cytokeratin 6 (CK6) (Chen et al., 2014; Takamochi et al., 2016). LCC 
accounts for 10% of total lung cancers. It has large peripheral masses and is 
poorly differentiated (Duma et al., 2019; Patz, 2000) and is also associated with 
smoking (Muscat et al., 1997). 
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1.2. Molecular alteration of NSCLC 
Molecular and genomic profiling of lung tumour samples has identified 
subsets of molecular alterations including oncogenes and tumour suppressor 
genes that provide an understanding of tumorigenesis and are excellent 
biomarkers and targets for cancer therapy (Fujimoto & Wistuba, 2014). The 
frequency of these alterations depends on factors such as smoking history, age, 
sex, and race (Nagashima et al., 2013; Riely et al., 2008; Sun et al., 2010). 
Adenocarcinoma demonstrated high rates of somatic mutation with 8.9 
mutations per DNA megabase (Collisson et al., 2014). Genetic alterations such as 
point mutation, somatic copy number alteration and genomic translocation have 
been reported. These include: gain of function mutation in oncogenic drivers 
such as epidermal growth factor receptor (EGFR), kirsten rat sarcoma viral 
oncogene homolog (KRAS), B-raf proto-oncogene, serine/threonine kinase 
(BRAF), human epidermal growth factor receptor 2 (HER2), hepatocyte growth 
factor receptor (MET), phosphoinositide 3 kinase (PI3KC), loss of function 
mutation in tumour suppressor such as tumour protein p53 (TP53), phosphatase 
and tensin homolog (PTEN), retinoblastoma protein (RB1), neurofibromin 1 
(NF1), serine/threonine kinase 11 (STK11), cyclin-dependent kinase inhibitor 2A 
(CDKN2A), and kelch-like ECH-associated protein 1 (KEAP1), structural 
rearrangement (translocation, inversion) of anaplastic lymphoma kinase (ALK), 
ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) and rearranged during 
transfection (RET),  amplification of proto-oncogenes such as MET, fibroblast 
growth factor receptor 1 (FGR1), discoidin domain-containing receptor 2 (DDR2) 
(Bergethon et al., 2012; Collisson et al., 2014; Ding et al., 2008; Imielinski et al., 
2012; Paez et al., 2004; Sanchez-Cespedes et al., 2002; Takahashi et al., 1989). The 
frequency of molecular alteration in NSCLC and potential drugs are summarised 
in Table 1.2. Genetic alterations aberrantly activate proto-oncogenes resulting in 
a deleterious effect on protein function and on downstream signalling pathways 
that plays a critical role in regulating cellular functions including proliferation 
and apoptosis (Collisson et al., 2014). Therefore, understanding the complex 
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molecular biology of NSCLC is important for the development of personalised 
therapy that can produce a superior clinical outcome in NSCLC patients. 
1.2.1. Receptor tyrosine kinase 
Most of the oncogenic mutations that have been proven to be important in 
lung cancer are associated with RTKs. These are single pass transmembrane 
receptors that are essential components of signal transduction pathways. RTKs 
belong to the family of protein tyrosine kinase and are key regulators of a cellular 
process such as cell growth, differentiation, migration, motility, metabolism and 
survival (Hubbard & Miller, 2007; Schlessinger, 2000). All RTKs have an 
extracellular region, a single transmembrane helix and an intracellular tyrosine 
kinase domain. They catalyse the transfer of the phosphoryl group of ATP to 
tyrosine residues on target proteins and mediate cell to cell communications 
(Hubbard, 1999; Hunter, 1998). Ligand binding to RTKs leads to activation of the 
receptor by oligomerisation or dimerisation. This, in turn facilitates 
autophosphorylation of tyrosine residue that serves as a recruitment site for 
adaptor proteins and initiates various signalling cascades (Hubbard & Miller, 
2007; Schlessinger, 2000). The signal from activated RTKs is strictly regulated 
through dephosphorylation by protein tyrosine phosphatase and degradation 
via ubiquitination (Joazeiro et al., 1999). 
Despite tight regulation and control of RTK activity, aberrant kinase 
activity has been reported in various cancer including lung cancers (Blume-
Jensen & Hunter, 2001). This can be due to mutation, overexpression, autocrine 
activation or chromosomal translocation that constitutively activates RTKs 
resulting in malignant transformation and carcinogenesis. Studies have 
demonstrated that more than 50% of known RTKs have been implicated in 
oncogenic malignancies including: EGFR, ALK, insulin growth factor receptor 
(IGFR), MET, vascular endothelial growth factor receptor (VEGFR), and platelet 
derived growth factor receptor (PDGFR) (Blume-Jensen & Hunter, 2001). 
Identification of oncogenic RTKs has led to the development of small 
molecule tyrosine kinase inhibitor (TKI) that primarily inhibit the activation of 
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RTKs and its downstream signalling. Imatinib was the first TKI approved by 
FDA in 2001 followed by gefitinib, sunitinib, dosatinib, crizotinib, afatinib, 
erlotinib, ceritinib, alectinib, brigatinib (Jiao et al., 2018).
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Table 1.2  Molecular alteration in NSCLC  
Gene Alteration Frequency 
(%) AC   
Frequency 
(%) SCC 
Potential targeted therapy Reference 
EGFR Mutation 10-15 2-3 Erlotinib, gefitinib, afatinib (Paez et al., 2004) 
ALK Fusion 2-7 rare Crizotinib, ceritinib, alectinib, loratinib (Lin et al., 2017; Soda et al., 
2007) 
HER2 Mutation <5 N/A Neratinib, afatinib, trastuzumab (Pao & Girard, 2011) 
MET Mutation <5 <5 Tivantinib, cabozantinib, onartuzumab (Pao & Girard, 2011) 
BRAF mutation 1-6 4-5 Vemurafenib, dabrafenib, trametinib (Paik et al., 2011) 
ROS1 Fusion 1-2 N/A Crizotinib (Rikova et al., 2007; 
Takeuchi et al., 2012) 
NF1 Mutation 12 10 N/A (Collisson et al., 2014; 
Kandoth et al., 2013) 
FGR1 Amplification N/A 20 Dovitinib, ponatinib, AZD4547, BGJ398 (Weiss et al., 2010) 
KRAS Mutation 15-25 1-2 Selumetinib plus docetaxel combination (Mascaux et al., 2005) 
PI3CA Mutation 5 15 BEZ235, BKM120, GDC0941 (Kawano et al., 2006) 
KEAP1 Mutation 17 12 N/A (Singh et al., 2006) 
CDKN2A Mutation 7 15 N/A (Lou-Qian et al., 2013) 
TP53 Mutation 52 79 N/A (Mitsudomi et al., 2000) 
PTEN Mutation 2 10 GDC0941, BEZ235, BKM120  (Jin et al., 2010) 
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Gene Alteration Frequency 
(%) AC   
Frequency 
(%) SCC 
Potential targeted therapy Reference 
RET Fusion 1 N/A Carbozantinib, vandetanib (Kohno et al., 2012) 
DDR2 Mutation N/A 2-3 Dasatinib (Hammerman et al., 2011) 
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1.3. ALK-positive non-small cell lung cancer 
ALK-positive NSCLC is one of the subtypes of NSCLC that is commonly 
associated with young age patients (Hallberg & Palmer, 2011). Previously, ALK 
was believed to be mutually exclusive to other oncogenic mutations such as 
EGFR and KRAS (Gainor et al., 2013; Zhang et al., 2010). The clinical genotyping 
data from 1,683 NSCLC patients and 34 ALK-positive NSCLC patients 
progressed on crizotinib showed absence in EGFR or KRAS mutations (Gainor 
et al., 2013). However, recent studies have demonstrated the concomitant 
presence of mutations such as EGFR and KRAS in around 0.6 % to 19 %patients 
with ALK-positive NSCLC (Rossing et al., 2013; Sahnane et al., 2016; Yang et al., 
2014). The patients harbouring both ALK rearrangement and EGFR mutations 
were benefited from crizotinib compared to erlotinib treatment, whereas 
response to crizotinib in patients with ALK and KRAS was opposite (Sahnane et 
al., 2016). This shows that different oncogenic driver mutations may co-exist in 
AC making it genetically heterogeneous and thus integrated therapy could be a 
better option for these patients (Sahnane et al., 2016).   
1.3.1. Anaplastic Lymphoma Kinase (ALK) 
ALK, a transmembrane receptor tyrosine kinase (RTK), is a member of the 
insulin receptor superfamily (Palmer et al., 2009). The ALK gene is located on the 
short arm of chromosome 2 at position 23 and encodes anaplastic lymphoma 
kinase receptor tyrosine kinase (ALK RTK). ALK was first identified in 1994 as a 
fusion partner of nucleophosmin (NPM) in anaplastic large cell lymphoma 
(ALCL) (Morris et al., 1994). Here, the kinase domain of ALK was fused with the 
N-terminus of NPM. Subsequently, the full length ALK receptor was identified 
in 1994 (Iwahara et al., 1997; Morris et al., 1997). 
ALK is highly expressed during foetal development and diminishes shortly 
after the birth (Soda et al., 2007).  In adults, expression of ALK is restricted to a 
subset of neuronal cells, the small intestine, and testes (Morris et al., 1994; Shaw 
& Engelman, 2013). The role of ALK in human physiology is not clearly 
understood. However, ALK is believed to play a role in the development and 
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maintenance of the nervous system (Iwahara et al., 1997). In mice, ALK knockout 
resulted in a normal lifespan with mild abnormalities in the hippocampus, 
frontal cortex and hypogonadotropic hypogonadism (Bilsland et al., 2008; Witek 
et al., 2015). Furthermore, ALK regulates canonical signalling pathways such as 
mitogen activated protein kinase (MAPK), janus activated kinase-signal 
transducer and activator of transcription (JAK-STAT), phosphoinositide 3-kinase 
(PI3K)-protein kinase B (AKT) and phospholipase C gamma (PLCγ) pathways 
that play a major role in regulation of cellular proliferation and survival (Chiarle 
et al., 2008; Hallberg & Palmer, 2013) . 
1.3.2. ALK structure and ligands 
ALK is a highly conserved RTK that has a ligand binding extracellular 
domain, a hydrophobic putative transmembrane region, and an intracellular 
tyrosine kinase domain (Figure 1.1B). The extracellular domain consists of a 
glycine rich domain, low density lipoprotein class A (LDLa) and two meprin A-
5 protein and receptor protein tyrosine phosphatase Mu (MAM) domains 
(Figure 1.1B). The functions of each of these domains are unclear (Iwahara et al., 
1997; Loren et al., 2001; Morris et al., 1997; Stoica et al., 2001). However, LDLa is 
speculated to be involved in ligand binding while MAM domains are believed 
to be involved in cell-cell interactions (Beckmann & Bork, 1993; Daly et al., 1995; 
Fass et al., 1997). The transmembrane domains connect the extracellular region 
with the intracellular kinase domain, which contains small N-terminal and large 
C-terminal lobes that are linked by a hinge region forming a cleft for ATP or 
substrate binding. The C-terminal lobe contains an activation loop that 
comprises of three tyrosine containing motifs (tyrosine 1278, 1282 and 1283) 
(Bossi et al., 2010; Lee, Jia, et al., 2010). Mouse and human ALK have high 
similarity (87% at protein level) except one extra tyrosine at position 1604 in 
human ALK that plays an important role in tumour progression (Bai et al., 1998). 
Human ALK consists of 1620 amino acids while mouse, Drosophila and C. elegans 
ALK is made up of 1621, 1701 and 1421 amino acids (Bai et al., 1998; Iwahara et 
al., 1997; Liao et al., 2004; Morris et al., 1997; Reiner et al., 2008). Molecular weight 
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of human ALK is around 180 kDa. However, ALK in SDS-PAGE is usually 
detected at 220 kDa due to posttranslational modification such as glycosylation 
(Morris et al., 1997).  
ALK was initially described as an orphan receptor with no known 
activating ligands. The small heparin-binding growth factors such as midkine 
(MK) and pleiotrophin (PTN) have been reported as the activating ligands for 
mammalian ALK (Stoica et al., 2001; Stoica et al., 2002). However, subsequent 
studies have found contradictory results and are controversial (Dirks et al., 2002; 
Mathivet et al., 2007; Moog-Lutz et al., 2005; Motegi et al., 2004). PTN failed to 
phosphorylate and activate ALK in glioblastoma/neuroblastoma cells (Mathivet 
et al., 2007) and in 293ALK cells (Dirks et al., 2002). Later in 2015, heparin and 
the novel cytokine augmentor α and β (FAM 150) were reported as a ligand of 
ALK (Murray et al., 2015; Reshetnyak et al., 2015). Long-chain heparin binds to 
the extracellular domain of ALK thereby inducing dimerization and activation 
of ALK in neuroblastoma cells (Murray et al., 2015). Similarly, augmentor α and 
β bind to ALK resulting in its phosphorylation and activation in NIH/3T3 cells 
harbouring ALK (Reshetnyak et al., 2015). 
1.3.3. ALK rearrangement 
Genomic alterations including chromosomal translocation, mutation, and 
overexpression of ALK is observed in many cancers including NSCLC (Hallberg 
& Palmer, 2013). The frequency of ALK gene rearrangements is comparatively 
higher in NSCLC compared to other cancer types such as breast, colorectal, renal 
cell, ovarian (Lin et al., 2017). The most common rearrangement in NSCLC is 
echinoderm microtubule-associated protein-like 4 (EML4)-ALK that was first 
identified by Soda et al. in 2007 (Soda et al., 2007). EML4 is a cytoplasmic protein 
that has an essential role in the formation of microtubules and microtubule-
binding proteins (Houtman et al., 2007). EML4 consists of an amino-terminal 
coiled-coil (CC) domain, basic domain, hydrophobic echinoderm microtubule 
associated protein-like protein (HELP) domain and C-terminus with four WD 
repeats (Figure 1.1B) (Pollmann et al., 2006). ALK and EML4 genes are located 
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on chromosome 2p23 and 2p21, respectively, and are separated by 12.7 
megabases and are oriented in opposite direction. A small inversion within the 
short arm of chromosome 2 juxtaposes the 5’end of the EML4 gene and the 3’ 
end of the ALK gene leading to the formation of EML4-ALK fusion oncogene 
(Figure 1.1A). The EML4-ALK fusion oncogene in turn encodes EML4-ALK 
oncoproteins that consist of the intracellular tyrosine kinase domain of ALK and 
an amino-terminal portion of EML4 (Figure 1.1B). The EML4 domain mediates 
constitutive dimerisation and activation of the ALK kinase domain, independent 
of ligand and thereby induces aberrant activation of ALK downstream signalling 
(RAS-MAPK, PI3-AKT, JAK-STAT) that promotes cell proliferation and survival 
(Soda et al., 2007). Multiple chimeric EML4-ALK variants have been identified 
that contain the same intracellular tyrosine kinase domains of ALK but have a 
different section of EML4. Out of 15 different variants identified, variant 1 (E13; 
A20) is the most common found in 33% of NSCLC. This is followed by variant 
3a/b (E6a/b;A20) detected in 29% of NSCLC (Sasaki et al., 2010).  
Apart from EML4, other fusion partners of ALK are TRK-fused gene (TFG), 
kinesin family member 5B (KIF5B), kinesin light chain 1 (KLC1), protein tyrosine 
phosphatase nonreceptor type 3 (PTPN3), translocated promoter region (TPR) 
and all are detected less frequently in NSCLC (Table 1.3) (Rikova et al., 2007; 
Takeuchi et al., 2009; Togashi et al., 2012). All fusion partners share some 
common characteristics: 1) Promoter of partner protein determines the initiation 
of transcription of the fusion protein. 2)  Sub-cellular localisation of the fusion 
protein is controlled by the partner protein. 3) The partner protein induces the 
dimerisation or oligomerisation of ALK fusion that facilitates 
autophosphorylation and activation of the ALK kinase domain. 
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Table 1.3: ALK fusions in NSCLC 
Fusion protein Chromosomal  
translocation 
Frequency Reference 
EML4-ALK Inv(2)(p21;p23) 2-7 (Lin et al., 2017; Soda et 
al., 2007) 
TFG-ALK t(2;3)(p23;q21) 2 (Rikova et al., 2007) 
KIF5B-ALK t(2;10)(p23;p11) <1 (Takeuchi et al., 2009) 
KLC1-ALK t(2;14)(p23;q32) <5 (Togashi et al., 2012) 
PTPN3-ALK t(2;9)(p23;q31) N/A (Jung et al., 2012) 
TPR-ALK t(1;2)(p23;q31.1) N/A (Choi et al., 2014) 
DCTN1-ALK t(2;2)(p13;p23) N/A (Iyevleva et al., 2015) 
GCC2-ALK t(2;2)(p23;q12) N/A (Jiang et al., 2018) 
Abbreviations:  ALK, Anaplastic lymphoma kinase; DCTN1, Dynactin subunit 1; EML4, echinoderm 
microtubule associated protein like 4; GCC2, GRIP and coiled-coil domain-containing protein 2; KIF5B; 
kinesin family member 5B; KLC1, kinesin light chain 1; PTPN3, protein tyrosine phosphatase nonreceptor 
type 3; TFG, TRK-fused gene; TPR, translocated promoter region 
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Figure 1.1 EML4-ALK fusion in non-small cell lung cancer. (A) A small inversion on 
short arm of chromosome 2 causes fusion of exon 13 of EML4 (5’) to exon 20 of ALK (3’) 
resulting in the formation of EML4-ALK fusion oncogene. (B) General structure of ALK, 
EML4 and EML4-ALK (variant 1) fusion oncoprotein. Structure of ALK consists of 
extracellular portion comprised of two MAM domain (amino acids 264-427 and 480-
626), an LDL domain (453-471) and glycine rich domain (816-940); transmembrane 
domain (1039-1059) and intracellular tyrosine kinase domain (1116-1383). EML4 is 
comprised of N-terminal CC that is separated from C-terminal HELP and WD repeat 
domain by a basic region. 
Adapted from (Bayliss et al., 1209; Gandhi et al., 2015; Roskoski, 2013; Soda et al., 2007).   
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1.3.4. Clinical detection of ALK 
Molecular testing of prognostic biomarkers is crucial for the selection of 
appropriate therapy in non-small cell lung cancer. The National Comprehensive 
Cancer Network (NCCN) Clinical Practice Guideline in Oncology and Guideline 
from the College of American Pathologist (CAP) recommend molecular testing 
for ALK rearrangements/fusions in patients with metastatic non-squamous or 
advanced stage adenocarcinoma NSCLC (Lindeman et al., 2013; NCCN Clinical 
Practice Guidelines in Oncology (NCCN Guidelines®), 2020). Methods to detect 
ALK rearrangement include fluorescence in situ hybridisation (FISH), 
immunohistochemistry (IHC), next-generation sequencing (NGS) and reverse 
transcriptase-polymerase chain reaction (RT-PCR) assays. Each method has its 
own benefits and drawbacks. 
1.3.4.1. Fluorescence in situ hybridisation 
 FISH is the gold standard assay for the detection of ALK rearrangements 
in NSCLC (Martelli et al., 2009; Perner et al., 2008; Shaw et al., 2009; Tang et al., 
2019). The Vysis ALK Break-Apart FISH probe kit (Abbott molecular Inc) has 
been approved by the food and drug administration (FDA) as a companion 
diagnostic test prior to administration of ALK tyrosine kinase inhibitors (Tang et 
al., 2019; Weickhardt et al., 2013). This method uses fluorescently labelled DNA 
probes that bind to and localise specific genomic region in the nuclei of tumour 
samples. The Vysis ALK Break-Apart probe kit consists of a 5’ ALK probe of 
approximately 442 kb labelled with green fluorophores and a 3’ ALK probe of 
approximately 300 kb labelled with orange fluorophores. In non-rearranged 
cells, the orange and green probes are closely located resulting in a merged 
(yellow) signal. Whereas in ALK rearrangement cells, these probes are separated 
resulting in a split (green and orange) signal. Furthermore, the presence of an 
isolated red signal without coexistence of a green signal is considered positive. 
This suggests that ALK rearrangement has occurred with either loss of the 5’ 
probe binding site or masking within the plane of the section (Tang et al., 2019; 
Weickhardt et al., 2013).  
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The FISH assay can detect ALK rearrangement regardless of fusion partner 
and variant (Weickhardt et al., 2013).  However, the major challenge is the 
interpretation of the results that require technical expertise. It is difficult to 
identify a split signal in the fusion gene with small physical separation between 
5’ and 3’ ALK sequences such as EML4-ALK that are separated by only 12 Mb 
(Camidge et al., 2010). Moreover, FISH cannot distinguish between different 
EML4-ALK fusion variants (Cha et al., 2016). Apart from this, FISH is an 
expensive, time-consuming assay that requires specialised equipment and 
laboratory techniques (Kerr, 2014).  
1.3.4.2. Immunohistochemistry 
IHC is a reliable alternative diagnostic approach for the detection of ALK 
rearrangements (Conklin et al., 2013; Sun et al., 2012; To et al., 2013). The 
VENTANA ALK (D5F3) CDx assay (Ventana Medical Systems, Inc) has been 
approved by the FDA as companion diagnostic test to identify ALK 
rearrangement (Conde et al., 2016; Marchetti et al., 2016).  IHC uses specific 
monoclonal antibodies that bind to the specific epitope of the ALK fusion protein 
regardless of variant and fusion partner. Unlike ALCL, NSCLC has a low 
expression level of ALK fusion protein that decreases the sensitivity of IHC for 
the detection of ALK rearrangement. The sensitivity and specificity of IHC were 
improved by using high-affinity antibodies such as D5F3 (Cell Signaling 
Technology). and 5A4 (Novocastra, Leica Biosystems), and a highly sensitive 
detection system. Moreover, IHC is cost effective and easier to perform thereby, 
making it an efficient method for screening ALK rearrangement in NSCLC 
(Conklin et al., 2013; Minca et al., 2013; Mino-Kenudson et al., 2010; Park et al., 
2012). 
1.3.4.3. Next generation sequencing 
NGS has emerged as reliable alternative diagnostic approach to FISH or 
IHC (Dacic et al., 2016; Lin et al., 2019). The FoundationOne CDx assay 
(Foundation Medicine, Inc) has been approved by the FDA as a companion 
diagnostic test for recognition of ALK rearrangement (U.S. Food and Drug 
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Administration, 2020b). This method allows simultaneous parallel sequencing of 
multiple analytes for the detection of potentially targetable genetic alteration 
such as gene mutation, rearrangement and copy number alterations in a variety 
of cancers, including ALK, within a single assay (Lin et al., 2019; Vigneswaran et 
al., 2016; Weickhardt et al., 2013). Comprehensive profiling of genome identified 
ALK rearrangement in a subset of NSCLC patients who showed negative results 
in the prior FISH assay. These patients exhibited responses to ALK inhibitors 
that were similar to the response rate in patients with positive results in FISH 
assay (Ali et al., 2016; Peled et al., 2012). Furthermore, NGS is cost effective 
method and can be a suitable option in the cases where the results from FISH or 
IHC are inconclusive (Lin et al., 2019). NGS can identify different ALK fusion 
subtypes and concomitant mutation allowing the discovery of new fusions 
beyond NSCLC (Beadling et al., 2016; Vendrell et al., 2017). 
1.3.4.4. Reverse transcriptase-polymerase chain reaction 
RT-PCR is a RNA based highly specific diagnostic test for detection of ALK 
rearrangement (Liu et al., 2016; Soda et al., 2012; Takeuchi et al., 2008). This 
method was originally used to identify EML4-ALK gene rearrangement in 
NSCLC (Soda et al., 2007). However, it is not recommended as an alternative to 
FISH for the detection of ALK prior to the administration of ALK inhibitors 
(Lindeman et al., 2013). RT-PCR can detect known ALK fusions and variants but 
may misdiagnose novel ALK fusion partners. The challenge is increasing the 
number of ALK fusion partners that require a multiplex RT-PCR approach with 
multiple validated primers. Furthermore, the extraction of RNA and cDNA 
synthesis from FFPE tumour samples is difficult due to the degradation of 
messenger RNA making it less feasible (Kerr, 2014; Sanders et al., 2011; Solomon 
et al., 2009). However, this method can be applied to the cytology specimens such 
as bronchial lavage fluid, sputum, pleural effusion (Soda et al., 2012; Wang et al., 
2016). 
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1.3.5. Prevalence of ALK positive non-small cell lung cancer 
ALK gene rearrangement is found in 2-7% of patient with NSCLC 
(Koivunen et al., 2008; Perner et al., 2008; Soda et al., 2007; Wong et al., 2009). 
ALK-positive NSCLC has adenocarcinoma histology and is observed in younger 
age patients with non-smoking or light smoking history (Shaw et al., 2009; 
Toyokawa & Seto, 2014b; Wong et al., 2009). In New Zealand, 8.4% of the patients 
diagnosed with nonsquamous NSCLC tested positive for ALK gene 
rearrangement (McKeage et al., 2019). Furthermore, ALK-positive NSCLC was 
more prevalent in younger (13.8%) compared to older (7.1%) patients, non-
smokers (22.3%) versus smokers (2.9%) and in Maori (6.9%), Pacific (10.8%) or 
Asian (22.0%) ethnic groups versus New Zealand Europeans (4.4%) (McKeage et 
al., 2019). 
1.3.6. Treatment approach for ALK-positive NSCLC 
The treatment approach for the advanced stage non-squamous NSCLC has 
evolved and is continuously changing with time (Melosky, 2018). Chemotherapy 
was the preferred choice of treatment for stage III and IV NSCLC until the 
discovery of targeted therapy (Dong et al., 2019). Platinum based doublets with 
third generations chemotherapy drugs were used for the treatment of advanced 
stage NSCLC. However, chemotherapy drugs exhibit strong treatment related 
adverse events, thereby limiting their clinical benefits (Nagasaka & Gadgeel, 
2018; Schiller et al., 2002). Advances in the understanding of tumour biology 
have led to the development of small molecule inhibitors that target the specific 
genomic abnormalities including EGFR, ALK in NSCLC (Dong et al., 2019). 
ALK tyrosine kinase inhibitors (TKIs) are the preferred first line therapy for 
NSCLC patients with advanced ALK rearrangement. The presence of an ALK 
fusion oncogene should be detected by FISH or IHC prior to the administration 
of ALK-TKIs (Barrows et al., 2019; Khan et al., 2018; Solomon, Wilner, et al., 
2014). However, systemic chemotherapy is indicated if urgent treatment is 
required before the confirmation of genotype. The treatment plan is reassessed 
when the test result is available. Since no clinical trials report the optimal timing 
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for the administration of an ALK inhibitor in patients already on chemotherapy, 
the patients testing positive for ALK fusion oncogene are switched to ALK 
inhibitors (Moran & Sequist, 2012; Solomon, 2020).  
Alectinib, a second generation ALK TKIs, is currently approved by FDA as 
a first line treatment for the patients with ALK-positive NSCLC (McCusker et al., 
2019; U.S. Food and Drug Administration, 2017a). Second generation ALK TKIs 
such as ceritinib and brigatinib demonstrate greater potency than crizotinib and 
may be an alternative to alectinib. However, brigatinib is not yet approved by 
FDA as first-line treatment (Melosky, 2018; Solomon, 2020). Crizotinib was the 
first ALK TKI approved by FDA for the treatment of ALK-positive NSCLC 
(Kazandjian et al., 2014; Solomon, Mok, et al., 2014). Although alectinib is now 
the preferred first-line treatment, some parts of the world still use crizotinib due 
to its superiority over standard chemotherapy (McCusker et al., 2019). Moreover, 
NCCN Clinical Practice Guideline in Oncology has indicated that alectinib, 
ceritinib, brigatinib and crizotinib are all first line therapies in advanced or 
metastatic ALK-positive NSCLC (NCCN Clinical Practice Guidelines in 
Oncology (NCCN Guidelines®), 2020). Prior to the ALK-TKIs, chemotherapy 
was used for the treatment of these patients. (Barrows et al., 2019). The current 
treatment approaches for ALK-TKI naïve or resistant ALK-positive NSCLC 
patients are illustrated in Figure 1.2. 
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Figure 1.2 Schematic diagram showing the proposed treatment algorithm in ALK-
positive NSCLC. Adapted from (NCCN Clinical Practice Guidelines in Oncology 
(NCCN Guidelines®), 2020) 




Crizotinib is an orally active aminopyridine-based RTK inhibitor described 
chemically as (R)-3-[l-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-
yl)-1H-pyrazol-4-yl] pyridin‑2‑amine4 (Figure 1.3). The molecular formula and 
molecular weight of crizotinib is C21H22Cl2FN5O and 450.34 daltons, respectively. 
 
Figure 1.3 Chemical Structure of crizotinib. (Figure is obtained from Wikipedia – in 
public domain)  
Crizotinib is a highly selective ATP competitive small molecule inhibitor of 
ALK, MET and ROS1 receptor tyrosine kinases and their variants. Crizotinib 
binds to the ATP binding site of these RTKs and inhibits their 
autophosphorylation and their subsequent downstream signalling pathways 
(Bergethon et al., 2012; Cui et al., 2011). Crizotinib has an anti-proliferative 
activity that is associated with G1-S–phase cell cycle arrest and induction of 
apoptosis (Christensen et al., 2007; Toyokawa & Seto, 2014a). Initially, it was 
developed as MET inhibitor. However, higher selectivity and specificity of 
crizotinib for ALK and better clinical outcome in ALK rearranged lung cancer 
patients made it the first line therapy for ALK-positive NSCLC. Based on good 
clinical results from phase I and II clinical trials, the FDA and the European 
medicines evaluation agency (EMEM) approved crizotinib for treatment of 
locally advanced or metastatic ALK+ NSCLC in 2011 and 2012, respectively 
(Kazandjian et al., 2014; Metro et al., 2017).




A dose escalation phase I trial determined that 250 mg BID is the maximum 
tolerated dose (MTD) of crizotinib (Kwak et al., 2010; Kwak et al., 2009). After 
administration of a single oral dose of crizotinib (250 mg), the peak plasma 
concentration (Cmax) was reached after approximately 4-6 h with a terminal half-
life of 43-51 h. Steady-state concentrations were obtained within 15 days of 
starting crizotinib treatment (250 mg BID), with a mean plasma trough of 256 
ng/ml. This was higher than the efficacious concentration (120 ng/ml) for ALK 
inihibition found in preclinical models (Hamilton et al., 2015). Administration of 
crizotinib results in an equal distribution of the drug between blood cells and 
plasma. More than 90% of crizotinib binds to human plasma protein, and a lesser 
extent to serum albumin and α-1 acid glycoproteins. Following intravenous (IV) 
administration of crizotinib, the mean volume of distribution was 1772 L, 
showing the extensive distribution of crizotinib from plasma into tissues. 
However, the penetration of crizotinib into cerebrospinal fluid and across blood-
brain barrier (BBB) is poor, with cerebrospinal fluid and plasma ratio being 
0.0026. The total bioavailability of crizotinib is 43%. Administration of a single 
dose of crizotinib (250 mg) together with a standard high fat meal did not change 
the exposure and Cmax to a clinically relevant level. Thus, crizotinib is 
recommended to be taken with or without food (Curran, 2012; Frampton, 2013; 
Hamilton et al., 2015). 
Crizotinib is predominantly metabolised in the liver by cytochrome P450 
(CYP) 3A4/5 isoenzymes by both O-dealkylation, with the subsequent 
conjugation of the O-dealkylated metabolites and oxidation of piperidine ring to 
crizotinib lactam (active metabolite) (Pfizer Inc., 2019). Co-administration of 
crizotinib with potent CYP3A inducers and CYP3A inhibitors may alter the 
plasma concentration of crizotinib (Pfizer Inc., 2019). Furthermore, both in vitro 
and in vivo studies showed that crizotinib is a moderate time dependent inhibitor 
and weak inducer of CYP3A enzymes (Johnson et al., 2015; Mao et al., 2013). 
Therefore, crizotinib may alter the plasma concentration of CYP3A substrate 
when given concomitantly (Pfizer Inc., 2019). The potential drug interactions of 
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crizotinib are presented in Table 1.4. Crizotnib and its metabolites are primarily 
excreted from faecal route with 63% being eliminated via the faeces (53% as 
unchanged drug) and then from biliary route where 22% is eliminated in the 
urine (1.3-2.3% as unchanged drug) (Curran, 2012). 
 
Table 1.4: Potential drug interaction of crizotinib (Pfizer Inc., 2012) 














phenytoin, rifabutin, St. 
John’s Wort. 
 





Inhibition of CYP3A 
enzyme by crizotinib 
Increase the plasma 
concentration of CYP3A 
substrate 
1.4.2. Preclinical Studies 
Biochemical and cell-based phosphorylation assays showed the selectivity 
of crizotinib was around 20-fold higher for ALK and MET compared to over 120 
other tyrosine and serine-threonine kinases (Christensen et al., 2007; Zou et al., 
2007). Cell viability assays demonstrated that crizotinib inhibited the survival of 
SU-DHL-1 and Karpas299 cells expressing the NPM-ALK fusion gene with IC50 
values of 43±2 nmol/L and 32±1 nmol/L, respectively. Christensen et al. also 
found that the phosphorylation of NPM-ALK in anaplastic large cell lymphoma 
cell line (SU-DHL-1 and Karpas299) was potently inhibited by crizotinib at mean 
IC50 value of 24 nmol/L. Also, immunodeficient Beige mice bearing Karpas299 
ALCL tumour xenografts were orally administered with crizotinib which led to 
complete regression of all tumours at a dose of 100 mg/kg within 15 days 
(Christensen et al., 2007).  
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Crizotinib potently inhibited the cell viability of the neuroblastoma line 
NB-1 by suppressing proliferation and ALK mediated signalling. Furthermore, 
strong inhibition of ERK and AKT signalling was observed in crizotinib treated 
NB-1 neuroblastoma cells (McDermott et al., 2008).  Similarly, cell proliferation 
of a non-small cell lung cancer cell line, H3122, harbouring the EML4-ALK 
variant 1 and kelly neuroblastoma with an activating mutation was also 
suppressed by crizotinib (McDermott et al., 2008). These results from preclinical 
studies demonstrated that crizotinib could act as a potential therapeutic target in 
ALK rearranged NSCLC and lead quickly to clinical studies. 
1.4.3. Clinical Studies 
Based on preclinical results obtained from in vitro and in vivo animal 
experiment, clinical studies of crizotinib began in 2006. The clinical efficacy of 
crizotinib in ALK-positive NSCLC patient with advanced or metastatic tumours 
has been analysed in phase I (Profile 1001), phase II (Profile1005) and phase III 
(Profile1007 and Profile1014) clinical trials (Camidge et al., 2012; Kwak et al., 
2010). 
1.4.3.1. Phase I clinical trial (Profile 1001) 
The therapeutic efficacy and toxicity of crizotinib were evaluated in an 
open-label, noncomparative, multicentre two-part trial Phase I clinical trial 
(Camidge et al., 2012; Kwak et al., 2010). The first part consisted of standard dose-
escalation pharmacokinetic evaluation, where the maximum tolerated dose of 
crizotinib was determined. Thirty-seven patients with any solid tumour type 
including pancreatic, colorectal, ALCL and NSCLC were administered crizotinib 
at doses ranging from 50 mg OD to 300 mg BID on a continuous schedule. Three 
dose limiting toxicities were observed where one patient receiving 200 mg OD 
developed grade 3 elevation of alanine aminotransferase (ALT), and the other 
two patients receiving 300 mg BID had grade 3 level fatigue. Reduction of dose 
to 250 mg BID was tolerable with mild grade 1 and 2 adverse effect including 
vomiting, nausea, and diarrhoea. Furthermore, out of 37 patients, 2 patients with 
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ALK rearrangement showed improved clinical outcome (Kwak et al., 2010; 
Kwak et al., 2009).  
Next, the therapeutic efficacy of crizotinib was evaluated in an expanded 
cohort of patients harbouring ALK rearrangement. A total of 1500 NSCLC 
patient were screened for the presence of ALK rearrangement, with only 82 
patients testing positive for ALK. Crizotinib (250 mg BID) was orally 
administered to 82 patients in a 28-day cycle. The objective response rate (ORR) 
was 57% (i.e., 47 patients out of 82 respond to the treatment). Among these 47 
patients, 46 had partial response whereas 1 showed a complete response. The 
remaining 33% (27 patients) had stable diseases. Mean duration of treatment was 
6.4 months where 63 patients (77%) continued to receive crizotinib even after the 
data cutoff (Kwak et al., 2010). 
Furthermore, Camidge et al. have reported updated result from phase I 
study (Camidge et al., 2012). A total of 149 patients with locally advanced or 
metastatic ALK-positive NSCLC (stage III or IV) received oral crizotinib 250 mg 
twice daily in 28-day cycles. Mean duration of treatment was 10.8 months and 
55% of patients continued to receive crizotinib after data cutoff point. An 
objective response (OR) of 60.8% was observed in 87 patients with three patients 
responding completely and 84 of them partially to crizotinib treatment. Mean 
progression free survival (PFS) was 9.7 months whereas PFS was longer (median 
18.3 months) for patients receiving crizotinib as first line therapy. The estimated 
overall survival at 6 and 12 months was 87.9% and 74.8%, respectively. The 
majority of patients (97%) exhibited grade 1 or 2 adverse events including 
nausea, diarrhoea, vomiting, constipation and peripheral oedema. Severe 
adverse event (grade 3 or 4) was experienced by a number of patients (36 
patients) that included neutropenia, raised ALT, lymphopaenia and 
pneumonitis (Camidge et al., 2012). 
1.4.3.2. Phase II clinical trial (Profile 1005) 
Profile 1005 was a single-arm, multicentre, open-label study that evaluated 
the efficacy and safety of orally administered crizotinib at a dose of 250 mg BID 
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in a 21-day cycle (Blackhall et al., 2017). Patients with advanced ALK-positive 
NSCLC whose disease progressed after one or more chemotherapies were 
included. This study was conducted with 1066 participants that were divided 
into two groups. First group comprised of 908 patients whose ALK-positive 
status was determined in a central laboratory and second group comprised of 
158 patients whose ALK-positive status was determined locally. An ORR of 54% 
and 41%, median PFS of 8.4 months and 6.9 months and median OS of 21.8 
months and 16.9 months was observed in the first and the second group, 
respectively. Majority of patients (96%) experienced treatment related adverse 
events. The most commonly observed adverse events of any grade were visual 
disorder (58%), nausea (51%), vomiting (47%) and diarrhoea (47%). Grade 3 or 4 
neutropenia and elevated transaminases were found in 13% and 8% patients, 
respectively (Blackhall et al., 2017).  
Thus, the results from phase I and II studies demonstrated the potent 
antitumor activity of crizotinib in patients with advanced ALK-positive NSCLC. 
1.4.3.3. Phase III clinical trial (Profile 1007 and 1014) 
The therapeutic efficacy of crizotinib was compared with chemotherapy in 
a randomised, open-labelled phase III (Profile 1007) clinical trial. The study 
enrolled 347 patients with locally advanced or metastatic ALK-positive NSCLC 
and with Eastern Cooperative Oncology Group (ECOG) performance status 
ranging from 0-2 and had received one prior platinum-based chemotherapy 
regimen. Most patients were younger (<65 years), non-smokers and had 
adenocarcinoma histology. Of 347 patients, 173 received oral crizotinib at a dose 
of 250 mg BID while the remaining 174 subjects received intravenous 
chemotherapy (either pemetrexed 500 mg/m2 body surface area or docetaxel 75 
mg/m2) every 3 weeks.  PFS was the primary end point of the study, whereas 
secondary end points were OS, response rate that include partial and complete 
responses, safety, and patient reported outcomes. Crizotinib treatment 
demonstrated superior therapeutic efficacy with longer median PFS rate of 7.7 
months (95% CI, 6.0 to 8.8) and higher ORR of 65% (95%CI, 58 to 72) compared 
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to chemotherapy (pemetrexed or docetaxel) with only 3 months (95% CI, 2.6 to 
4.3) of PFS and 20% (95% CI, 14 to 26) of ORR. However, there was no significant 
improvement in OS of patients receiving crizotinib (median 20.3 months) 
compared to chemotherapy (median 22.8 months). Adverse events including 
visual disorder, gastrointestinal side effects, elevated ALT was common among 
patients receiving crizotinib, whereas dyspnea, alopecia, and fatigue were 
common in those treated with chemotherapy (Shaw et al., 2013). 
The randomised, multicentre, open labelled Profile 1014 trial compared the 
clinical efficacy and safety of crizotinib as a first line treatment against standard 
chemotherapy (pemetrexed plus platinum) in patients with locally advanced 
and metastatic ALK-positive NSCLC. 343 patients were enrolled in this study 
where 172 received oral crizotinib (250 mg BID) and the remaining 171 received 
standard chemotherapy (pemetrexed, 500 mg/m2 of body surface and either 
cisplatin, 75 mg/m2 or carboplatin, target AUC of 5 to 6 mg/ml/min) for 3 weeks 
for up to 6 cycles. Crizotinib demonstrated superior efficacy compared to 
pemetrexed plus platinum standard chemotherapy in treatment naïve ALK-
positive NSCLC patients. The median PFS was significantly longer in patients 
assigned to crizotinib (10.9 months, 95% CI, 8.3 to 13.9) compared to those treated 
with chemotherapy (7.0 months, 95% CI, 6.8 to 8.2). Similarly, patients assigned 
to crizotinib had significantly higher ORR of 74% (95% CI, 67 to 81) than those 
receiving chemotherapy (45%, 95% CI, 37 to 53). Both treatment groups 
experienced grade 1 and 2 adverse events where vision disorder, nausea, 
vomiting, oedema were common in the crizotinib treatment group and nausea, 
fatigue, and decreased appetite were mostly observed in the chemotherapy 
group. Crizotinib led to greater suppression in lung cancer symptoms and 
improvement in a quality of life (Solomon, Mok, et al., 2014). Overall, both Profile 
1007 and profile 1014 demonstrated the superior efficacy of crizotinib over 
standard chemotherapy in patients previously untreated or treated with one or 
more platinum-based chemotherapy. 
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1.5. Limitation of crizotinib 
The clinical benefit of crizotinib is highly limited due to relapse of diseases 
in the central nervous system and development of systemic resistance. Despite 
the significant response of crizotinib in ALK-positive NSCLC, the majority of 
patients eventually progress to a diseases of the central nervous system (Kim et 
al., 2016; Shaw et al., 2011). Retrospective analysis of data from two clinical trials 
(PROFILE 1005 and PROFILE 1007) found low intracranial ORR to crizotinib in 
patients with ALK-positive NSCLC and previously treated or untreated brain 
metastases (Costa et al., 2015). The poor CNS activity may be due to the poor 
BBB penetration of crizotinib (Costa et al., 2011; Maillet et al., 2013). Costa et al. 
reported that crizotinib has a low cerebrospinal fluid (CSF) concentration of 
0.616 ng/ml compared to its plasma concentration (237 ng/ml) (Costa et al., 
2011). Furthermore, the majority of patients treated with tyrosine kinase 
inhibitors including crizotinib exhibit systemic resistance. Understanding the 
underlying mechanism of resistance is crucial to select optimal therapy that can 
combat resistance and improve patient outcome (Camidge & Doebele, 2012; Lin 
et al., 2017). Both patient-derived and cell-based resistant models of crizotinib 
have provided a better understanding of underlying molecular mechanism of 
crizotinib resistance (Crystal et al., 2014). Resistance to crizotinib can be either 
primary (intrinsic) or secondary (acquired) resistance (Lovly & Shaw, 2014). 
1.5.1. Primary resistance 
Despite the presence of ALK rearrangement, approximately 40% of patients 
do not respond to crizotinib (Kwak et al., 2010). The underlying mechanism of 
primary resistance to crizotinib is not fully understood. One study suggested 
that the presence of different ALK fusion genes and EML4-ALK variants may 
contribute to the heterogenous response of ALK-positive tumours to ALK 
inhibitor. They showed that different ALK fusion genes and EML4-ALK variants 
((v1, v2, v3a and v3b) exhibited different sensitivity to crizotinib. The EML4-ALK 
variants v2 and v3a a showed significant difference in sensitivity to crizotinib 
with growth inhibitory concentration (GI50) of 150 and 1000 nmol/L, where as 
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v1 and v3b have GI50 values of 470 nmol/L (Heuckmann et al., 2012). 
Furthermore, some studies suggested that intratumoural heterogeneity may be 
the underlying reason behind intrinsic resistance to crizotinib. Cai et al. 
identified intratumoural genetic heterogeneity in ALK-rearranged NSCLC 
harbouring ALK/EGFR coalteration. The distribution of ALK fusion and EGFR 
in tumour tissue was very random where some tumour cells had concomitant 
coexistence of both, and some had either one of them (Cai et al., 2015). Moreover, 
ALK-positive NSCLC patients harbouring both ALK and KRAS poorly 
responded to crizotinib (Sahnane et al., 2016). The genetic diversity within the 
tumour tissue can hinder accurate diagnosis and selection of appropriate 
treatment that may lead to intrinsic resistance. 
1.5.2. Secondary resistance 
Despite the initial response to crizotinib, the majority of patients eventually 
develop acquired resistance within a year of therapy (Choi et al., 2010; Katayama 
et al., 2011). Resistance mechanisms are further classified into ALK dominant 
(on-target) mechanism where tumour cells solely depend on ALK signalling and 
ALK non-dominant (off-target) mechanism where tumour cells rely on different 
signalling pathways other than ALK (Figure 1.4) (Drizou et al., 2017; Lin et al., 
2017).
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Figure 1.4 Overview of mechanism of acquired resistance to crizotinib. Treatment 
with crizotinib binds to the ATP binding site and thereby inhibit EML4-ALK activation. 
However, acquired resistance is developed that is classified into ALK dominant (on 
target) and ALK non-dominant (off target) resistance. Adapted from (Steuer & 
Ramalingam, 2014). 
1.5.2.1. ALK dominant mechanism 
The ALK dominant mechanism includes secondary mutation and 
amplification (copy number gain) of ALK that re-establish kinase activity and 
preserve the dominance of ALK signalling (Camidge & Doebele, 2012; Lin et al., 
2017). Almost 30% of cases with acquired crizotinib resistance develop 
secondary mutations in the kinase domain of ALK (Doebele et al., 2012; 
Katayama et al., 2012). Choi et al. identified two de novo mutations, L1196M and 
C1156Y, through the molecular analyses of sputum and pleural-effusion 
specimens of crizotinib resistant ALK-positive NSCLC patients. Interestingly, 
BA/F3 cells harbouring L1196M mutation were more resistant to crizotinib 
compared to those expressing C1156Y mutations (Choi et al., 2010). The L1196M 
is a gatekeeper mutation, analogous to T790M in EGFR that alters ATP binding 
pocket and impairs crizotinib binding through steric interference (Choi et al., 
2010; Gainor & Shaw, 2013; Lin et al., 2017; Steuer & Ramalingam, 2014). 
Similarly, several studies have identified other secondary mutations such as 
F1174L/C/V, L1152R, I115Tins, G1202R, G1202del, S1206Y/C, G1269A/S, 
G1123S/D, E1210K, I1171T/N/S, L1198P and D1203N (Doebele et al., 2012; 
Gainor et al., 2016; Heuckmann et al., 2011; Ignatius Ou et al., 2014; Katayama et 
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al., 2012; Sasaki et al., 2011; Zhang, Wang, et al., 2011). The G1269A mutation lies 
within the active site and hinders crizotinib binding (Doebele et al., 2012). While 
the C1156Y, L1152R and I115Tins affect residues adjacent to the N-terminus and 
F1174C/L/V mutations affect residues at the C-terminus(Choi et al., 2010; 
Friboulet et al., 2014; Katayama et al., 2012). Solvent-front mutations (G1202R, 
G1202del, D1203N, and S1206Y/C) impair crizotinib binding via steric 
hindrance (Friboulet et al., 2014; Gainor et al., 2016; Ignatius Ou et al., 2014; 
Katayama et al., 2012), while the I1171T/N/S mutation may hinder ALK-TKI 
binding by distorting the αC helix of ALK (Katayama et al., 2014; Toyokawa et 
al., 2014). Furthermore, amplification of ALK alone or in combination with 
secondary mutations was observed in crizotinib resistant ALK positive NSCLC 
patients (Doebele et al., 2012; Katayama et al., 2012). Katayama et al. noted the 
ALK amplification as a potential resistance mechanism in an in vitro resistant 
model of crizotinib that was developed by exposure of ALK-positive NSCLC 
(H3122) cells to increasing concentration of crizotinib. Cells exposed to an 
intermediate concentration of crizotinib (0.6 μM) harboured ALK amplification, 
whereas higher concentration (1 μM) of crizotinib exhibited both ALK 
amplification and L1196M gatekeeper mutation (Katayama et al., 2011). 
1.5.2.2. ALK non-dominant mechanism 
The ALK non-dominant mechanism includes activation of alternative 
signalling pathways (bypass tracks) through genetic alterations (mutations or 
amplification), dysregulation of feedback mechanism or autocrine signalling, 
leading to ALK independent growth and survival of tumour cells (Dagogo-Jack 
& Shaw, 2016; Lin et al., 2017). Approximately 40% of patients who develop 
resistance to crizotinib do not harbour ALK amplifications or secondary 
mutations, instead bypass signalling tracks are activated (Katayama et al., 2015). 
Sasaki et al. was first to identify the activation of EGFR as the possible bypass 
mechanism in in vitro resistant model of crizotinib (Sasaki et al., 2011). This was 
further supported with clinical analysis of ALK-positive tumour biopsies from 
patients resistant to crizotinib (Doebele et al., 2012; Katayama et al., 2012). The 
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possible mechanism of EGFR activation in crizotinib resistant patients includes 
an increase in EGFR phosphorylation, upregulation of EGFR ligands and 
mutation or amplification of EGFR (Doebele et al., 2012; Kang et al., 2018; 
Katayama et al., 2012; Tanizaki, Okamoto, Okabe, et al., 2012). Other potential 
bypass mechanism include mutations of KRAS, PIK3CA, MET, amplifications 
(copy number gains) of, cKIT, HGF, and activation of SRC, IGFR, HER2, (Boland 
et al., 2013; Crystal et al., 2014; Doebele et al., 2012; Kang et al., 2018; Katayama 
et al., 2012; Lovly et al., 2014; Sasaki et al., 2011; Tanizaki, Okamoto, Okabe, et 
al., 2012). 
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1.6. Strategies to overcome crizotinib resistance 
Understanding the diverse molecular mechanisms of resistance have 
provided knowledge for the development of novel therapeutic strategies. These 
strategies should effectively treat the relapse by overcoming the resistance as 
well as improve patient outcome by preventing or delaying the emergence of 
resistance (Dagogo-Jack & Shaw, 2016; Lin et al., 2017; Lovly & Pao, 2012). The 
selection of appropriate treatment strategies depends on the type of resistance 
mechanism involved (Lovly & Pao, 2012).  
1.6.1. Next generation ALK tyrosine kinase inhibitor 
One of the most common strategies to combat resistance is the use of next 
generation ALK-TKIs. Crizotinib resistant patients who harbour ALK mutation 
or amplification and are still addicted to ALK signalling are treated with next 
generation ALK-TKIs (Shaw & Engelman, 2013). In comparison to crizotinib, 
these TKIs are highly potent and have better penetration of the BBB (Pirker & 
Filipits, 2019; Shaw & Engelman, 2013). Currently, three second generation ALK-
TKIs ceritinib, alectinib and brigatinib have been approved by the FDA as the 
second line treatment of crizotinib-resistant patients (U.S. Food and Drug 
Administration, 2017a, 2017b, 2017c). Recently, a third generation ALK-TKI, 
loratinib, has been approved by the FDA as the second- or third-line treatment 
of patients who have progressed on crizotinib (U.S. Food and Drug 
Administration, 2018b). The treatment approach for ALK-positive NSCLC using 
next generation ALK-TKIs is illustrated in Figure 1.2. 
1.6.1.1. Ceritinib 
Ceritinib was the first second generation ALK-TKI approved by the FDA in 2014 
for the treatment of ALK-positive NSCLC patients resistant to crizotinib (U.S. 
Food and Drug Administration, 2017c). It is a highly potent (20-fold more potent 
than crizotinib), ATP competitive, small molecule inhibitor of ALK (Friboulet et 
al., 2014; Marsilje et al., 2013). In an in vitro crizotinib resistant model, ceritinib 
effectively overcame resistant conferring mutations, L1196M, G1269A, I1171T 
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and S1206Y, but was ineffective at inhibiting G1202R and F1174C mutations 
(Friboulet et al., 2014). A phase I (ASCEND-1) trial demonstrated the anti-
tumour activity of ceritinib in both crizotinib naïve and crizotinib pretreated 
ALK-positive NSCLC patients (Kim et al., 2016; Shaw & Engelman, 2014). 
Similarly, single-arm phase II trials evaluated efficacy and safety of ceritinib in 
chemotherapy and crizotinib pretreated (ASCEND-2) and ALK-TKI naïve 
(ASCEND-3) patients. In both studies, ceritinib demonstrated clinically 
meaningful and improved responses (Crino et al., 2016; Felip et al., 2015). In 
phase III (ASCEND-4) trial, ceritinib demonstrated superior efficacy compared 
to platinum-pemetrexed doublet chemotherapy with an ORR (72.5% versus 
26.7%) and PFS (16.6 versus 8.1 months) (Soria et al., 2017). Based on results from 
the ASCEND-4 trials, ceritinib was approved by the FDA in 2017 for the 
treatment of patients with metastatic ALK-positive NSCLC (U.S. Food and Drug 
Administration, 2017c). Furthermore, a phase III (ASCEND-5) trial 
demonstrated that ceritinib was more efficacious over single-agent 
chemotherapy in patients pretreated with crizotinib and platinum-based doublet 
chemotherapy (Shaw, Kim, et al., 2017). The most common adverse events 
associated with ceritinib were diarrhoea, nausea, vomiting, fatigue, rise in ALT 
and AST (Kim et al., 2016; Shaw, Kim, et al., 2017).  
1.6.1.2. Alectinib 
Alectinib is an orally available, highly potent and selective small molecule 
inhibitor of ALK. Preclinical studies have demonstrated that alectinib is active 
against the crizotinib-resistant ALK mutations including L1196M, F1174L, 
C1156Y, G1269A, 1151Tins and L1152R, but less potent against G1202R ALK 
mutation (Kodama et al., 2014; Sakamoto et al., 2011). Alectinib was granted 
breakthrough therapy designation in 2013 and was finally approved in 2015 by 
the FDA for the treatment of metastatic ALK-positive NSCLC patients who had 
progressed on crizotinib (Larkins et al., 2016). In phase I/II trial, alectinib 
demonstrated promising anti-tumour activity in crizotinib resistant ALK-
positive NSCLC patients, including those with CNS metastases. It also 
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confirmed grade 3 neutropenia and headache as the dose-limiting toxicities and 
determined 600 mg BID as a recommended dose for phase II trials (Gadgeel et 
al., 2014). A single-group, multicentre, phase II trial evaluated the efficacy and 
safety of alectinib in crizotinib resistant ALK-positive NSCLC patients. Alectinib 
showed promising efficacy and was well tolerated (Shaw, Gandhi, et al., 2016). 
Furthermore, two phase III trials compared the efficacy of alectinib over 
crizotinib in treatment naïve ALK-positive NSCLC patients. Both studies 
demonstrated the superiority of alectinib over crizotinib with improved mPFS 
(Hida et al., 2017; Peters et al., 2017). These results led to the approval of alectinib 
by the FDA in 2017 (U.S. Food and Drug Administration, 2017a). The common 
adverse event associated with alectinib were grade 1-2: constipation, fatigue, 
myalgia, peripheral oedema and grade 3-4 increase in blood creatine 
phosphokinase, ALT and AST (Shaw, Gandhi, et al., 2016).  
1.6.1.3. Brigatinib 
Brigatinib is an orally available, potent multiple tyrosine kinase inhibitors 
of ALK, ROS1, fms like tyrosine kinase 3 (FLT3) and EGFR (Huang et al., 2016; 
Zhang et al., 2016). Cell based studies have demonstrated broad spectrum 
activity of brigatinib against ALK mutations conferring resistance to ALK-TKIs 
including L1196M, C1156Y, 1151Tins, D1203N, F1174L/V, E1210K, G1269A, 
V1180L, I1171N but less potency against G1202R mutation (Gainor et al., 2016; 
Zhang et al., 2016). In a single-arm phase I/II trial, brigatinib demonstrated 
promising clinical activity with an acceptable safety profile. A dose escalation 
phase I study established grade 3 increased ALT (240 mg daily) and grade 4 
dyspnoea (300 mg daily) as dose limiting toxicities and determined 180 mg daily 
as the recommended dose for phase II trial. However, due to early pulmonary 
toxicity at 180 mg, two additional regimens were assessed, 90 mg once daily and 
180 mg once daily with a 7-day lead-in at 90 mg daily (Gettinger et al., 2016). In 
a randomised, multicentre phase II trial, two regimens of brigatinib were 
evaluated in crizotinib refractory ALK-positive NSCLC patients. Brigatinib 
demonstrated substantial and better response along with intracranial disease 
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control (Kim et al., 2017). Furthermore, in phase III (ALTA-1L) trial, brigatinib 
demonstrated superior efficacy over crizotinib in crizotinib naïve ALK-positive 
NSCLC patients with a higher rate of PFS at 1 year (67% vs 43%), ORR (71% vs 
60%) and intracranial response (78% vs 29%) (Camidge et al., 2018). The most 
common adverse event associated with brigatinib included grade 1-2 nausea, 
fatigue, diarrhea and grade 3-4 elevated lipase, dyspnoea, hypertension, 
elevated CPK and pneumonitis (Camidge et al., 2018; Gettinger et al., 2016). 
1.6.1.4. Loratinib 
Loratinib is a novel highly potent, selective, ATP competitive small 
molecule inhibitor of ALK and ROS1. It is effective against all known mutation 
(L1196M, C1156Y, L1198F, E1210K, L1152R, S1206Y G1269A, 1151Tins, 
F1174L/C) including the highly resistant G1202R mutation (Gainor et al., 2016; 
Johnson, Richardson, et al., 2014; Zou et al., 2015). A single-arm phase I trial 
demonstrated robust systemic and intracranial activity of loratinib in metastatic 
ALK-positive NSCLC patients, most of whom had brain metastases and had 
been pre-treated with two or more TKIs. The study selected a phase 2 dose of 100 
mg OD but failed to identify MTD (Shaw, Felip, et al., 2017). A phase II trial 
further confirmed the efficacy of loratinib in both treatment naïve and ALK-TKI 
pretreated ALK-positive NSCLC patients. Adverse events associated with 
loratinib were hypercholesterolaemia, hypertriglyceridemia, peripheral 
neuropathy and oedema (Solomon et al., 2018). A recent study reported greater 
efficacy of loratinib in patients harbouring ALK mutation compared with 
patients without ALK mutation. They also suggested that tumour genotyping 
for ALK mutation may identify patients who are more likely to benefit from 
loratinib (Shaw et al., 2019). Currently, randomised phase III trial is ongoing, 
where loratinib is being compared with crizotinib in treatment naïve ALK-
positive NSCLC patients (ClinicalTrials.gov National Library of Medicine (US), 
2017). 
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1.6.2. Upfront combination therapy 
Although mono or sequential therapy of ALK-TKIs is highly effective in 
treatment of ALK-TKIs naïve/refractory ALK-positive NSCLC patients, 
acquired resistance invariably develop (Lin et al., 2017; Metro et al., 2017; 
Recondo et al., 2020). Combination therapy is another effective strategy that can 
overcome and delay the emergence of resistance (Bozic et al., 2013; Crystal et al., 
2014; Lovly & Pao, 2012; Zhou & Cox, 2015). The combination of two drugs 
targets key pathways in a synergistic or additive manner that in turn enhances 
therapeutic efficacy even at lower dose (Bayat Mokhtari et al., 2017; Saputra et 
al., 2018). This strategy requires an understanding of the most critical signalling 
event essential for the proliferation and survival of tumour cells (Hrustanovic et 
al., 2015). In patients with identified bypass tracks, co-targeting primary 
oncoproteins and critical downstream effectors may be an effective strategy to 
overcome resistance (Crystal et al., 2014). Furthermore, Bozic et al. found that the 
combination of two drugs with no cross-resistance may result in long-term 
disease control in most patients. They also reported that upfront combination of 
two drugs to be highly effective compared to sequential therapy. They even 
suggested triple therapy in patients with a large disease burden (Bozic et al., 
2013). 
Identifying the secondary target for combination therapy requires the 
understanding of the cellular process and downstream signalling pathway that 
are critical in the survival of tumour cells. The following sections contain detailed 
information on molecular mechanism involved in tumour progression and 
downstream signalling in ALK-positive NSCLC.
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1.7. Molecular mechanism involved in regulation of tumour 
progression 
Cancer is an extremely diverse and heterogenous disease with underlying 
molecular events that drive the transformation of normal cells into malignant 
cancer cells. The underlying mechanisms that are critical for tumour progression 
include but is not limited to proliferation, apoptosis, angiogenesis (Evan & 
Vousden, 2001). Hanahan and Weinberg proposed distinct hallmarks of cancer 
that include sustained proliferation, resistance to apoptosis, induction of 
angiogenesis, activation of invasion and metastasis, deregulation of cellular 
metabolism, evading tumour suppression, and avoiding immune destruction 
(Hanahan & Weinberg, 2000, 2011). Therapeutic strategies targeting these critical 
molecular events can causes suppression in tumour growth and survival 
(Feitelson et al., 2015; Ferrara & Kerbel, 2005; Pfeffer & Singh, 2018; Zhao & Adjei, 
2015). The majority of drugs used for the treatment of cancer including ALK-
positive NSCLC either induce apoptosis or inhibit proliferation, angiogenesis to 
suppress cancer proliferation and survival (Christensen et al., 2007; Kaufmann 
& Earnshaw, 2000; Padma, 2015; Schirrmacher, 2019; Zhou et al., 2016). 
1.7.1. Proliferation 
Proliferation is a fundamental biological process that is essential for normal 
growth and development. In normal cells, proliferation is tightly regulated with 
control being a balance between growth-promoting and growth-inhibiting 
signals and is responsible for maintenance of tissue homeostasis (Barbarino et 
al., 2017). Cell proliferation depends on the rate of cell division, the fraction of 
cell undergoing cell division, and the rate of cell death (Andreeff et al., 2000). 
However, cancer cells lose their ability of control cell division, disturbing the fine 
balance between cell gain and cell loss, that causes aberrant cell proliferation and 
growth (Farber, 1995). 
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1.7.1.1.  Cell cycle 
The cell cycle is a series of event that facilitates DNA replication and 
division of a cell into two daughter cells. It consists of four sequential phases 
including first gap (G1), synthesis (S), second gap (G2) and the mitotic (M) 
phases.  S and M phase are functional phases where DNA replication occurs 
during S phase and cell division during M phase. G1 and G2 phase are 
preparatory phases that precede S and M phases, respectively. G1 and G2 phase 
are involved in protein synthesis to support the DNA synthesis and cell division 
in the following phase, respectively. G0 is a quiescent state where the cell has 
stopped dividing and exited the cell cycle. Cells in G0 phase can remain there or 
re-enter the cell cycle (Norbury & Nurse, 1992; Schafer, 1998). Cell cycle 
checkpoints ensure that the events of cell cycle occur in correct order. Two types 
of cell cycle checkpoints have been elucidated – 1) DNA damage checkpoints in 
G, S and G2 phases, and 2) spindle assembly checkpoints in the M phase. DNA 
damage checkpoints ensure that only normal DNA is replicated and passed on 
to daughter cells. In presence of damaged DNA, these checkpoints arrest the cell 
cycle that allows time for DNA repair. Spindle assembly checkpoints ensure that 
a complete set of chromosomes is passed on to daughter cells. In the presence of 
improper alignment of chromosomes on the mitotic spindle, it arrests the cell 
cycle at metaphase until accurate chromosome segregation can be guaranteed 
(Elledge, 1996; Hartwell & Weinert, 1989; Vermeulen et al., 2003).  
Cell cycle progression through each phase is regulated by two key 
regulatory molecules: cyclin dependent kinases (CDKs) and cyclins. CDKs are 
serine/threonine protein kinase that requires binding of regulatory subunits 
(cyclins) for their catalytic activity. The activated CDKs-cyclin heterodimer 
phosphorylates targeted substrate that regulates the transition of cell cycle 
phases. Association of cyclin D (D1, D2, D3) with CDK4 and CDK6 are essential 
for G1 progression, complexes of cyclin E (E1 and E2) with CDK2 are required 
for G1-S transition, complexes of cyclin A (A1 and A2) with CDK2 is required 
for progression of S phase and functions through G2, complexes of cyclin A with 
CDK1 promotes entry into M phase and association of cyclin B (B1, B2 and B3) 
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with CDK1 is required during mitosis (Lees, 1995; Nigg, 1995; Vermeulen et al., 
2003).  
The activity of cyclin-CDK complexes are regulated by different 
mechanisms – 1) synthesis and degradation of cyclins at a particular stage of the 
cell cycle, 2) activation of CDK by phosphorylation of threonine and tyrosine 
residues by CDK activating kinase (CAK), 3) deactivation of CDK by 
phosphorylation of its ATP binding site, 4) inactivation of CDKs or cyclin-CDKs 
complex by cyclin dependent kinase inhibitors (CKIs) (Lees, 1995). Two families 
of CKIs – INK4 and Cip/Kip regulate the activity of CDKs and cyclin-CDKs 
complexes. INK4 families include p16INK4A, p15INK4B, p18INK4C, and 
p19INK4D that specifically bind to and inhibit CDK4 and CDK6. Cip/Kip 
families include p21CIP1, p27KIP1, and p57KIP2 that inhibit CDK2 and CDK2-
cyclin complexes (Lees, 1995; Vermeulen et al., 2003). 
1.7.2. Apoptosis 
Apoptosis, also known as programmed cell death, is a physiological 
process that is responsible for balancing proliferation and maintaining tissue 
homeostasis (Fulda & Debatin, 2006). It also provides a defence mechanism by 
eliminating damaged, stressed and potentially dangerous cells (Norbury & 
Hickson, 2001). The term apoptosis was first used by Kerr et al. in 1972 to 
introduce a morphologically distinct type of cell death (Kerr et al., 1972). A 
typical morphological and biochemical feature of apoptosis includes membrane 
blebbing, cell shrinkage and DNA fragmentation (Hengartner, 2000; Kerr et al., 
1972). Caspases are the key effectors of apoptosis that are initially expressed as 
an inactive proenzyme. Based on their activity, caspase can be divided into – 1) 
initiators (caspase-2,-8,-9,-10), executioners (caspase-3,-6,-7) and inflammatory 
caspases (caspase-1,-4,-5). In response to cell damage, initiator caspases get 
activated that in turn activate executioner caspases. This activation initiates a 
cascade of events leading to apoptosis (Cohen, 1997; Degterev et al., 2003; Shi, 
2002).  
Chapter 1: Introduction 
43  
 
There are two major types of apoptosis pathways – the extrinsic pathway 
(the death receptor pathway) and the intrinsic pathway (the mitochondrial 
pathway) (Figure 1.5) (Igney & Krammer, 2002). Both pathways eventually 
merge to a common pathway also called as execution pathway. Dysregulation of 
these pathways can lead to various pathological conditions including cancer 
(Solary et al., 1996). 
Figure 1.5 Schematic representation of apoptotic pathway. Apoptotic pathway is 
classified into extrinsic pathway that is mediated by death receptor and intrinsic 
pathway that is initiated by cell in the response to damage and mediated by 
mitochondria. Adapted from (Baig et al., 2016; D'Arcy, 2019; Elmore, 2007). 
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1.7.2.1. Extrinsic pathway 
The extrinsic pathway is mediated by death receptors present on the cell 
surface, such as tumour necrosis factor receptor (TNF), fatty acid synthetase 
receptor (FasR), TNF-related apoptosis-inducing ligand receptor (TRAIL-R). The 
death receptor consists of a cysteine rich extracellular domain and intracellular 
cytoplasmic death domain (Ashkenazi & Dixit, 1998). Binding of death ligands 
such as fatty acid synthetase ligand (FasL) or tumour necrosis factor alpha 
(TNFα) induces oligomerisation of the receptor that causes conformational 
change and activation of death domain. This is followed by the recruitment of 
the adaptor proteins such as Fas-associated death domain (FADD) and TNF 
receptor-associated death domain (TRADD) and procaspase-8 that forms death 
inducing signalling complex (DISC) (Aggarwal, 2003; Hsu et al., 1995; Oberst et 
al., 2010; Wajant, 2002; Walczak & Sprick, 2001). DISC facilitates dimerisation 
and auto-catalytic activation of procaspase-8 to caspase 8 (Kischkel et al., 1995; 
Oberst et al., 2010). The activated caspase-8 then initiates apoptosis by activation 
of executioner caspase (Jin & El-Deiry, 2005; Kominami et al., 2012). 
1.7.2.2. Intrinsic pathway 
The intrinsic pathway is mediated by diverse internal stimuli such as 
genetic damage, hypoxia, radiation, toxins, surplus Ca 2+, oxidative stress, viral 
infections, upregulation of oncogenes and deprivation of growth factors, 
hormones and cytokines (Elmore, 2007). This pathway is tightly regulated by 
Bcl-2 family of proteins that are further divided in to anti-apoptotic/ pro-
survival (Bcl-2, Bcl-XL, Bcl-W, Bcl-B, Mcl-1, Bfl-1/A1, Bcl2l 12) or Bcl-2 homology 
3 (BH3) only proapoptotic (Bim, Bad, Puma, Bid, Noxa, Bmf, Diva, Bik) or 
proapoptotic effector (Bak, bax, bok) proteins (Tzifi et al., 2012; Warren et al., 
2019). In response to internal stimuli, BH3 only pro-apoptotic proteins are 
activated which then initiates apoptosis either by direct activation of Bcl-2-
associated X protein (Bax) and Bcl-2 antagonist/killer-1 (Bak) at the 
mitochondrion or neutralisation of anti-apoptotic Bcl-2 family proteins (Chen et 
al., 2005; Kim et al., 2006; Kuwana et al., 2005; Merino et al., 2009; Willis et al., 
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2005). The activated Bax and Bak undergoes homo-oligomerisation that 
permeabilise the mitochondrial outer membrane (Kuwana et al., 2002; Mikhailov 
et al., 2003). The mitochondrial outer membrane permeabilisation allows the 
release of various apoptogenic factors into the cytosol including cytochrome c, 
second mitochondria-derived activator of caspase/direct inhibitor of apoptosis-
binding protein with low pI (Smac/DIABLO), serine proteinase omi/high 
temperature requirement protein A Omi/HtrA (Du et al., 2000; Garrido et al., 
2006; Suzuki et al., 2001; Verhagen et al., 2000). The cytochrome c then binds to 
apoptosis protease activating factor (Apaf-1) and procaspase-9 to form a 
complex called as apoptosome (Cain et al., 2002; Riedl & Salvesen, 2007). The 
apoptosome facilitates the activation of procaspase-9 to caspase-9 that in turn 
activates the executioner caspases resulting in induction of apoptosis (Brenner & 
Mak, 2009; Cain et al., 2002; Kroemer et al., 2007; Wang, 2001). On the other hand, 
Smac/DIABLO and Omi/HtrA promote apoptosis by inhibiting the activity of 
inhibitors of apoptosis proteins (IAPs) (Du et al., 2000; Yang et al., 2003). 
1.7.2.3. Execution pathway 
Both the intrinsic and extrinsic pathway of apoptosis converge to the 
execution pathway where the executioner caspases (capases-3,-6,-7) are cleaved 
and activated by initiator caspases (Igney & Krammer, 2002). The activated 
executioner caspases, most importantly caspase-3, mediate apoptosis through 
the cleavage of multiple cellular proteins including cellular DNA repair proteins, 
structural proteins, mediators and regulators of apoptosis, and cell cycle related 
proteins (Degterev et al., 2003). Caspase-3 cleaves the inhibitor of the DNase 
caspase activated deoxyribonuclease (ICAD) and releases endonuclease, that 
migrates to nucleus and causes DNA fragmentation. Cleavage of structural 
proteins such as actin by caspase-3 leads to membrane blebbing and cell 
fragmentation (Igney & Krammer, 2002). Similarly, capase-3 mediate cleavage of 
DNA repair proteins such as poly (ADP-ribose) polymerase (PARP). PARP is a 
nuclear protein that is activated by a breakdown of single or double stranded 
DNA. PARP facilitates DNA repair by catalysing the attachment of ADP-ribose 
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polymer to multiple nuclear factor (Degterev et al., 2003; Smulson et al., 2000). 
These cleavages of cellular proteins by caspase-3 contribute to typical 
biochemical and morphological changes in apoptotic cells (Igney & Krammer, 
2002). The last step of apoptosis is the formation of apoptotic bodies that are 
recognised by the phagocytes where they are engulfed and eliminated (Elmore, 
2007; Jin & El-Deiry, 2005). 
1.7.3. Angiogenesis 
Angiogenesis is the physiological process that is involved in formation and 
growth of new capillary blood vessels from pre-existing vessels (Carmeliet, 2000; 
Hanahan & Folkman, 1996). The process of angiogenesis is complex and consists 
of multiple-steps: 1) Degradation of basement membrane and extracellular 
matrix components surrounding the endothelial tube by proteolytic enzymes, 2) 
activation and migration of endothelial cells, 3) proliferation of endothelial cells, 
4) conversion of endothelial cells into tube like structures and formation of 
capillary tubes (Fan et al., 1995). Angiogenesis generally occurs during 
embryonic development, wound healing, and female reproductive cycling. In 
normal conditions, there is a tight balance between inhibitors and inducers of 
angiogenesis (Folkman & Shing, 1992). However, this process is deregulated in 
many pathological conditions including cancer (Folkman, 1995; Nishida et al., 
2006). 
Studies have shown that tumours become dormant with tiny diameters of 
2-3 mm in the absence of neovascularisation. During tumour progression, the 
tumour itself initiates angiogenesis to sustain its growth and survival (Folkman, 
1972; Gimbrone et al., 1972; Hanahan & Folkman, 1996). There is activation of 
the angiogenic switch leading to continuous sprouting of new vessels (Hanahan 
& Folkman, 1996). Angiogenic switch is initiated by upregulation of pro-
angiogenic factors and downregulation of anti-angiogenic factors (Baeriswyl & 
Christofori, 2009; Bergers & Benjamin, 2003). The vascular endothelial growth 
factor (VEGF) is a key regulator of tumour angiogenesis (Ferrara et al., 2003; 
Yancopoulos et al., 2000). In presence of hypoxia, tumours induce the production 
Chapter 1: Introduction 
47  
 
of VEGF (Brogi et al., 1994; Shweiki et al., 1992). Binding of VEGF-A to VEGF 
receptor-2 (VEGFR-2) on endothelial cells causes receptor dimerisation and 
autophosphorylation that in turn activates several downstream signalling 
pathways including MAPK/ERK, PI3K/AKT that promotes the formation of 
new blood vessels (Hofer & Schweighofer, 2007; Munoz-Chapuli et al., 2004). 
Conversely, VEGF-B and VEGF-C binds to VEGFR-3 on lymphatic endothelial 
cells and promotes lymph-angiogenesis (Alitalo et al., 2005). Other 
proangiogenic factors that have a role in tumour angiogenesis include epidermal 
growth factor (EGF), transforming growth factor (TGF), basic fibroblast growth 
factor (FGF), platelet-derived growth factor (PDGF) (Li et al., 2018; Nishida et al., 
2006) 
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1.8.  Key signalling pathways of ALK 
Understanding the downstream signalling of ALK and the mechanism 
responsible for its deregulation provides information regarding ALK mediated 
cellular transformation and thus can be a basis for personalised therapy. Studies 
have reported several ALK downstream signalling that is best characterised 
from the ALK fusion forms such as ALK-NPM and ALK-EML4. The major 
signalling pathways downstream of ALK include RAS/MAPK, AKT/mTOR, 
JAK/STAT, PLCγ pathway (Figure 1.6) (Chiarle et al., 2008; Hallberg & Palmer, 
2013). 
 
Figure 1.6 Schematic representation of ALK downstream signalling pathway. ALK 
activation results in upregulation of downstream signalling pathway such as PLCγ, 
AKT/mTOR, RAS/MAPK and JAK/STAT that promotes cancer cell proliferation and 
survival. Adapted from (Hallberg & Palmer, 2013; Lin et al., 2017; Shaw & Solomon, 
2011; Solomon, Wilner, et al., 2014).
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1.8.1.  RAS/MAPK pathway 
The mitogen-activated protein kinase (MAPK) pathway involve highly 
conserved kinase modules that transfer extracellular signal to intracellular 
machinery that controls fundamental cellular processes such as proliferation, 
growth, differentiation, migration, apoptosis (Molina & Adjei, 2006; Morrison, 
2012; Zhang & Liu, 2002). In this pathway, binding of ligand to RTK or genomic 
alteration such as chromosomal translocation facilitates dimerisation and 
autophosphorylation of tyrosine kinase residues. Adaptor proteins such as 
growth factor receptor bound protein 2 (Grb2) contain an SH2 domain that binds 
to the phosphor-tyrosine residue of activated receptor. Adaptor proteins then 
recruit guanine nucleotide exchange factors (GEFs) such as SOS that promote the 
association of Ras with guanosine-5'-triphosphate (GTP). The GTP bound Ras 
interacts with Raf and increases its activity. The activated Raf phosphorylates 
downstream MEK, which in turn phosphorylates and activates ERK also known 
as mitogen-activated protein kinase (MAPK). The ERK then phosphorylates 
various downstream substrates in cytosol and nucleus including ribosomal S6 
kinases (RSKs), SRC-1, Elk-1, c-Fos, c-Myc that are responsible for cellular 
process (Avruch et al., 1994; Cobb & Goldsmith, 1995; Molina & Adjei, 2006; 
Roux & Blenis, 2004; Seger & Krebs, 1995). 
Dysregulation of this pathway has been reported in one third of cancers 
including ALK-positive NSCLC (Dhillon et al., 2007; Hilger et al., 2002; Hoshino 
et al., 1999). Both patient derived tissue samples and cell lines harbouring NPM-
ALK fusion showed upregulation of the RAS/MAPK pathway (Marzec, 
Kasprzycka, Liu, Raghunath, et al., 2007; Staber et al., 2007). Adaptor proteins 
such as insulin receptor substrate-1 (IRS- 1), src homology 2 containing (Shc) and 
Grb2 interact with auto phosphorylated tyrosine kinase residues of NPM-ALK 
that activates RAS/MAPK downstream signalling (Crockett et al., 2004; 
Fujimoto et al., 1996; Riera et al., 2010). Recently, Marzec et al observed direct 
activation of MEK by NPM-ALK independent of Raf (Marzec, Kasprzycka, Liu, 
Raghunath, et al., 2007).   
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The RAS/MAPK pathway has been reported to be the major downstream 
signalling pathway in ALK-positive NSCLC harbouring EML4-ALK 
(Hrustanovic et al., 2015; Zhou & Cox, 2015). EML4-ALK activates all three Ras 
isoforms (N-Ras, K-Ras, H-Ras) in the lung adenocarcinoma cells leading to 
upregulation of RAS/MAPK signalling. The HELP domain of EML4 plays an 
important role in activation of Ras. The hydrophobic residue of HELP domain 
may mediate the membrane association and access to Ras. However, deletion of 
the HELP domain impaired the ability of EML4-ALK to activate Ras and its 
downstream RAS/MAPK signalling (Hrustanovic et al., 2015). 
1.8.2. AKT/mTOR pathway 
AKT/mTOR pathway is an important signalling network that converts 
extracellular stimuli into intracellular signals and regulates cellular function 
such as cell growth, survival, proliferation, and motility (Papadimitrakopoulou, 
2012). Phosphatidylinositol 3-kinases (PI3Ks) belongs to the family of lipid 
kinases that are divided into three classes (Class I, II, III) based on their structure 
and substrate specificity. Class I PI3Ks are heterodimers composed of catalytic 
(i.e. p110) and regulatory subunits (i.e. p85). The Class I PI3Ks are further 
divided into Class IA (PI3Kα, β, and δ), that is activated by receptors with 
tyrosine kinase activity, and Class IB (PI3Kγ), that is activated by G protein 
coupled receptors (Fruman et al., 1998). Activation and autophosphorylation of 
RTKs result in recruitment of PI3K to the plasma membrane by direct binding to 
phosphorylated tyrosine kinase residue or indirect binding to adaptor proteins 
via Src-homology 2 (SH2) domain of p85 regulatory subunits. This leads to the 
activation of a catalytic p110 subunit that in turn phosphorylates 
phosphatidylinositol-4,5-bisphosphate (PIP2) to generate phosphatidylinositol-
3,4,5-trisphosphate (PIP3). PIP3 then binds to AKT (serine/threonine protein 
kinase B) through its pleckstrin homology (PH) domain allowing the 
phosphorylation and activation of AKT by phosphoinositide dependent kinase 
1 (PDK1) at Thr308 and by the mammalian target of rapamycin complex 2 
(mTORC2) at Ser-473 (Porta et al., 2014; Yip, 2015). The activated AKT then 
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phosphorylates substrates in the nucleus and cytoplasm including inhibitory 
phosphorylation of glycogen synthase kinase 3  (GSK-3), pro-apoptotic factors 
such as Bcl-2 associated dead promoter (BAD) and Forkhead box on (FOXO), 
tuberous sclerosis protein 2 (TSC2) and activation of murine double minute 2 
(MDM2) (Porta et al., 2014; Yip, 2015). The inhibition of TSC2 leads to the 
activation of mammalian target of rapamycin (mTOR) that in turn 
phosphorylates 4E-binding protein 1 (4EBP1), and ribosomal protein S6 kinase 
beta-1 70kD (S6K1) resulting in increased protein synthesis (Porta et al., 2014; 
Yip, 2015). 
AKT/mTOR pathway is crucial for transforming the activity of EML4-ALK 
in ALK-positive NSCLC. Inhibition of this pathway reduced the growth of 
tumour in both in vitro and in vivo xenograft model of EML4-ALK-positive 
NSCLC (Chen et al., 2010; Koivunen et al., 2008). Furthermore, activation of the 
AKT/mTOR pathway has been reported in cell lines and patients derived tissue 
samples of NPM-ALK-positive anaplastic large cell lymphoma (ALCL) (Bai et 
al., 2000; Slupianek et al., 2001). Polgar et al. showed that NPM-ALK interacted 
with regulatory subunit p85 and activates PI3K and its downstream effector, 
serine/threonine kinase (Akt) (Polgar et al., 2005). The activated pathway in turn 
phosphorylated downstream substrates such as mTOR, GSK3, FOXO3 and 
promoted oncogenesis (Gu et al., 2004; Marzec, Kasprzycka, Liu, El-Salem, et al., 
2007; McDonnell et al., 2012).   
1.8.3. JAK/STAT pathway 
The JAK/STAT pathway communicates information from extracellular 
stimuli to the cell nucleus and plays an important role in cell proliferation, 
survival, differentiation and apoptosis (Harrison, 2012). There are four members 
of the JAK family (JAK1, JAK2, JAK3, TYK2) and seven members of STATs 
(STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, and STAT6) (Aaronson & 
Horvath, 2002). Dimerisation of receptor brings JAKs into close proximity that 
allows transphosphorylation and activation of JAKs. The activated JAKs then 
phosphorylate tyrosine kinase residue of receptors, thereby creating docking 
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sites for adaptor proteins including STATs. STATs when bound to the receptor 
become phosphorylated by JAKs. Activated STATs then dissociate, dimerise and 
translocate to nucleus and regulate transcription of target genes including c-Jun, 
c-Myc, Bcl-2, Mcl-1, p21waf1, and p27kip1 (Amin et al., 2003; Kisseleva et al., 2002; 
Rawlings et al., 2004).  
The JAK/STAT pathway is constitutively active in NPM-ALK-positive 
ALCL. Some studies have reported that JAK3 binding and activation is essential 
for activation of STAT3 by NPM-ALK. While others have suggested that 
activation of STAT3 by NPM-ALK is independent of JAK3. The activated STAT3 
then regulates the transcription of proteins such as c-Myc, survivin, Bcl-2, cyclin 
D1 and promotes cell survival of NPM-ALK-positive ALCL (Amin et al., 2003; 
Chiarle et al., 2005; Marzec et al., 2005; Zamo et al., 2002). Moreover, the 
JAK/STAT pathway is also important for transforming the activity of EML4-
ALK in ALK-positive NSCLC (Roux & Blenis, 2004) 
1.8.4.  PLCγ pathway 
The PLCγ pathway is involved in regulation of cellular process such as cell 
proliferation, differentiation, survival and migration (Falasca et al., 1998). Two 
isoforms PLCγ1 and PLCγ2 have been identified where each isoform has a 
putative pleckstrin homology (PH) domain, two catalytic domains separated by 
two SH2 domains, an SH3 domain and a putative split PH domain (Carpenter & 
Ji, 1999; Falasca et al., 1998). Activation of the receptor facilitates the binding of 
PLCγ to tyrosine phosphorylation sites of the receptor via the SH2 domain, 
leading to tyrosine phosphorylation and activation of PLCγ. The activated PLCγ 
in turn induces the hydrolysis of PIP2 to inositol-1,4,5-triphosphate (IP3) and 
diacylglycerol (DAG). These two molecules act as the intracellular secondary 
messengers that mediate the release of calcium from the endoplasmic reticulum 
into the cytosol as well as activates the serine/threonine, protein kinase C (PKC). 
The activated PKC then phosphorylates various substrate that are involved in 
cell cycle progression and proliferation (Berridge, 2009; Falasca et al., 1998; 
Nishizuka, 1995). 
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The activation of the PLCγ pathway in NPM-ALK- ALCL was first reported 
by Bai et al in 1998 (Bai et al., 1998). PLCγ binds to the phosphorylated tyrosine 
664 of NPM-ALK via its SH2 domain that in turn causes phosphorylation and 
activation of PLCγ. They also found that transfection of NPM-ALKY664F, 
mutation of Y664 to phenylalnine, in Ba/F3 cells abrogated its transforming 
ability (Bai et al., 1998). 
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1.9. MEK inhibitors 
MEK inhibitors are the small molecule inhibitor of mitogen activated 
protein kinase kinase enzymes (MEK1/2) (Cheng & Tian, 2017; Kim & Giaccone, 
2018; Wang et al., 2007). They have demonstrated potent anti-tumour activity in 
both preclinical and clinical study of various cancer including melanoma and 
NSCLC (Cheng & Tian, 2017; Kim & Giaccone, 2018; Wang et al., 2007). Several 
MEK inhibitors have been developed till date including trametinib, cobimetinib, 
binimetinib that are approved by the FDA for the treatment of advance 
melanoma harboring BRAF mutation (U.S. Food and Drug Administration, 
2017d, 2018a, 2020a; Wright & McCormack, 2013). Whereas some are under 
clinical trials including selumetinib, PD-325901, refametinib (Cheng & Tian, 
2017; Kim & Giaccone, 2018; Wang et al., 2007). 
1.9.1. Trametinib 
Trametinib is the first MEK inhibitor that was approved by the FDA for 
treatment of advance melanoma (Wright & McCormack, 2013). It is ATP-
noncompetitive, highly selective, allosteric inhibitor of MEK 1/2 (Abe et al., 2011; 
Gilmartin et al., 2011). Preclinical studies demonstrated the potent anti-tumour 
activity of trametinib resulting in significant tumour suppression in various 
cancers (Abe et al., 2011; Gilmartin et al., 2011; Yamaguchi et al., 2011). In clinical 
study trametinib showed the greater efficacy with prolonged PFS and overall 
survival in BRAF mutant melanoma (Falchook et al., 2012; Flaherty, Infante, et 
al., 2012; Flaherty, Robert, et al., 2012; Infante et al., 2012; Menzies & Long, 2014).  
Furthermore, combination of trametinib with BRAF inhibitor, dobrafenib 
improved OS and prolonged PFS of patients with BRAF mutation melanoma 
(Flaherty, Infante, et al., 2012; Menzies & Long, 2014). The most common adverse 
events were rash, diarrhoea, peripheral edema and dermatitis acneiform 
(Flaherty, Infante, et al., 2012; Flaherty, Robert, et al., 2012).
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1.9.2.  Cobimetinib 
Cobimetinib is selective, ATP-noncompetitive, allosteric inhibitor of MEK 
1/2 (Hoeflich et al., 2012; Rice et al., 2012). Preclinical studies in BRAF and KRAS 
mutant cells showed the broad anti-tumour efficacy of cobimetinib (Choo et al., 
2013). A phase I clinical trial investigated the pharmacokinetics, efficacy and 
safety of cobimetinib in patients with advance solid tumour (Rosen et al., 2016). 
Cobimetinib demonstrated durable response with tolerable adverse events. The 
most common adverse events were diarrhoea, rash, fatigue, nausea, vomiting 
and edema (Rosen et al., 2016). In phase III clinical trial, combination of 
cobimetinib with vemurafenib showed greater therapeutic efficacy with prolong 
PFS (12.3 months vs 7.2 months) compared to vemurafenib monotherapy in 
BRAF mutant melanoma (Ascierto et al., 2016). This has led to the approval of 
combination treatment of cobimetinib and vemurafenib by FDA in 2015. 
1.9.3.  Binimetinib 
Binimetinib is highly selective, potent, ATP-noncompetitive, allosteric 
inhibitor of MEK 1/2 (Bendell et al., 2017; Watanabe et al., 2016). Binimetinib 
alone demonstrated potent anti-tumour activity in preclinical model of various 
cancer (Lee, Wallace, et al., 2010). A phase II study evaluated the therapeutic 
efficacy and safety of binimetinib in advanced melanoma patients harbouring 
NRAS or BRAF mutation (Ascierto et al., 2013). Binimetinib showed anti-tumour 
activity in patients with NRAS or BRAF mutation. The most frequent adverse 
events were acneiform dermatitis, rash, facial oedema, diarrhoea (Ascierto et al., 
2013). A phase III clinical trial compared the binimetinib monotherapy with 
dacarbazine. Binimetinib demonstrated greater efficacy with improved PFS 
compared to dacarbazine (Dummer et al., 2017). 
Among various MEK inhibitor available, in this thesis, selumetinib was 
selected for the combination with crizotinib. The detail information of 
selumetinib is given in following section 1.10.




Selumetinib (AZD6244: ARRY-142866) is chemically described as 6-(4-
bromo-2-chloroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-
5-carboxamide and has the molecular formula C17H15BrClFN4O3 and molecular 
weight of 457.681403 g/mol (Figure 1.7). It is an orally available, potent, non-
ATP competitive inhibitor of marker extraction kernel 1/2 (MEK 1/2) that can 
effectively suppress RAS/MAPK pathway. Selumetinib is highly selective for 
MEK1/2 compared to more than 40 other kinases at a concentration of 10 
µmol/L. It inhibits the enzymatic kinase activity of purified constitutively active 
MEK1 with an IC50 of 14 µmol/L. (Yeh et al., 2007). Binding of selumetinib to the 
allosteric-inhibitor binding site in MEK1/2 induces conformational changes that 
inhibit the catalytic activity of MEK, resulting in an inhibition of ERK 
phosphorylation and its downstream signalling (Davies et al., 2007; Yeh et al., 
2007). 
 
Figure 1.7 Chemical structure of selumetinib. (Figure is obtained from Wikipedia 
licensed under Creative Commons CC0 1.0 Universal Public Domain Dedication) 
1.10.1. Pharmacokinetics 
The MTD of selumetinib free base suspension and hydrogen sulphate 
capsule is 100 mg BID and 75 mg BID, respectively (Adjei et al., 2008; Banerji et 
al., 2010). After the administration of a single dose of free-base suspension, the 
median terminal half-life (t1/2) was 8 h (Adjei et al., 2008). Similarly, after the 
administration of a single dose of hydrogen sulphate capsule, the Cmax was 
reached after 1-1.6 h with a mean t1/2 of 5-8 h. The total body clearance (CL/F) 
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and volume of distribution at steady state (Vss/F) were consistent across the 
range of doses, with mean values of 12-23.1 h and 87-126.1 L, respectively. 
Furthermore, the comparison of pharmacokinetics (PKs) of two formulations 
demonstrated significantly higher maximum plasma concentration (1316 
ng/ml vs. 523 ng/mL) and AUC over 24 h (4454 ng/mL/h vs. 2260 ng/mL/h) 
of hydrogen sulphate capsule compared to freebase solutions (Banerji et al., 
2010). The administration of selumetinib with food decreased the Cmax and 
AUC by 62% and 19%, respectively, compared with fasting. In the presence of 
food, the rate of absorption of selumetinib was delayed by approximately 2.5 
h. Therefore, selumetinib is recommended to be taken on an empty stomach 
(Leijen et al., 2011). 
 In vitro studies showed that selumetinib may be metabolised via CYP 
enzymes and uridine diphosphate glucuronosyltransferase (UGT) (Dymond et 
al., 2016; Dymond et al., 2017). Leijen et al. reported that selumetinib is 
metabolised in the liver through CYP1A2, CYP2C19 and CYP3A4 (Leijen et al., 
2011). Thus, coadministration of selumetinib with potent CYP3A4/CYP2C19 
inducers or inhibitors may alter the plasma concentration of selumetinib 
(Dymond et al., 2017). Selumetinib is likely to be eliminated through 
glucuronidation as the majority of selumetinib metabolites were detected as 
glucuronide conjugates (Leijen et al., 2011). Selumetinib and its metabolites are 
predominantly excreted from faeces route (59%) and moderately eliminated in 
the urine (33%) (Dymond et al., 2016).   
1.10.2. Preclinical studies 
Selumetinib causes inhibition of cellular growth in various cancer cells 
including NSCLC, colorectal, pancreatic and melanoma (Davies et al., 2007; Yeh 
et al., 2007). Yeh et al. reported that selumetinib was highly potent in cell lines 
harbouring activating RAS and B-Raf mutations. However, it had minimal effect 
on Malme-3M cell line (control cell line to melanoma), suggesting that inhibition 
of cell growth is not due to general cytotoxicity (Yeh et al., 2007). Furthermore, 
selumetinib suppressed tumour growth in an in vivo xenograft model of BRAF 
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and KRAS mutation. It exhibited potent anti-tumour activity through inhibition 
of cell proliferation and induction of apoptosis (Davies et al., 2007; Meng, Dai, et 
al., 2010). The activity of selumetinib was highly enhanced when combined with 
targeted agents such as AKT, mTOR and VEGFR inhibitors, EGFR inhibitors and 
chemotherapy drugs such as docetexal, temozolomide (Haass et al., 2008; Holt, 
Logie, Davies, et al., 2012; Holt, Logie, Odedra, et al., 2012; Meng, Dai, et al., 2010; 
Takahashi et al., 2012). Most of these combinations resulted in synergistic 
inhibition of tumour growth in preclinical in vivo studies. 
1.10.3. Clinical Studies 
Based on the promising activity of selumetinib in preclinical models, 
several clinical studies have been performed in patients with advanced cancer to 
evaluate the efficacy of selumetinib as a monotherapy or in combination with 
cytotoxic agents such as docetaxel and targeted agents such as VEGFR, EGFR 
inhibitors.  
1.10.3.1.  Phase I trials 
Two phase I studies were performed to evaluate tolerability, PKs, 
pharmacodynamics (PDs) of selumetinib (formulated as free base suspension 
and hydrogen sulphate capsule) in patients with advanced cancer (Adjei et al., 
2008; Banerji et al., 2010). The MTD for selumetinib free base suspension was 200 
mg BID, but a lower dose level (100 mg BID) was recommended for phase II trials 
due to the presence of a dose-dependent increase in the frequency and severity 
of rash. The most frequent and dose-limiting toxicity was rash, occurring in 
almost 74% of all patients. Other most common adverse events were grade 1-2 
diarrhoea, nausea, fatigue and grade 3-4 oedema and elevation of ALT (Adjei et 
al., 2008). The adverse events were mostly dose dependent and was resolved 
after dose interruption or reduction (Adjei et al., 2008; Banerji et al., 2010). The 
MTD for selumetinib formulated as hydrogen sulphate capsule was 75 mg BID. 
The toxicity profile was similar to that observed with the free-base suspension of 
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selumetinib. The most common toxicities included fatigue, acneiform, nausea, 
dermatitis, diarrhoea, peripheral oedema (Banerji et al., 2010). 
Phase I trial evaluated the safety, tolerability, PKs and MTD of selumetinib 
in combination with docetaxel 75 mg/m2 iv or dacarbazine 1000 mg/m2 iv 
administered every 21 days in patients with advanced solid tumours. The MTD 
of selumetinib in combination with docetaxel or dacarbazine was 75 mg BID. The 
common adverse events were peripheral oedema, diarrhoea, fatigue, nausea, 
vomiting (LoRusso et al., 2017). Furthermore, phase I trials investigated the 
combination of selumetinib with targeted agents such as vandetanib (dual EGFR 
and VEGFR inhibitor), gefitinib, erlotinib (EGFR inhibitor), temsirolimus (mTOR 
inhibitor) (ClinicalTrials.gov National Library of Medicine (US), 2012, 2013; 
Infante et al., 2017). The main aims were to determine the safety, toxicity and PKs 
profile of these combinations and establish the MTD. The MTD of selumetinib in 
combination with vandetanib was 100 mg OD or 50 mg BID. (Saka et al., 2015). 
The MTD of selumetinib recommended in combination with erlotinib 100 mg od 
was 100 mg and with temsirolimus 25 mg once weekly was 50 mg BID. The 
combinations had overlapping toxicities, but PK profile was similar to 
monotherapy (Infante et al., 2017).  
1.10.3.2.  Phase II trials 
In a phase II trial, efficacy of selumetinib was evaluated over pemetrexed 
as a second- or third-line treatment in patients with advanced NSCLC. 84 
patients were randomised to receive selumetinib 100 mg oral free-based 
suspension BID or pemetrexed 500 mg/m2 every 3 weeks. This study failed to 
show the superiority of selumetinib monotherapy over pemetrexed with mPFS 
of 67 and 90 days, respectively. Disease progressions were observed in 28 (70%) 
and 26 (59%) patients in the selumetinib and pemetrexed groups, respectively 
(Hainsworth et al., 2010). 
A multicentre phase II trial evaluated the efficacy and safety of selumetinib 
in combination with docetaxel in previously treated advanced KRAS-mutant 
NSCLC patients. 87 patients were randomised in 1:1 ratio to receive docetaxel 75 
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mg/m2 iv. every 21 days in combination with either selumetinib hydrogen-
sulphate capsules 75 mg BID (n=44) or placebo (n=43). The selumetinib 
treatment group had improvement in median OS (9.4 vs. 5.2 months), mPFS (5.3 
vs. 2.1 months), ORR (37% vs. 0%) compared to placebo. The adverse events were 
more common in the selumetinib group that included grade 3-4 neutropenia, 
febrile neutropenia and asthenia (Janne et al., 2013). 
The clinical efficacy of the combination of selumetinib and erlotinib was 
investigated in randomised phase II trial. Patients (n=89) were divided into two 
groups based on the presence of KRAS mutation. The combination failed to show 
improvement in ORR or PFS compared to selumetinib monotherapy in both 
groups. Furthermore, combination treatment increased toxicities, thereby 
suggesting the requirement of dose reduction (Carter et al., 2016).  
1.10.3.3. Phase III trials 
A randomised, double blinded phase III trial (SELECT-1) was conducted to 
assess the safety and efficacy of selumetinib plus docetaxel compared with 
docetaxel alone as a second line treatment in advanced NSCLC bearing KRAS 
mutation. The primary end point was PFS and secondary end points were ORR, 
OS, duration of response and safety and tolerability. The combination of 
selumetinib and docetaxel failed to meet the primary end point with no 
significant difference in PFS between combination and docetaxel group (3.9 vs. 
2.8 months, respectively). The median OS was 8.7 months with the combination 
and 7.9 months with docetaxel alone. ORR was slightly higher in the 
combination group (20.1%) compared to docetaxel (13.7%). Furthermore, 
adverse events of grade 3 or higher were more common with combination (67%) 
than docetaxel (45%) (Janne et al., 2017). 
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1.11. Hypothesis and Aims 
1.11.1. Hypothesis 
1. The combination of crizotinib and selumetinib will produce improved 
efficacy in both crizotinib naïve and crizotinib resistant ALK-positive 
NSCLC cells.  
2.  The combination treatment will suppress the major downstream 
RAS/MAPK signalling pathway. 
3.  The combination treatment will reduce tumour growth by induction of 
apoptosis and inhibition of proliferation. 
4. Administration of crizotinib and selumetinib will be safe in vivo with no 
drug interaction. 
5. An orthotopic model of lung cancer can be developed via tail vein 
injection of ALK-positive NSCLC cells (H3122). 
1.11.2. Aims 
1. To investigate the effect of crizotinib or selumetinib and their combination 
treatment in crizotinib naïve and crizotinib resistant ALK-positive 
NSCLC cell lines. 
2. To examine potential molecular mechanism behind the synergistic effect 
of crizotinib and selumetinib combination treatment. 
3. To examine the efficacy of crizotinib and selumetinib combination 
treatment in a xenograft model of ALK-positive NSCLC. 
4. To evaluate the preclinical toxicity of crizotinib and selumetinib 
combination therapy in male Balb/c mice. 
5. To establish an orthotopic lung cancer model in male 
immunocompromised SCID mice. 
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Crizotinib is a first generation ALK-TKI that demonstrated superiority over 
standard chemotherapy, with longer progression free survival and a higher 
objective response rate (Solomon, Mok, et al., 2014). Crizotinib has been rapidly 
followed by second and third generation ALK inhibitors such as ceritinib, 
alectinib, brigatinib and lorlatinib (Lin et al., 2017). Despite the marked anti-
tumour activity of crizotinib and other ALK inhibitors, cancer drug resistance 
develops typically within a few years of treatment. 
Mechanisms of resistance to crizotinib involve the alteration of the target 
gene itself either by mutation or amplification, and activation of bypass 
signalling pathways (Choi et al., 2010; Doebele et al., 2012; Heuckmann et al., 
2011; Hrustanovic et al., 2015; Katayama et al., 2012; Sasaki et al., 2011; Tanizaki, 
Okamoto, Okabe, et al., 2012; Zhang, Wang, et al., 2011) . Some mediators in these 
signalling pathways are druggable targets and have been under investigation for 
combination drug treatment. Upfront combination drug treatment of several 
targets has been argued as one strategy to delay or overcome drug resistance 
(Crystal et al., 2014; Zhou & Cox, 2015). Bozic et al. have argued that the 
probability of a combination being curative increases if the mutation of the 
locations in the genome that confer resistance to the combination decreases 
(Bozic & Nowak, 2016; Bozic et al., 2013). Following this, the drug targets was 
termed “independent” if mutations that provide resistance to drugs against one 
target in a combination do not necessarily cause resistance to drugs against the 
other target(s).  
ALK overexpression and constitutive activation is unique to ALK-positive 
NSCLC cells; thus, with a highly specific first target established, the search for 
secondary targets is facilitated. One strategy to this search is to investigate 
mediators of bypass signalling pathways as co-targets for combination with ALK 
inhibitors. These include RTKs such as EGFR, IGFR, HER2 and cKIT, or mutation 
in EGFR or KRAS. These can regulate downstream signalling independently, 
promoting the growth and survival of cells irrespective of ALK inhibition 
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(Hrustanovic et al., 2015; Katayama et al., 2012; Lovly et al., 2014; Sasaki et al., 
2011; Tanizaki, Okamoto, Okabe, et al., 2012). Promisingly, Hrustanovic et al. 
have demonstrated in vitro and in vivo that targeting MEK together with ALK in 
cancer cells harbouring EML4-ALK is highly effective at suppressing cell 
proliferation compared to inhibition of either target alone (Hrustanovic et al., 
2015). Upfront combination of ALK and MEK inhibition has improved the 
response in a preclinical model of EML4-ALK NSCLC, and in a patient-derived 
acquired resistant cellular model of EML4-ALK (Crystal et al., 2014). 
In this study, the dual inhibition of ALK and MEK was further investigated 
in ALK-positive NSCLC. Selumetinib, a potent, non-ATP competitive inhibitor 
of marker extraction kernel 1/2 (MEK1/2), was selected as a co-target for the 
upfront combination. Selumetinib inhibits the phosphorylation of MEK and 
downregulates the RAS/MAPK signalling pathway (Yeh et al., 2007). It has 
demonstrated potent anti-tumour activity in preclinical and clinical trials of 
various cancers including NSCLC (Davies et al., 2007; Garon et al., 2010; 
Hainsworth et al., 2010).  
Furthermore, the ALK-positive NSCLC cell line (H3122) was used in this 
study to explore the effect of combination and its underlying mechanism of 
inhibition of cancer cell proliferation. H3122 cells were derived from the pleural 
fluid of a 54-year-old female patient with stage IV adenocarcinoma (Fujishita et 
al., 2003). Various ALK-positive NSCLC cell lines such as H3122, STE-1, DFCI032 
and H2228 cells are available (Koivunen et al., 2008; Lovly et al., 2014). H3122, 
DFCI032 and STE-1 cells harbour EML4-ALK E13:A20 (variant 1) resulting from 
the fusion of exon 13 of EML4 and 20 of ALK. Whereas H2228 cells harbour 
EML4-ALK E6a/b: A20 (variant 3) resulting from the fusion of exon 6 of EML4 
with exon 20 of ALK (Koivunen et al., 2008; Lovly et al., 2014). H3122 cells were 
chosen in this study as they harbour EML4-ALK variant 1 that is commonly 
expressed in NSCLC (Cha et al., 2016; Koivunen et al., 2008; Sabir et al., 2017; 
Yoshida et al., 3383). H3122 cells are highly sensitive to ALK inhibitor 
(particularly to crizotinib) and are clinically relevant to human treatment (Cha et 
al., 2016; Sabir et al., 2017; Yoshida et al., 3383). 
Chapter 2: Exploring the anti-cancer activity of combination of crizotinib and selumetinib 
65  
 
2.2.  Aims and objectives 
The aims of this chapter were (1) to explore if the combination of 
ALK/MEK inhibition is consistent with “independent” drug action as described 
above, (2) to investigate whether the development of ALK-inhibitor resistance 
leads to cross-resistance to MEK inhibition, (3) to examine whether the combined 
drug action was greater than that predicted by a Loewe model – a model for 
measuring the effect of drug combinations, (4) to explore the molecular 
mechanism behind the superiority of combination over single-drug treatment.  
The specific objectives were: (1) to determine the effect of crizotinib and 
selumetinib single drug treatment on cell viability of ALK-negative (A549), 
crizotinib naive (H3122) and crizotinib resistant (CR-H3122) ALK-positive 
NSCLC cell lines, (2) to examine the combined effect of crizotinib and 
selumetinib on cell viability of A549, H3122 and CR-H3122 cell lines, (3) to 
determine the effect of the combination on downstream RAS/MAPK signalling 
pathway, (4) to evaluate the effect of the combination on cell cycle phases and 
mode of cell death, (5) to determine the effect of the combination on the 
endogenous expression of proteins involved in cell cycle and apoptosis. 
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2.3. Methods and Materials 
2.3.1. Materials 
2.3.1.1. Chemical reagents 
Crizotinib and selumetinib were purchased from LC laboratories (Woburn, 
MA, USA). Bovine serum albumin (BSA), Foetal bovine serum (FBS), 
penicillin/streptomycin, Rosswell park memorial institute medium (RPMI), 
TrypLE Express were purchased from Life Technologies (Auckland, New 
Zealand). Acrylamide (1:30) and precision plus protein kaleidoscope were 
obtained from Bio-Rad Laboratories (Hercules, CA, USA). CL-XPosure film, 
supersignal west pico were obtained from Thermo Fisher Scientific (Auckland, 
New Zealand). Acetic acid, ammonium persulphate, bicinchoninic acid (BCA) 
solution, bromophenol blue, citric acid, copper sulphate (CuSO4), 
Ethylenediaminetetraacetic acid (EDTA), 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), nonidet P-40 (NP-40), 
phenylmethanesulfonyl fluoride (PMSF), phosphate buffered saline (PBS), 
ponceau red stain, propidium iodide (PI), sodium dodecyl sulphate  (SDS), 
sodium bicarbonate (NaHCO3), sodium chloride (NaCl), sodium orthovanadate 
(Na3VO4), tetrasodium pyrophosphate (Na4P2O7), sodium fluoride (NAF), 
sodium hydroxide (NaOH), sulforhodamine B (SRB), trizma base, trizma 
hydrochloride (Tris-HCL), triton-x 100, N,N,N,N-tetramethyethylene diamine 
(TEMED), hydrochloric acid (HCl), dimethyl sulfoxide (DMSO), and Propidium 
iodide were purchased from Sigma- Aldrich (St Louis, MO, USA). FxCycle 
PI/RNase was from Life Technologies (Carlsbad, CA, USA). Annexin V-APC 
and Ac-DEVD-AFC caspase-3 fluorogenic substrate were purchased from BD 
Biosciences (San Jose, CA, USA). Trichloroacetic acid (TCA) was purchased from 
Global Science (Auckland, New Zealand). Glycine and polyoxyethylene (20) 
sorbitan monolaurate were from Calbiochem (San Diego, CA, USA). 
Polyvinylidene fluoride (PVDF) membrane was purchased from Millipore 
Corporation (Ramona, CA, USA). Milk powder was purchased from Pam’s 
product limited (Auckland, New Zealand). 




Antibodies against ALK (D5F3), p-ALK (Tyr1604), p-ERK, Bcl2, Bim, PARP, 
cleaved PARP, caspase-3, cleaved caspase-3, cyclinD1, P27 were purchased from 
Cell Signaling Technology (Danvers, MA, USA). Erk1/2, β-tubulin were 
obtained from Sigma Aldrich (St Louis, MO, USA). HRP-conjugated goat anti-
rabbit and HRP-conjugated goat anti-mouse were obtained from Calbiochem 
(San Diego, CA, US). 
2.3.2. Methods 
2.3.2.1. Cell culture 
The human adenocarcinoma ALK-positive non-small cell lung cancer 
(H3122) cell line harbouring EML4-ALK variant 1 fusion gene was gifted from 
Professor Daniel Costa, Harvard University. Human adenocarcinoma non-small 
cell lung cancer cell line (A549) harbouring K-RAS gene codon 12-point mutation 
was kindly provided by Dr Gregory Giles, University of Otago. Crizotinib-
resistant ALK-positive non-small cell lung cancer (CR-H3122) cells were 
generated as described in Wilson et al. (Wilson et al., 2017). Briefly, H3122 cells 
were cultured with increasing concentrations of crizotinib starting from 0.4 µM 
for 24 h followed by 0.56 µM for the next 24 h. Cells were then maintained in 0.80 
µM from the 3rd day to 4 months. The Media was changed every 2-3 days 
supplemented with crizotinib (0.80 µM), 10% foetal bovine serum (FBS), 
penicillin (100 U/mL), streptomycin (100 μg/mL). H3122 and A549 cells were 
maintained in Rosswell Park Memorial Institute medium (RPMI) supplemented 
with penicillin (100 U/mL), streptomycin (100 μg/mL) and 5% and 2% of FBS, 
respectively.  
Cells were cultured in 75 cm2 culture flask and incubated at 37° C, 5% CO2, 
95% humidified air. Cells were passaged under the aseptic condition when 90% 
confluency was reached. Cells were washed with 5 ml of isotonic phosphate 
buffered saline (1x PBS) solution twice and then incubated with trypsin solution 
(2.69 mM EDTA, 1g/L trypsin, 0.14 M NaCl, 76.78 mM Tris HCl; pH 8) for 2-3 
minutes such that all the cells were detached from the flask. An equal volume of 
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media was added to the flask and cells were collected and transferred into a 50 
ml conical tube. This was followed by centrifugation at 1200 rpm for 3 mins at 
4oC. The supernatant was discarded, and cell pellets were suspended in fresh 
growth media. All the procedures were performed in a biosafety cabinet to 
prevent any cross-contamination. Cell count was performed under a microscope 
by using a haemocytometer and the required number of cells was used for 
respective experiments. 
2.3.2.2. Cell viability assay 
H3122, A549, CR-H3122 were seeded in triplicate into a 96 well plate at the 
concentration of 7×103, 4×103, and 10×103 cells per well, respectively, and were 
incubated at 37oC, 95% humidified and 5% CO2 for 24 h. Next, cells were treated 
with a respective concentration of drug solution made in DMSO and was further 
incubated for 72 h. Vehicle control cells were treated with 0.1-0.5% of DMSO.  
To determine the inhibitory effect of crizotinib, selumetinib, and their 
combination on cell survival, the sulforhodamine B (SRB) colourimetric assay 
was performed as described by Skehan et al. (Skehan et al., 1990). Briefly, after 
72 h of drug treatment, the media was aspirated, and cells were fixed using 0.5 
ml of 10% trichloroacetic acid (TCA) solution. The plates were incubated at 4°C 
for 30 min followed by washing with distilled water (dH2O) for 3 times. Next, 
plates were either air-dried overnight at room temperature or dried in a hot air 
drier for 45 min. Cells were then stained by adding 0.5 mL of SRB (0.4% of SRB 
made in 1% acetic acid) and incubated for 10 min at room temperature. SRB 
binds to basic amino acids residues under mild acidic conditions, thereby giving 
pink staining to the protein. SRB reagent was aspirated off the plate and 
remaining unbound SRB stain was removed by washing with 1% acetic acid for 
three times. The plates were dried in a hot air drier for 45 min followed by 
addition of 0.1 mL of 10 mM Tris base pH 10.5 and incubation for 10 min at room 
temperature to allow the solubilization of SRB in Tris solution. The absorbance 
was read at 510 nm using Spectramax Plus plate reader and data was obtained 
by SoftMax Pro software. The amount of dye extracted from stained cells is 
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proportional to the cell mass which can be extrapolated to measure cell number 
(Orellana & Kasinski, 2016; Vichai & Kirtikara, 2006). The standard calibration 
curve was used to determine the cell number. The concentration of each drug 
required to reduce the cell viability by 50% (IC50) was determined by nonlinear 
regression using Graphpad Prism software. Three independent experiments 
were performed in triplicate. 
2.3.2.3. Western blotting 
Cell lysate preparation 
H3122 and CR-H3122 cells were seeded in Petri dishes at a density of 2.0 × 
106 cells per dish and incubated in 5% CO2, 95% humidified air, 37° C for 24 h. 
H3122 cells were treated with vehicle (DMSO 0.1%), crizotinib (0.25 µM), 
selumetinib (7.5 µM) and their combination for 24 h and 48 h. CR-H3122 cells 
were treated with vehicle (DMSO 0.1%), crizotinib (2.5 µM), selumetinib (7.0 µM) 
and their combination for 24 h. On the following day, cells were washed with 5 
ml of ice-cold 1x PBS (isotonic) for two time and lysed with lysis buffer (50 mM 
Tris base (pH-7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 0.5% NP-40, 0.5% 
SDS, 1 mM sodium orthovanadate, 2.5 mM sodium pyrophosphate, 10 mM 
sodium fluoride, 1 mM PMSF, complete protease inhibitor cocktail and 
phosphatase inhibitor). Cells were scraped with a scraper and then collected in 
a 1.5 mL Eppendorf tube. Cell lysates were sonicated three times for 7 sec each 
followed by centrifugation at 14000 rpm for 8 min at 4oC. The supernatant was 
transferred to a new Eppendorf tube before protein concentration was 
determined. 
Bicinchoninic Acid (BCA) assay 
The protein concentration of cell lysates was determined by bicinchoninic 
acid (BCA) assay as described in Smith et al. (Smith et al., 1985). Briefly, bovine 
serum albumin protein standard 0.5 mg/mL was used to obtain the standard 
curve. First, 2 µL of cell lysate of each sample was pipetted into 96 well plates in 
triplicate. BCA solution (50:1) was prepared freshly by adding 50 volumes of 
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BCA and 1 volume of 4% copper sulphate pentahydrated (CuSO4.5H2O) 
solution. BCA solution (200 µL) was added to each well and incubated in dark at 
37oC. Absorbance was measured at 562 nm using Biorad Benchmark Plus 
microplate reader and data was obtained from Microplate Manager Software. A 
standard curve was used to determine the protein concentration of samples and 
each sample was normalised to obtain 2 µg/ µL of protein. 4x laemmli sample 
buffer (62.5 mM Tris HCl, 1% SDS, 10% glycerol, 0.005% bromophenol blue, 355 
mM β-mercaptoethanol, pH 6.8) was added to each sample and denatured by 
boiling at 95oC for 5 min. The samples were frozen at -20oC until required. 
Gel electrophoresis 
Sodium dodecylsulphate-polyacrylamide gel (SDS-PAGE) electrophoresis 
was used to separate proteins based on their molecular weight (MW) as 
described in Laemmli, 1970 (Laemmli, 1970). Different percentage of resolving 
gel ranging from 10% to 12% (30% acrylamide/bisacrylamide (29:1) solution, 1.5 
M lower Tris buffer, pH8.8, 50% glycerol, 10% APS, H2O, TEMED) and a stacking 
gel (30% acrylamide/bisacrylamide (29:1) solution, 0.5 M upper Tris buffer, 10% 
of APS, dH2O, TEMED) was made depending upon the type of proteins of 
interest. Samples were defrosted and 20 µL of protein was loaded on each well 
of gels. Molecular weight protein marker was loaded in each gel to identify the 
respective proteins based on their molecular weight. Gels were run in Bio-Rad 
Mini-Protean III apparatus at 80 V in SDS-running buffer (25 mM Tris-base, pH 
8.3, 0.192 M glycine, 0.1% (w/v) SDS) for approx. for 20 mins until the protein 
get migrated to the end of stacking gel. Then, the voltage was increased to 120 V 
until the protein reached to the bottom of resolving gel.  
Transfer and Antibody staining 
The proteins were transferred to methanol activated PVDF membrane in 
transfer buffer (25 mM Tris-base, pH 8.3, 0.192 M glycine and 10% methanol) 
using Bio-Rad wet transfer system at 100 V for 1.5 h. After the completion of the 
transfer, membranes were washed with TBS (0.025 mM Tris-base, 0.1 M NaCl, 
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pH 7.4) and stained with ponceau red for 1 min. Next, membranes were washed 
with TBST (0.025 mM Tris-base, 0.1 M NaCl, pH 7.4 and 0.5% Tween 20) for 3 
times and then incubated in blocking buffer (2 % BSA) for 1 h at room 
temperature. This was followed by washing the membranes with TBS and 
incubation with respective primary antibody (2% BSA) overnight at 4°C. The 
dilution of primary antibody used was – Erk ½ (1:5000), pERK ½ (1:1000), ALK 
(1:1000), pALK (1:1000), BCl2 (1:1000), Bim (1:1000), p27 (1:1000), cyclinD1 
(1:1000), total caspase-3 (1:1000), cleaved caspase-3 (1:1000), total PARP (1:1000), 
cleaved PARP (1:1000), β-tubulin (1: 2000). After this, membranes were washed 
in TBST (0.05% Tween 20, 0.025 mM Tris-base, 0.1 M NaCl, pH 7.4) for 5 times (5 
min each) and incubated with horseradish-peroxidase conjugated goat anti-
mouse or goat anti-rabbit secondary antibody (1: 3000 in 5% non-fat milk in 
TBST) for 1 h at room temperature. Following incubation, membranes were 
washed with TBST 5 times (5 min each). Proteins bands were visualised using 
SuperSignal West Pico Chemiluminescent Substrate and developed in x-ray 
films using 100 plus Automatic X-ray film processor from ALL-Pro Imaging. The 
images were scanned using Bio-Rad GS-710 densitometer and densities of each 
band were quantified using Quantity One software (BioRad). The densities of 
the respective proteins were normalised to β-tubulin. Three independent 
experiments were performed. 
2.3.2.4. Cell cycle assay 
The effect of drug treatment on the different phases of the cell cycle was 
determined by analysing cellular DNA content by flow cytometer. H3122 
(300,000 cells/well) and CR-H3122 (350,000 cells/well) cells were seeded into 6 
well plates and incubated for 24 h in 5% CO2, 95% humidified air at 37° C. H3122 
cells were treated with vehicle (DMSO 0.1%), crizotinib (0.25 µM), selumetinib 
(7.5 µM) and their combination for 24 h and 48 h. CR-H3122 cells were treated 
with vehicle (DMSO 0.1%), crizotinib (2.5 µM), selumetinib (7.0 µM) and their 
combination for 24 h and 48 h. Following the incubation period, the cells were 
washed twice with 1 mL of warmed isotonic PBS. Trypsin (200 µL) was added to 
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each well and were incubated at 37°C for 4 min to allow the detachment of cells 
from the base of the wells. Cells were then collected in 15 mL falcon tube with 2 
mL of warmed RPMI media and were centrifuged at 2000 rpm for 3 min at 4°C. 
The supernatant was aspirated, and cell pellets were resuspended in 1 mL of 
isotonic cold PBS (4°C) and were centrifuged again. The supernatant was 
removed, and cells pellets were resuspended in 300 µL of PBS and were fixed by 
adding 600 µL of ice-cold 70% ethanol dropwise while vortexing gently to avoid 
clumping of cells. The tubes were sealed with paraffin and were stored at 4°C. 
Next, the cells were centrifuged at 2000 rpm for 3 min at 4°C. The 
supernatant was aspirated, and the cell pellets were washed and resuspended in 
300 µL of ice-cold isotonic PBS (4°C) and centrifuged. Finally, cell pellets were 
resuspended in 150 µL of FxCycle PI/RNase staining solution and incubated in 
the dark for 30 min at room temperature. The samples were transferred to FAC 
tube and analysed by Gallious BD flow cytometer. The Data obtained was 
analysed using FlowJo version 10 software. Three independent experiments 
were performed. 
2.3.2.5. Apoptosis assay 
The effect of drug treatment on the mode of cell death was determined 
using propidium iodide/ annexin V staining by fluorescence-activated cell 
sorting (FACS). H3122 (300,000 cells/well) and CR-H3122 (350,000 cells/well) 
cells were seeded into 6 well plates and incubated in 5% CO2, 95% humidified 
air for 24 h at 37°C. H3122 cells were treated with vehicle (DMSO 0.1%), 
crizotinib (0.25 µM), selumetinib (7.5 µM) and their combination for 24 h, 48 h 
and 72 h. CR-H3122 cells were treated with vehicle (DMSO 0.1%), crizotinib (2.5 
µM), selumetinib (7.0 µM) and their combination for 24 h and 48 h. After the 
incubation period, cells were washed with warm isotonic PBS (37°C) for two 
times and incubated with 200 µL of trypsin for 4 min at 37°C allowing the cells 
to detach from the wells. Cells were then collected in a fresh 15 ml tube with 2 
ml of warm media and centrifuged at 2000 rpm for 3 min at 4°C. The supernatant 
was aspirated, and cell pellets were resuspended and washed with ice-cold 
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isotonic PBS followed by centrifugation. The supernatant was discarded, and cell 
pellets were resuspended in 100 µL of binding buffer (10 mM HEPES, 140 mM 
NaCl, 2.5 mM CaCl2) and transferred to FACS tube. Annexin V-APC (5 µL) was 
added to each tube containing cells and mixed gently followed by incubation for 
15 min in the dark at room temperature. Next, 2.5 µL of 50 µg/mL propidium 
iodide and 200 µL of the binding solution was added to each tube and was 
further incubated for 15 min in the dark at room temperature. Finally, the 
samples were analysed on BD Gallios flow cytometer. Data obtained were 
analysed using Kaluza analysis Software. Three independent experiments were 
performed. 
2.3.2.6. Ac-DEVD-AMC Caspase-3 activity assay 
H3122 (3 × 105 cells/well) and CR-H3122 (3.5 × 105 cells/well) cells were 
seeded in 6-well culture plates and incubated for 24 h. H3122 cells were treated 
with vehicle (DMSO 0.1%), crizotinib (0.25 µM), selumetinib (7.5 µM) and their 
combination for 48 h. CR-H3122 cells were treated with vehicle (DMSO 0.1%), 
crizotinib (2.5 µM), selumetinib (7.0 µM) and their combination for 24 h. H3122 
and CRH3122 cells were treated with 5 µM and 100 µM of cisplatin (positive 
control), respectively. Following incubation, cells were washed with isotonic PBS 
2 times and treated with trypsin for 2-3 mins allowing the cells to detached from 
the wells. Cells were then collected, washed with isotonic 0.01 M PBS and 
centrifuged for 5 min at 5000 rpm. The supernatant was discarded, and cell 
pellets were suspended in 100 µL buffer (100 mM HEPES pH 7.5, 10% sucrose, 
0.1% CHAPS and 0.0001%NP-40) supplemented with 1 M dithiothreitol (DTT) 
and caspase-3 substrate. The mixture was further incubated for 30 min at 37°C. 
The samples were diluted to 1:5 in a buffer (100 mM HEPES pH 7.5, 10% sucrose, 
0.1% CHAPS and 0.0001%NP-40) and the intensity emitted by the Ac-DEVD-
AMC caspase-3 fluorogenic substrate was examined using Cary Eclipse 
fluorescence spectrofluorometer with an excitation wavelength of 380 and 
emission wavelength range of 400- 500 nm. The assay buffer supplied with DTT 
was used as the blank. Three independent experiments were performed. 
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2.3.2.7. Data analysis 
Cell viability data were normalised to control and analysed by nonlinear 
regression model using Graphpad Prism V7 software. Cell cycle and apoptosis 
data were analysed using a two-way ANOVA coupled with Bonferroni post-hoc 
test. All other data that did not involve time were analysed using a one-way 
ANOVA coupled with Bonferroni post-hoc test. All data are presented as the 
mean ± SEM. P < 0.05 was the minimal requirement for a statistically significant 
difference. 
To determine if crizotinib and selumetinib suppress cell proliferation in a 
manner consistent with independent drug action in both H3122 and CR-H3122 
cells, combination treatment data was modelled by calculating the combination 
index (CI) described by Chou and Talalay using CompuSyn software (Chou & 
Talalay, 1983). The Chou Talalay CI was calculated using the equation 2.1. CI >1, 
=1, <1 indicate antagonistic, additive, or synergistic interaction respectively. 
Commonly used in the study of drug synergy (positive interaction), this 
approach is derived from the zero-interaction (additivity) model of Loewe. This 
model is based on the assumption of a shared target for two drugs. Therefore, an 
effect greater than predicted by Loewe additivity (Chou-Talaly CI < 1) means 
that the central assumption of the Loewe model is falsified; thus, that the drugs 








Equation 2.1 Chou Talalay combination index equation 
where, d1 and d2 are the concentration of drug 1 and drug 2 that in combination 
give same response as drug 1 alone (D1) and drug 2 alone (D2). 
Determining whether drugs that act on separate targets have a positive 
interaction (synergy) requires a different zero-interaction model (the Bliss 
model) (Goldoni & Johansson, 2007). The Bliss model assumed that the two or 
more drugs in the combination will have independent target. Bliss model CI is 
calculated using equation 2.2. CI >1, =1, <1 indicate antagonistic, additive, or 
synergistic interaction respectively. This analysis was not carried out since the 
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aim of this study was to test the synergistic interaction rather than independent 
drug action. 
𝐂𝐂𝐂𝐂 =
𝑬𝑬𝟏𝟏 + 𝑬𝑬𝟐𝟐 − 𝑬𝑬𝟏𝟏 ∙ 𝑬𝑬𝟐𝟐
𝑬𝑬𝟏𝟏𝟐𝟐
 
Equation 2.2 Bliss model combination index equation 
where, E1 is the degree of effect produced by drug 1, E2 is the degree of effect 
produced by drug 2, E12 is the degree of effect produced by the combination of 
drug 1 and 2.




2.4.1. Mechanism of suppression of cell proliferation by the combination 
treatment in H3122 cell line 
2.4.1.1. IC50 values following crizotinib and selumetinib single drug treatment 
The relative potency of crizotinib and selumetinib single drug treatment 
was initially examined in H3122 and A549 non-small cell lung cancer cells. Both 
cell lines were treated with a range of drug concentrations (0.001- 40 µM) for 72 
h. H3122 cells were highly sensitive to crizotinib compared to selumetinib, with 
IC50 values of 0.1 ± 0.07 and 3.1 ± 0.65 µM, respectively (Figure 2.1A). Sensitivity 
to crizotinib by ALK-negative A549 cells was markedly less than for ALK-
positive cells with an IC50 value of 0.8 ± 0.07µM (Figure 2.1B). IC50 value for 
selumetinib was similar in A549 cells as in H1322 cells, with IC50 values of 2.0 ± 
0.14 (Figure 2.1B). 
 
Figure 2.1 Cytotoxicity of crizotinib and selumetinib in non-small cell lung cancer 
cells. (A) H3122 cells were seeded in 96 wells plates at 7 ×103 cells per well and treated 
with crizotinib (0.001 – 10 µM), selumetinib (0.001 – 30 µM) or vehicle control (0.1% 
DMSO) for 72 h. (B) A549 cells were seeded in 96 wells plates at 4 ×103 cells per wells 
and treated with crizotinib (0.001 – 30 µM), selumetinib (0.001 – 40 µM) or control (0.1% 
DMSO) for 72 h. SRB assay was performed. All data are presented as mean ± SEM. Three 
independent experiments were performed in triplicate. IC50 values were determined by 
non-linear regression analysis. 
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Table 2.1 Summary of IC50 values of crizotinib and selumetinib   
Drug Cell line IC50 (µM) a 
Crizotinib H3122 0.1 ± 0.07  
Selumetinib H3122 3.1 ± 0.65 
Crizotinib A549 0.8 ± 0.07 
Selumetinib A549 2.0 ± 0.14 
a Values are the mean ± SEM 
2.4.1.2. The combined effect of crizotinib and selumetinib treatment on cell 
viability 
The effect of crizotinib and selumetinib combination treatment was then 
investigated in H3122 and A549 cells. Six different combinations were selected 
using equivalent potencies relative to each drug’s IC50 value. For each 
concentration, the two drugs alone were compared with the combination of the 
two. Chou-Talalay analysis was performed to determine if the two drugs acted 
with greater than Loewe additivity (Chou & Talalay, 1983). The results showed 
that 3 out of 6 drug combinations elicited a significant reduction in cell viability 
compared to both single drug treatments (p < 0.05, one-way ANOVA) (Figure 
2.2A). Interestingly, all drug combinations showed greater than Loewe 
additivity (Chou-Talalay Combination index < 1) (Figure 2.2B). Contrary to 
H3122 cells, the combined effect of crizotinib and selumetinib was solely driven 
by selumetinib in A549 cells (Figure 2.2C). Only one of the combinations showed 
a significant decrease in cell viability compared to either single drug treatment 
(p < 0.05, one-way ANOVA) (Figure 2.2C). Furthermore, combination indices 
showed that all combinations except the higher concentrations were mutually 
antagonistic (CI > 1) (Figure 2.2D). 
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Figure 2.2 Effect of crizotinib, selumetinib and their combination treatment in non-
small cell lung cancer. (A) H3122 cells were seeded in 96 well plates at 7 ×103 cells per 
well and (C) A549 cells 4 ×103 cells per well and then treated with the indicated 
concentration of crizotinib, selumetinib and their combinations for 72 h. SRB assay was 
performed. Bar denotes; ■ DMSO control, ■ crizotinib, ■ selumetinib and □ combination 
of both. Combination index plot for drug combination in (B) H3122 and (D) A549 cells. 
The horizontal line represents Loewe additivity. CI > 1, = 1, < 1 indicate antagonistic, 
additive or synergistic interaction respectively. Bars represent the mean ± SEM. 
Significance was determined by one-way-ANOVA with a Bonferroni post-hoc test. 
Three independent experiments were performed in triplicate. *p < 0.05 for crizotinib vs. 
combination and #p < 0.05 for selumetinib vs. combination. 
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2.4.1.3. Effect of combination treatment on downstream signalling pathway 
To investigate the mechanisms involved in the suppression of cell 
proliferation by the combination treatment, key proteins downstream of the 
RAS/MAPK signalling pathway were examined. Western blotting was 
performed to determine the activation of ALK and MEK, by measuring the 
expression of ALK, phosphorylated-ALK (p-ALK), ERK and phosphorylated-
ERK (p-ERK). H3122 cells were treated with vehicle control (DMSO 0.1%), 
crizotinib (0.25 µM), selumetinib (7.5 µM) and their combination for 24 h. After 
24 h, p-ALK/ALK was decreased 90% by both crizotinib alone and the 
combination of crizotinib and selumetinib, whereas there was no change 
following selumetinib (Figure 2.2B). Additionally, p-ERK/ERK was reduced 
64% by crizotinib, 95% by selumetinib, and 99% by the drugs in combination (p 
< 0.05, one-way ANOVA) (Figure 2.3C).




Figure 2.3 Effect of crizotinib, selumetinib and their combination on downstream 
RAS/MAPK signalling pathways in H3122 cells. (A) Representative Western blots of 
ALK, p-ALK, ERK, p-ERK. Cells were treated with vehicle control (0.1%DMSO), 
crizotinib (0.25 µM), selumetinib (7.5 µM) and their combinations for 24 h. Cell lysates 
were subjected to SDS-PAGE and probed with specific antibodies. Densitometry of 
Western blots of (B) p-ALK/ALK and (C) p-ERK/ERK. All data are presented as mean 
± SEM. Significance was determined by one-way-ANOVA with Bonferroni post-hoc 
test. Three independent experiments were performed in triplicate. * p < 0.05 for 
crizotinib vs. combination and #p < 0.05 for selumetinib vs. combination. 
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2.4.1.4. Effect of combination on cell cycle progression and cell cycle markers 
The impact of combination treatment on cell cycle progression was 
investigated in H3122 cells. Cells were treated with vehicle control (DMSO 0.1%), 
crizotinib (0.25 µM), selumetinib (7.5 µM) and their combination for 24 h and 48 
h and analysed by flow cytometry with PI staining. 
Cell cycle analysis showed that both crizotinib and selumetinib as single 
drug treatments significantly increased the accumulation of cells in the G1 phase 
by 10% and 17%, respectively, compared to the control after 24 h (p < 0.05, two-
way ANOVA), (Figure 2.4A). After 48 h of drug treatment, selumetinib 
significantly increased the accumulation of cells in the G1 phase compared to the 
control by 5.5% (p < 0.05, two-way ANOVA), while that for crizotinib decreased 
by 2%. Furthermore, the combination of the two drugs significantly increased 
the percentage of cells in the G1 phase by 16% and 8%, respectively, compared 
to crizotinib and selumetinib single drug treatment after 24 h (p < 0.05, two-way 
ANOVA). Following 48 h, the combination significantly increased the 
percentage of cells in G1 phase compared to crizotinib by 6%, whereas that for 
the combination treatment decreased by 2% compared to selumetinib.  
In contrast, both the crizotinib and selumetinib single drug treatment 
decreased the percentage of cells in S phase by 3% and 5 %, respectively after 24 
h and 0.5% and 3%, respectively after 48 h compared to the control. Moreover, 
the combination treatment further decreased the percentage of cells in S phase 
by 5% and 2% after 24 h compared to crizotinib and selumetinib, respectively. 
While after 48 h, the combination treatment decreased the percentage of cells in 
S phase by 2% compared to crizotinib only.  
Next, the endogenous expression of proteins involved in the G1 to S phase 
transition such as cyclin D1 and the cyclin dependent kinase inhibitor, p27, were 
examined using Western blotting. H3122 cells were treated with vehicle control 
(DMSO 0.1%), crizotinib (0.25 µM), selumetinib (7.5 µM) and their combination 
for 24 h and the respective proteins were probed using specific antibodies. The 
expression of cyclin D1 was significantly decreased following crizotinib (62%) 
and selumetinib (76%) compared to the control (p < 0.05, one-way ANOVA). 
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Furthermore, combination drug treatment significantly decreased the protein 
expression of cyclin D1 (> 80%) compared to both the single drug treatments (p 
< 0.05, one-way ANOVA) (Figure 2.4C). Furthermore, crizotinib and selumetinib 
single drug treatment significantly increased the endogenous expression of p27 
by 1.1-fold and 3.4-fold, respectively, compared to the control (p < 0.05, one-way 
ANOVA). Similarly, the expression level of p27 was significantly increased by 
4.0- and 1.3-fold following combination treatment compared to crizotinib or 
selumetinib alone (p < 0.05, one-way ANOVA) (Figure 2.4E). Hence, selumetinib 
enhanced the anti-proliferative effect of crizotinib by increasing G1 phase arrest, 
which resulted from a decrease in cyclin D1 and an increase in p27 expression. 
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Figure 2.4 Effect of crizotinib, selumetinib and their combination on cell cycle 
progression and cell cycle markers in H3122 cells. (A) cell cycle progression. Cells were 
treated with vehicle control (DMSO 0.1%), crizotinib (0.25 µM), selumetinib (7.5 µM) 
and their combination for 24 h and 48 h. Propidium iodide staining and flow cytometry 
was used to determine the proportion of cells in different cell cycle phases. Bar denotes; 
■ > G2, ■ G2/M, ■ S, ■ G1, □ sub G1. Significance was determined by two-way-ANOVA 
with Bonferroni post-hoc test. Representative Western blots of (B) cyclinD1 and (D) p27 
after 24 h exposure of drugs treatment. Cell lysate were subjected to SDS-PAGE and 
probed with specific antibodies. Densitometry of Western blots of (C) cyclinD1 and (E) 
p27. Significance was determined by one-way-ANOVA with Bonferroni post-hoc test. 
All data are presented as mean ± SEM.  Three independent experiments were 
performed. *p < 0.05 for crizotinib vs. combination and #p < 0.05 for selumetinib vs. 
combination. 
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2.4.1.5. Effect of combination treatment on the induction of apoptosis and 
apoptotic markers 
Crizotinib also exhibits anti-tumour activity via induction of apoptosis 
(Christensen et al., 2007). Similarly, selumetinib, a potent MEK1/2 inhibitor, 
downregulates the RAS/MAPK signalling pathway leading to activation of 
downstream apoptotic signalling (Holt, Logie, Odedra, et al., 2012). Therefore, 
whether the combination of crizotinib with selumetinib could enhance the 
induction of apoptosis in H3122 cells was investigated. Cells were treated with 
vehicle control (DMSO 0.1%), crizotinib (0.25 µM), selumetinib (7.5 µM) and their 
combination for 24 h, 48 h and 72 h and analysed by flow cytometry with PI and 
Annexin V staining. 
Following drug treatment, apoptosis was initiated at 24 h, reached 
maximum at 48 h and entered late apoptotic phase at 72 h (Figure 2.5). The 
percentage of early apoptotic cells was slightly higher with crizotinib and 
selumetinib single drug treatment (4% and 5 %, respectively, after 24 h), (4% and 
7%, respectively, after 48 h) than the control (2% after 24 h and 48 h). Whereas 
the combination treatment resulted in a significantly higher percentage of early 
apoptotic cells (9% and 17% after 24 h and 48 h, respectively) compared to either 
of the single drug treatments (p < 0.05, two-way ANOVA) (Figure 2.5). 
To determine the drivers of apoptosis, the endogenous expression of key 
regulators of intrinsic apoptosis such as Bcl2, Bim, caspase-3, cleaved caspase-3, 
were examined by Western blotting. Cells were treated with vehicle control 
(DMSO 0.1%), crizotinib (0.25 µM), selumetinib (7.5 µM) and their combination 
for 24 h and 48 h and the respective proteins were probed using specific 
antibodies. 
There was no change in the endogenous expression of Bcl2 with crizotinib, 
selumetinib and their combination treatment for 24 h (Figure 2.6B). On the other 
hand, the endogenous expression of Bim was increased by both crizotinib and 
selumetinib single-drug treatment compared to the control after 24 h and 48 h 
(Figure 2.6D). Furthermore, combination treatment significantly increased the 
endogenous expression of Bim after 24 h and 48 h by 1.5-fold and 3.0-fold, 
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respectively, compared to crizotinib (p < 0.05, one-way ANOVA), whereas there 
was slight increase (0.3-fold) compared to selumetinib (p > 0.05, one-way 
ANOVA) (Figure 2.6D). 
After 24 h of drug treatment, cleaved caspase-3 expression was negligible 
but was significantly increased after 48 h of combination treatment (Figure 2.7B). 
This observation is consistent with results from apoptosis assay suggesting that 
induction of apoptosis was maximal after 48 h of treatment. There was more than 
7-fold increase in expression of cleaved caspase-3 following crizotinib and 
selumetinib single-drug treatment compared to the control. Similarly, 
combination treatment significantly increased cleaved caspase-3 expression by 3 
to 7-fold compared to either drug alone (Figure 2.7B) (p < 0.05, one-way 
ANOVA). To confirm this, caspase-3 activity was determined where a sharp 
increase was seen after 48 h of treatment with the combination (Figure 2.7C) (p 
< 0.05, one-way ANOVA). This was consistent with the results from Western 
blotting. 
Next, to determine whether the caspase-3 mediate cleavage of PARP, the 
endogenous expression of PARP and cleaved PARP was examined. Crizotinib 
and selumetinib alone increased the expression of cleaved PARP by more than 
12-fold compared to the control. Moreover, the expression of cleaved PARP was 
markedly increased by 8 to 26-fold following combination treatment compared 
to either drug alone (p < 0.05, one-way ANOVA) (Figure 2.8B). These results 
showed that the combination of crizotinib and selumetinib significantly 
increased apoptosis by increasing the expression of Bim, cleaved caspase-3 and 
cleaved PARP to a degree that was not reached by crizotinib alone. 
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Figure 2.5 Mode of cell death following crizotinib, selumetinib and their combination 
in H3122 cells. Cells were treated with vehicle control (DMSO 0.1%), crizotinib (0.25 
µM), selumetinib (7.5 µM) and their combination for 24 h, 48 h and 72 h. Cells were 
stained with propidium iodide and Annexin V. The flow cytometry was used to 
determine the proportion of apoptotic cells. Bar denotes; ■ Early apoptotic, ■ late 
apoptotic Significance was determined by two-way-ANOVA with Bonferroni post-hoc 
test. All data are presented as mean ± SEM. Three independent experiments were 
performed. *p < 0.05 for crizotinib vs. combination and #p < 0.05 for selumetinib vs. 
combination. 
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Figure 2.6 Expression of Bcl2 and Bim following treatment with crizotinib, 
selumetinib and their combinations in H3122 cells. Representative Western blots of 
(A) Bcl2 and (C) Bim, respectively. Cells were treated with vehicle control (DMSO 0.1%), 
crizotinib (0.25 µM), selumetinib (7.5 µM) and their combination for the indicated time. 
Cell lysates were subjected to SDS-PAGE and probed with specific antibodies. 
Densitometry of Western blots of (B) Bcl2 and (D) Bim. Significance was determined by 
one-way-ANOVA with Bonferroni post-hoc test.  All data are presented as mean ± SEM.  
Three independent experiments were performed. *p < 0.05 for crizotinib vs. 
combination and #p < 0.05 for selumetinib vs. combination.  
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Figure 2.7 Effect of crizotinib, selumetinib and their combination on cleaved caspase-
3 in H3122 cells. (A) Representative Western blots total caspase-3 and cleaved caspase-
3. Cells were treated with vehicle control (DMSO 0.1%), crizotinib (0.25 µM), selumetinib 
(7.5 µM) and their combination for 24 h and 48 h. Cell lysates were subjected to SDS-
PAGE and probed with specific antibodies. (B) Densitometry of Western blots of cleaved 
caspase-3. (C) Caspase-3 activity after treatment with the indicated concentration of 
crizotinib, selumetinib, their combination and cisplatin (positive control) for 48 h. 
Significance was determined by one-way-ANOVA with Bonferroni post-hoc test.  All 
data are presented as mean ± SEM.  Three independent experiments were performed. 
*p < 0.05 for crizotinib vs. combination and #p < 0.05 for selumetinib vs. combination 
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Figure 2.8 Expression of cleaved PARP following treatment with crizotinib, 
selumetinib and their combination H3122 cells. (A) Representative Western blots total 
PARP and cleaved PARP. Cells were treated with vehicle control (DMSO 0.1%), 
crizotinib (0.25 µM), selumetinib (7.5 µM) and their combination for 24 h and 48 h. Cell 
lysates were subjected to SDS-PAGE and probed with specific antibodies. (B) 
Densitometry of Western blots of cleaved PARP. Significance was determined by one-
way-ANOVA with Bonferroni post-hoc test.  All data are presented as mean ± SEM. 
Three independent experiments were performed. *p < 0.05 for crizotinib vs. 
combination and #p < 0.05 for selumetinib vs. combination.  
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2.4.2. Mechanism of suppression of cell proliferation by the combination 
treatment in CR-H3122 cell line 
2.4.2.1. Effect of crizotinib, selumetinib and their combination treatment on 
cell viability 
The anti-proliferative effect of crizotinib and selumetinib single drug 
treatment was examined in crizotinib resistant ALK-positive NSCLC cells (CR-
H3122). CR-H3122 cells were treated with crizotinib (0.005- 40 µM) and 
selumetinib (0.001- 150 µM) for 72 h. The sensitivity of CR-H3122 cells to 
crizotinib was highly reduced compared to H3122 cells, with an IC50 value of 2.3 
± 0.5 µM (22-fold over the parental H3122 cells). The IC50 value for selumetinib 
was elevated in CR-H1322 cells to 11.1 ± 2.12 µM, a 3-fold increase compared to 
H3122 (Figure 2.9A). Interestingly, all of the various concentrations of the two 
drugs in combination significantly suppressed the cell proliferation of CR-H3122 
cells compared to single drug treatment (p < 0.05, one-way ANOVA) (Figure 
2.9B). Interestingly, the combination of crizotinib with selumetinib was highly 
potent in the resistant cells compared to the parental H3122 cells (Chou-Talalay 
Combination Indices < 0.3) (Figure 2.9C)
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Figure 2.9 Effect of crizotinib, selumetinib and their combination on cell viability of 
CR-H3122 cells. (A) Crizotinib and selumetinib single drug treatment (B) Combination 
treatment. Cells were seeded in 96 wells plate at 10 ×103 cells per well and treated with 
the indicated concentration of crizotinib, selumetinib and their combinations for 72 h. 
SRB assay was performed. Bar denotes: ■ DMSO control, ■ crizotinib, ■ selumetinib and 
□ combination of both. Significance was determined by one-way-ANOVA with 
Bonferroni post-hoc test. (C) Combination index plot for drug combination of crizotinib 
and selumetinib. The horizontal line represents Loewe additivity. CI >1, =1, <1 indicate 
antagonistic, additive or synergistic interaction respectively. All data are presented as 
mean ± SEM. Three independent experiments were performed in triplicate. *p < 0.05 for 
crizotinib vs. combination and #p < 0.05 for selumetinib vs. combination. 
 
Table 2.2 IC50 values of crizotinib and selumetinib in CR-H3122 cell lines  
Drug Cell line IC50 (µM)a 
Crizotinib CR-H3122 2.3 ± 0.5 
Selumetinib CR-H3122 11.1 ± 2.12 
a Values are the mean ± SEM 
 
Chapter 2: Exploring the anti-cancer activity of combination of crizotinib and selumetinib 
92  
 
2.4.2.2. Effect of combination treatment on downstream signalling pathways  
To further evaluate the mechanisms for the drug combination’s effects on 
crizotinib resistant cells, proteins downstream of the RAS/MAPK signalling 
pathway were examined. CR-H3122 cells were treated with vehicle control 
(DMSO 0.1%), crizotinib (2.5 µM), selumetinib (7.0 µM) and their combination 
for 24 h.  Crizotinib alone had almost no effect on the phosphorylation of ALK 
and ERK in CR-H1322 cells, consistent with ALK inhibitor resistance. Nor was 
there any significant reduction of ALK phosphorylation by the combination (< 
43%) compared to either of the single drug treatment (p > 0.05, one-way 
ANOVA) (Figure 2.10B). However, the cells remained sensitive to ERK 
phosphorylation by selumetinib, with a 93% decrease in pERK/ERK protein 
expression after 24 h. Moreover, the combination of crizotinib and selumetinib 
significantly decreased the protein expression of pERK/ERK by 99% (p < 0.05, 
one-way ANOVA).  




Figure 2.10 Effect of crizotinib, selumetinib and their combination on downstream 
RAS/MAPK signalling pathways in CR-H3122 cells. (A) Representative Western blots 
of ALK, p-ALK, ERK, p-ERK. Cells were treated with vehicle control (0.1%DMSO), 
crizotinib (2.5 µM), selumetinib (7.0 µM) and their combinations for 24 h. Cell lysates 
were subjected to SDS-PAGE and probed with specific antibodies. Densitometry of 
Western blots of (B) p-ALK/ALK and (C) p-ERK/ERK. All data are presented as mean 
± SEM. Significance was determined by one-way-ANOVA with Bonferroni post-hoc 
test. Three independent experiments were performed in triplicate. * p < 0.05 for 
crizotinib vs. combination and #p < 0.05 for selumetinib vs. combination. 
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2.4.2.3. Effect of the combination treatment on cell cycle progression and cell 
cycle markers 
To determine the effect of crizotinib, selumetinib and their combination 
treatment on cell cycle progression of crizotinib resistant cells, cell cycle assay 
was performed. CR-H3122 cells were treated with vehicle control (DMSO 0.1%), 
crizotinib (2.5 µM), selumetinib (7.0 µM) and their combination for 24 h and then 
analysed by flowcytometry with PI staining. Cell cycle analysis showed that after 
24 h and 48 h both crizotinib and selumetinib single drug treatment increased 
the percentage of cells arrested in the G1 phase by more than 4% compared to 
the control. Furthermore, the combination treatment significantly increased the 
percentage of cells in G1 phase after 24 h and 48 h by more than 16% compared 
to crizotinib (p < 0.05, two-way ANOVA) (Figure 2.11A). In contrast, the 
percentage of cells in G1 phase slightly decreased (1.3%) after 24 h followed by 
a marked increase (6 %) after 48 h with the combination compared to selumetinib 
(Figure 2.11A). However, both single and combination treatment of crizotinib 
and selumetinib decreased the percentage of cells arrested in the S phase by more 
than 2% compared to the control and either of the single drug treatment, 
respectively (Figure 2.11A). 
Next, the expression of cyclin D1 and P27 involved in the transition from 
G1 to S phase was examined using Western blotting. CR-H3122 cells were treated 
with vehicle control (DMSO 0.1%), crizotinib (2.5 µM), selumetinib (7.0 µM) and 
their combination for 24 h and the respective proteins were probed using specific 
antibodies. The expression of cyclin D1 was decreased with crizotinib (42%) and 
selumetinib (80%) compared to the control. Moreover, the drug combination 
decreased cyclin D1 expression by more than 97% compared to either single drug 
treatment (Figure 2.11C). The single drug treatment of crizotinib and selumetinib 
significantly increased the expression of p27 by 2.0- and 3.2-fold, respectively, 
compared to the control. (p < 0.05, one-way ANOVA). Similarly, the expression 
level of p27 was significantly increased by 1.8- and 1.2-fold with the combination 
treatment compared to crizotinib or selumetinib alone (p < 0.05, one-way 
ANOVA) (Figure 2.11E) 
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Figure 2.11 Effect of crizotinib, selumetinib and their combination on cell cycle 
progression and cell cycle markers in CR-H3122 cells. (A) cell cycle progression. Cells 
were treated with vehicle control (DMSO 0.1%), crizotinib (2.5 µM), selumetinib (7.0 µM) 
and their combination for 24 h and 48 h. Propidium iodide staining and flow cytometry 
was used to determine the proportion of cells in different cell cycle phases. Bar denotes; 
■ > G2, ■ G2/M, ■ S, ■ G1, □ sub G1.  Significance was determined by two-way-ANOVA 
with Bonferroni post-hoc test. Representative Western blots of (B) cyclinD1 and (D) p27 
after 24 h exposure to drugs treatment. Cell lysates were subjected to SDS-PAGE and 
probed with specific antibodies. Densitometry of Western blots of (C) cyclinD1 and (E) 
p27. Significance was determined by one-way-ANOVA with Bonferroni post-hoc test.  
All data are presented as mean ± SEM.  Three independent experiments were 
performed. *p < 0.05 for crizotinib vs. combination and #p < 0.05 for selumetinib vs. 
combination. 
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2.4.2.4.  Effect of combination treatment on the induction of apoptosis and 
apoptotic markers in CR-H3122 cells 
To determine the effect of crizotinib, selumetinib and their combination on 
the mode of cell death in CR-H3122 cells, apoptotic assay was performed. Cells 
were treated with vehicle control (DMSO 0.1%), crizotinib (2.5 µM), selumetinib 
(7.0 µM) and their combination for 24 h and 48 h and analysed by flow cytometry 
with PI and Annexin V staining. Following drug treatment, apoptosis was 
maximum at 24 h and entered late apoptotic phase at 48 h. After 24 h, the 
percentage of early apoptotic cells was slightly higher with crizotinib and 
selumetinib single drug treatment (8% and 5%, respectively), whereas the 
combination treatment resulted in a significantly higher percentage of early 
apoptotic cells (18%) (p < 0.05, two-way ANOVA) (Figure 2.12A).  
Western blotting was performed to determine the expression of apoptotic 
markers such as Bim, Bcl2, total caspase-3, cleaved caspase-3, PARP, and cleaved 
PARP. CR-H3122 cells were treated with vehicle control (DMSO 0.1%), crizotinib 
(2.5 µM), selumetinib (7.0 µM) and their combination for 24 h and 48 h. Similar 
to what was observed in H3122 cells, there was no change in expression of Bcl2 
with crizotinib, selumetinib and their combination (Figure 2.12C). On the other 
hand, combination treatment increased the expression of Bim by 12-fold (p < 
0.05, one-way ANOVA) and 0.26-fold (p > 0.05, one-way ANOVA) compared to 
crizotinib and selumetinib, respectively (Figure 2.12E). 
Furthermore, combination treatment significantly increased the expression 
of cleaved caspase-3 by 0.3- and 5.3-fold compared to crizotinib and selumetinib, 
respectively (p < 0.05, one-way ANOVA) (Figure 2.13B). This was further 
confirmed by performing a caspase-3 assay. Here, the combination treatment 
increased caspase-3 activity by 0.24- and 1.1-fold compared to crizotinib and 
selumetinib, respectively (Figure 2.13C) that was consistent with the result from 
Western blotting. Similarly, the expression of cleaved PARP was significantly 
increased with combination treatment by 0.9- and 3.2-fold compared to 
crizotinib and selumetinib, respectively (p < 0.05, one-way ANOVA) (Figure 
2.13E). 
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Figure 2.12 Effect of crizotinib, selumetinib and their combination on the mode of 
cell death and apoptotic marker in CR-H3122 cells. (A) Percentage of apoptotic cells 
after treatment with vehicle control (DMSO 0.1%), crizotinib (2.5 µM), selumetinib (7.0 
µM) and their combination for 24 h and 48. This was followed by staining with 
propidium iodide and Annexin V and analysing by flow cytometry. Bar denotes; ■ Early 
apoptotic, ■ late apoptotic. Significance was determined by two-way-ANOVA with 
Bonferroni post-hoc test. Representative Western blots of (B) Bcl2 and (D) Bim. Cells 
were treated with vehicle control (DMSO 0.1%), crizotinib (0.25 µM), selumetinib (7.5 
µM) and their combination for 24 h. Cell lysates were subjected to SDS-PAGE and 
probed with specific antibodies. Densitometry of Western blots of (C) Bcl2 and (E) Bim. 
Significance was determined by one-way-ANOVA with Bonferroni post-hoc test. All 
data are presented as mean ± SEM.  Three independent experiments were performed. 
*p < 0.05 for crizotinib vs. combination and #p < 0.05 for selumetinib vs. combination. 
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Figure 2.13 Effect of crizotinib, selumetinib and their combination on cleaved 
caspase-3 and cleaved PARP in CR-H3122 cells. Representative Western blots (A) 
cleaved caspase-3 and (D) cleaved PARP. Cells were treated with vehicle control (DMSO 
0.1%), crizotinib (2.5 µM), selumetinib (7.0 µM) and their combination for 24 h. Cell 
lysates were subjected to SDS-PAGE and probed with specific antibodies. Densitometry 
of Western blots of (B) cleaved caspase-3 and (E) cleaved PARP. (C) Caspase-3 activity 
after treatment with the indicated concentration of crizotinib, selumetinib, their 
combination and cisplatin (positive control) for 24 h. Significance was determined by 
one-way-ANOVA with Bonferroni post-hoc test. All data are presented as mean ± SEM. 
Three independent experiments were performed. *p < 0.05 for crizotinib vs. 
combination and #p < 0.05 for selumetinib vs. combination. 




The combined effect of crizotinib and selumetinib was investigated in both 
crizotinib naïve and crizotinib resistant ALK-positive NSCLC cells. Furthermore, 
the molecular mechanism behind the synergistic effect of combination treatment 
was explored. The combination treatment showed superiority over either of the 
single drug treatments by downregulating the major RAS/MAPK signalling 
pathway that in turn inhibits proliferation and induces apoptosis. 
The cell viability assay showed that H3122 cells were highly sensitive to 
crizotinib compared to selumetinib. Whereas the sensitivity to crizotinib was 
decreased in A549 cells suggesting that crizotinib is highly specific to EML4-ALK 
harbouring cell line. Furthermore, the development of crizotinib resistance did 
not cause appreciable cross-resistance to selumetinib in EML4-ALK- positive 
cells (IC50 values of crizotinib and selumetinib were increased by 22- and 3-fold, 
respectively, compared to parental H3122 cells). Combination of crizotinib and 
selumetinib inhibited cell viability in H3122 cells to a greater extent than 
predicted by Loewe additivity (CI < 1) (Chou & Talalay, 1983). Interestingly, this 
effect was found to an even greater degree in CR-H1322 cells (Chou-Talaly 
Combination Indices < 0.3) (Chou & Talalay, 1983). This is in contrast to a 
previous study on the combination of ALK/IGF-1R inhibition by Wilson et al., 
where the drug combination was effective against H3122 cells, but failed against 
CR-H1322 cells (Wilson et al., 2017).Together these results suggest that the 
development of resistance to crizotinib in our experiments did not involve 
mutations at points in the genome that confer resistance to both targets. 
The investigation of underlying mechanisms showed that the drug 
combination leads to a strong downregulation of the RAS/MAPK signalling 
pathway that in turn promotes both cell cycle arrest and apoptosis. In both 
H3122 and CR-H3122 cells, combination treatment significantly decreased the 
protein phosphorylation of pERK/ERK compared to crizotinib as a single drug 
treatment. Both crizotinib and selumetinib are known to exhibit anti-tumour 
activity via G1 cell cycle arrest and induction of apoptosis in various cancers 
including NSCLC (Christensen et al., 2007; Sale & Cook, 2013; Zhou et al., 2016). 
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As expected, crizotinib and selumetinib single drug treatment increased the 
accumulation of cells in the G1 phase compared to the control. And interestingly, 
their combination further increased this G1 phase arrest and suppressed the S 
phase. This may be due to a decrease in the activity of ERK following the 
combination treatment. The RAS/MAPK pathway is involved in the regulation 
of G1 cell cycle proteins. Phosphorylation of ERK leads to migration to the 
nucleus and activation of cyclin D1 and downregulation of p27. Thus, ERK plays 
an important role for entry into the S phase of the cell cycle (Bhatt et al., 2005).  
Combination treatment also significantly increased apoptosis compared to 
individual drugs in both crizotinib naïve and crizotinib resistant ALK-positive 
NSCLC cells. Specifically, cleaved caspase-3 and cleaved PARP were markedly 
increased following combination treatment, which was mediated by Bim, a pro-
apoptotic protein in the Bcl2 family (though Bcl2 itself was not changed). Both 
crizotinib and selumetinib individually increased the expression of Bim which is 
consistent with other studies in B-cell lymphoma and NSCLC cells (Bhalla et al., 
2011; Tanizaki et al., 2011). The mechanism behind the increase in expression of 
Bim is associated with a decrease in the phosphorylation of ERK, as it is well 
known that the RAS/MAPK signalling pathway phosphorylates Bim and 
promotes its proteasomal degradation thereby suppressing apoptosis (Ley et al., 
2003).  
Similarly, a significant increase in cleaved caspase-3 and cleaved PARP was 
observed in CR-H3122 cells following combination treatment. This effect was 
driven mostly by crizotinib where the contribution of selumetinib was minimal. 
Following selumetinib treatment, apoptosis was a Bim-dependent process, but 
apoptosis induced by crizotinib was independent of Bim. This may be because 
crizotinib can inhibit the RAS/MAPK pathway along with other ALK 
downstream pathways such as AKT/mTOR or JAK/STAT that may contribute 
to apoptosis with the involvement of other pro- or anti-apoptotic proteins 
(Hamedani et al., 2014; Zheng et al., 2013). Future studies will be required to 
determine the mechanism(s) involved in crizotinib resistant cell lines. 
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Notably, Bim, PARP and CDK, mediate complementary aspects of tumour 
cell suppression, namely cell death and proliferation, respectively. They are 
druggable targets, Bim by BH3 analogues, PARP by PARP inhibitors and CDK 
by specific inhibitors. Hence the results suggest that triple or even quadruple 
drug treatments should be screened (i.e., ALK, MEK, Bim, and PARP targeting) 
in the quest for even greater and longer-term cancer suppression. 
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In Chapter 2, it was demonstrated in in vitro studies that the combination 
of crizotinib and selumetinib strongly inhibited the proliferation of ALK-positive 
NSCLC cells. This resulted from a reduction in MAPK signalling that in-turn 
decreased cell proliferation and increased apoptosis via increased expression of 
apoptotic markers BIM, cleaved caspase-3, cleaved PARP and the cyclin 
dependent kinase inhibitor, p27 and decreased expression of the cell 
proliferation marker, cyclin D1. However, in vitro efficacy does not necessarily 
translate into in vivo efficacy. Therefore, this chapter reports the results of the 
singular and combined effect of crizotinib and selumetinib in a xenograft model 
of ALK-positive NSCLC. 
Efficacy is only one element of the usefulness of a therapeutic strategy. 
Equally important is potential toxicity. When crizotinib was approved for the 
treatment of ALK-positive NSCLC (Camidge et al., 2012; Kazandjian et al., 2014; 
Kwak et al., 2010) based on a Phase I dose escalation study, the maximum 
tolerated dose (MTD) for crizotinib in humans was calculated as 250 mg p.o. 
twice daily (Kwak et al., 2010; Kwak et al., 2009). Treatment related adverse 
events were mostly grade 1-2 such as gastrointestinal upset, visual disturbances, 
and peripheral oedema. Grade 3-4 adverse events including neutropenia, raised 
alanine aminotransferase (ALT) enzymes, lymphopenia and pneumonitis were 
observed in a minority of patients (Camidge et al., 2012). Similarly, MTD of 
selumetinib formulated as hydrogen sulphate was 75 mg p.o. twice daily (Banerji 
et al., 2010). The common adverse events were grade 1-2 diarrhoea, nausea, 
fatigue and grade 3-4 oedema, elevation of ALT, acneiform dermatitis, pleural 
effusion (Adjei et al., 2008; Banerji et al., 2010). The risk of toxicity, either additive 
or synergistic is increased when two drugs are given in combination (Farr & 
Bacon, 1995). Thus, it is important to investigate the potential toxicity of the 
combination of crizotinib and selumetinib. 
Investigation of drug-drug interaction for the combination of an anti-cancer 
drug is also crucial to assess its efficacy and toxicity (Scripture & Figg, 2006). 
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Crizotinib is predominantly metabolised by the cytochrome P450 isoform 
CYP3A and was reported to be both a time-dependent moderate inhibitor and 
weak inducer of CYP3A (Johnson et al., 2015; Mao et al., 2013). Similarly, CYP3A 
is the major enzyme responsible for the oxidative metabolism of selumetinib 
(Dymond et al., 2016). Therefore, it is crucial to investigate whether the two 
drugs potentially inhibit each other’s metabolism.  
Although ALK-positive NSCLC patients were highly responsive to 
crizotinib, the majority of patients developed resistance typically within a year 
of therapy (Solomon, Wilner, et al., 2014). This suggests the need for new 
therapeutic strategies such as combination therapy to overcome the resistance 
and improve the survival of patients. 
3.2. Aims and Objectives  
The aims of this chapter were (1) to investigate the efficacy of the 
combination treatment in a xenograft model of ALK-positive NSCLC, (2) to 
explore the underlying mechanism of tumour suppression by crizotinib, 
selumetinib and their combination treatment, (3) to evaluate the safety of single 
and combined treatment of crizotinib and selumetinib in male Balb/c mice and, 
(4) to examine whether the combination of crizotinib and selumetinib modulate 
CYP3A activity. 
The specific objectives were (1) to generate a xenograft model of ALK-
positive NSCLC, (2) to examine the singular and combined effect of crizotinib 
and selumetinib on suppression of tumour growth in the xenograft model , (3) 
to examine the effect of crizotinib and selumetinib singular and combination 
treatment on proliferation, apoptosis and angiogenesis of tumour cells, (4) to 
determine the adverse effect of the drugs treatment on kidney and liver function 
and, (5) to perform CYP3A activity assay and western blot to examine the activity 
and polypeptide level of CYP3A. 
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3.3. Methods and Materials 
3.3.1. Materials 
3.3.1.1. Chemical reagents 
Selumetinib and crizotinib were purchased from LC laboratories (Woburn, 
MA, USA). RPMI, BSA, FBS, penicillin/streptomycin were purchased from Life 
Technologies (Auckland, New Zealand). 3, 3’-diamino benzadine (DAB) 
substrate kit and streptavidin-horseradish peroxidase were purchased from BD 
Biosciences (San Diego, CA, USA). Haematoxylin quick stain (QS) (modified 
Mayer’s formula), avidin–biotin blocking kit were purchased from Vector 
Laboratories (Burlingame, CA, USA). Acrylamide (1:30) and precision plus 
protein kaleidoscope were obtained from Bio-Rad Laboratories (Hercules, CA, 
USA). Acetone, acetylacetone, hydrogen peroxide (30%) and methanol were 
obtained from Merck (Billerica, MA, USA). ALT assay kit, bicinchoninic acid 
assay kit, CL-XPosure film, cryomatrix, NADPH and supersignal west pico were 
purchased from Thermo Fisher Scientific (Waltham, MA, USA). Creatinine 
colourimetric assay kit was purchased from Cayman Chemical Company (Ann 
Arbor, MI, USA). Ammonium acetate, barium hydroxide, butylated 
hydroxytoluene (BHT), citric acid, DMSO, dithiothreitol (DTT), 
ethylenediaminetetraacetic acid (EDTA) eosin Y solution alcohol, glycerol 
matrigel, PBS, poly-L-lysine, potassium chloride (KCL), potassium 
pyrophosphate, trizma hydrochloride (Tris-HCL), xylene (DPX) mounting 
medium and zinc sulphate were purchased from Sigma Aldrich (St Louis, MO, 
USA). Xylene was purchased from Bio-lab (Auckland, New Zealand). Dako pen 
was purchased from Dako (Glostrup, Denmark). 
3.3.1.2. Antibodies 
Ki67 was purchased from Abcam (Cambridge, UK). CD105 was obtained 
from Antibodies- online.com (Limerick, USA). ApopTag peroxidase in situ 
apoptosis detection kit was obtained from Merck (Billerica, MA, USA). 
Antibodies against CYP3A and GAPDH antibody were purchased from Thermo 
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Fisher Scientific (Waltham, MA, USA). Polyclonal goat anti-rabbit 
immunoglobulin/biotinylated were purchased from Dako (Glostrup, Denmark). 
HRP-conjugated goat anti-rabbit and HRP-conjugated goat anti-mouse were 
obtained from Calbiochem (San Diego, CA, US). 
3.3.2. Methods 
3.3.2.1.  Animal housing and care 
Male nude (Nu/J) were purchased from the Animal Resource Centre 
(Canning Vale, Australia). Male Balb/c mice were purchased from the Hercus-
Taieri Resource Unit (University of Otago, Dunedin, New Zealand). Mice were 
housed in the pathogen-free condition supplied with free access to sterile water 
and food (Reliance rodent diet). The room was maintained at a temperature of 
21-24oC with relative humidity at 30 ± 5% on a scheduled 12 h light/dark cycle 
and mice were acclimatised for 4 days prior to the experiment. All animal 
experiments were approved by the University of Otago Animal Ethics 
Committee (AEC Approval No. 18-21 and 18-82). 
3.3.2.2. Drug efficacy in a xenograft model of ALK-positive non-small cell lung 
cancer 
An ALK-positive NSCLC xenograft model was established by 
subcutaneous injection of H3122 cells (2 × 106 cells in 50 µL Matrigel and 50 uL 
of media) in the flank region of Nu/J mice. Once the tumour volume had reached 
~100 mm3, the mice were randomised into four groups (n=7). Each group 
received either vehicle (25% DMSO/75% olive oil, 5 ml/kg), crizotinib 25 
mg/kg, selumetinib 25 mg/kg or their combination p.o once daily for 14 days. 
Animal equivalent dose was calculated from the equation as described in Nair 
et al. (Nair et al., 2018).The animal doses were chosen on the basis that it is lower 
or equivalent to a well-tolerated human dose (Banerji et al., 2010; Kwak et al., 
2010; Nair et al., 2018; Nencioni et al., 2014; Zhou et al., 2012). Body weight and 
tumour volume were measured daily. Tumour volume (mm3) was calculated by 
multiplying the length (L) x height (H) x width (W). At the end of treatment, 
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mice were euthanised by carbon dioxide inhalation. Mice were perfused with 
isotonic PBS and major organs including liver, kidney, spleen. heart, lung, testes 
were removed and weighed. Tumours were removed, weighed, and fixed in 4% 
paraformaldehyde for 24 h followed by 30% cold sucrose for 24 h at 4oC. 
Tumours were embedded in optimal cutting temperature compound (OCT) 
solution and frozen immediately in liquid nitrogen. The frozen tumours were 
stored at -20oC until further required. 
3.3.2.3.  Immunohistochemistry of tumour sections 
Ki67 
Cell proliferation in tumour sections was estimated by using Ki67 antibody. 
The tumours were sliced at a thickness of 10 µm and stored in -20oC. The sections 
were thawed at room temperature for 30 min and washed with isotonic PBS two 
times for 5 min each. Excess of PBS was aspirated, and the sections were fixed 
with 4% ice-cold acetone for 10 min at room temperature. Slides were then air-
dried and Dako pen was used to draw a circle around each section. Endogenous 
peroxidase activity was blocked with hydrogen peroxide (3% in methanol) for 
20 min at room temperature. The sections were washed with isotonic PBS three 
times for 5 min each. Heat mediated antigen retrieval was performed by 
incubating sections in 0.01 M citrate buffer with 0.05% Tween 20, pH 6.8 for 10 
min at 95oC. The sections were then incubated with blocking buffer (2% normal 
goat serum, 1% BSA, 4 drop/1 ml of avidin) for 1 h at room temperature in a 
humidified chamber. This was followed by overnight incubation with Ki67 
antibody (1:100 in 0.2% BSA with 4 drop/1 ml of biotin) at 4oC in a humidified 
chamber. For negative controls, the antibody was replaced with PBS. Next, the 
sections were washed with isotonic PBS two times for 5 min each and then 
incubated with biotinylated secondary antibody (1:500 in 0.2% BSA) for 30 min 
at room temperature. The streptavidin was applied for 30 min at room 
temperature and a signal was detected using DAB (5 min). The sections were 
counterstained with haematoxylin QS and dehydrated with increasing 
concentrations of ethanol (70%, 95%, 100%) for 2 min each. Lastly, the sections 
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were soaked in xylene two times for 5 min each and then mounted using DPX 
mounting solution. The slides were scanned with the Aperio Image ScanScope 
System (Leica, Chicago, IL, USA) and were analysed blinded to the treatment 
group. The nuclear image analysis algorithm was used to quantify Ki67 stained 
(proliferative) cells. 
TUNEL assay 
The TUNEL assay was performed to visualise apoptotic cells using the 
ApopTag in situ detection kit as per the manufacture’s instruction. Briefly, 
sections were washed in isotonic PBS two times. The sections were then fixed in 
ethanol-acetic acid solution (2:1) and incubated with 3% hydrogen peroxide (5 
min) to block endogenous peroxidases. The sections were incubated with an 
equilibrating buffer for 5 min followed by terminal deoxynucleotidyl transferase 
(TdT) enzyme for 1 h in a humidified chamber. For negative control, the TdT 
enzyme was replaced with PBS. The reaction was stopped using stop/wash 
buffer (10 min) and washed with isotonic PBS three times. This was followed by 
the incubation of the section with anti-digoxigenin peroxidase for 30 min at room 
temperature. Finally, the sections were stained with DAB, counterstained with 
haematoxylin QS, dehydrated and mounted. Slides were then scanned with the 
Aperio Image ScanScope System (Leica, Chicago, IL, USA) and were analysed 
blinded to the treatment group. The nuclear image analysis algorithm was used 
to quantify TUNEL stained (apoptotic) cells. 
CD105 
CD105, an indicator of microvessel density (MVD), is highly expressed in 
endothelial cells of tumour blood vessels. The tumours were sectioned (10 µm) 
and were fixed in acetone for 10 min. Endogenous peroxidase activity was 
blocked with 3% hydrogen peroxide and was incubated with blocking buffer in 
a humidified chamber for 1 h at room temperature. This was followed by 
overnight incubation with CD105 antibody (1:100 with biotin) in a humidified 
chamber at 4oC. For negative controls, the antibody was replaced with PBS. The 
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sections were incubated with biotinylated secondary antibody (1:100) for 30 min. 
The streptavidin was applied for 30 min at room temperature and a signal was 
detected using DAB. The sections were counterstained with haematoxylin QS, 
dehydrated and mounted. Slides were then scanned with the Aperio Image 
ScanScope System (Leica, Chicago, IL, USA). The microvessel analysis algorithm 
was used to quantify the MVD at a dark- and light-staining threshold of 180 and 
210, respectively 
3.3.2.4. In vivo toxicity studies 
Male Balb/c mice were divided into 2 groups. Group 1 (n=6) received 
either vehicle (10% DMSO/ 90% olive oil), crizotinib 5 mg/kg, selumetinib 25 
mg/kg or their combination p.o once daily for 14 days. Similarly, group 2 (n=6) 
received either vehicle (25% DMSO/ 75% olive oil 5mL/kg), crizotinib 25 mg/kg 
and a combination of crizotinib 25 mg/kg and selumetinib 25 mg/kg p.o once 
daily for 14 days. As a positive control for CYP3A induction, mice (n=5) were 
orally administered daily with dexamethasone (50 mg/kg) for 4 days (McCune 
et al., 2000; Valentine et al., 2006; Xu, Zhang, et al., 2018). At the end of treatment, 
mice were euthanised by carbon dioxide inhalation Blood was collected from the 
posterior vena cava using a heparinised syringe. The plasma was separated by 
centrifugation at 5000 rpm for 10 min at 4oC and stored at -20oC. Mice were 
perfused with isotonic PBS and major organs including liver, kidney, spleen. 
heart, lung, testes were removed, weighed, and washed with isotonic ice-cold 
PBS. The organs were then submerged in 10% formalin for 48 h followed by 30% 
starch solution for 24 h in a cold room (4oC). Finally, the organs were embedded 
in OCT solution and were frozen immediately in liquid nitrogen. The frozen 
organs were stored in -20oC until further required. The organ weight was 
determined and expressed as a percentage of total body weight. 
3.3.2.5. Alanine Transaminase activity 
Alanine transaminase (ALT), an indicator of hepatotoxicity, was 
determined using the commercially available Infinity ALT colourimetric assay 
kit. The assay was performed according to the manufacturer’s instruction. 
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Briefly, 10 µL of plasma was transferred to cuvette which was then diluted to 100 
µL with milli-Q water. This was followed by the addition of 1000 µL of warm 
ALT reagent (37oC). Absorbance was measured on a visible spectrophotometer 
at a wavelength of 340 nm for 0 to 3 min. ALT activity, expressed in international 
unit per litre (U/L), was determined from the following equations. 
𝑨𝑨𝑨𝑨𝑨𝑨 𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂 𝒂𝒂𝒊𝒊 𝑼𝑼𝒊𝒊𝒂𝒂𝒂𝒂𝑼𝑼 𝒑𝒑𝒑𝒑𝒑𝒑 𝒍𝒍𝒂𝒂𝒂𝒂𝒑𝒑𝒑𝒑 (𝑼𝑼/𝑨𝑨)  =  𝜟𝜟 𝑨𝑨𝑨𝑨𝑼𝑼/𝒎𝒎𝒂𝒂𝒊𝒊 ×  𝒇𝒇𝒂𝒂𝒂𝒂𝒂𝒂𝒇𝒇𝒑𝒑 
Equation 3.1 Calculation of alanine transaminase activity 
where, 𝜟𝜟 𝑨𝑨𝑨𝑨𝑼𝑼  is absorbance (0min)- absorbance (3min) and the factor was 
calculated as below: 
𝑭𝑭𝒂𝒂𝒂𝒂𝒂𝒂𝒇𝒇𝒑𝒑 =  𝑨𝑨𝑻𝑻 ×  𝟏𝟏𝟏𝟏𝟏𝟏𝟏𝟏/ 𝟔𝟔.𝟑𝟑 ×  𝑺𝑺𝑻𝑻 ×  𝑷𝑷 
Equation 3.2 Calculation of factor for alanine transaminase activity 
where, 𝑨𝑨𝑻𝑻 is total reaction volume in ml (1 ml), 𝑺𝑺𝑻𝑻 is Sample volume in ml (0.1 
ml), 𝟔𝟔.𝟑𝟑 is millimolar absorption coefficient of NADH at 340 nm, 𝑷𝑷 is cuvette 
pathlength in cm (1 cm). 
3.3.2.6. Creatinine assay 
Creatinine, an indicator of renal function, was determined using a 
commercially available creatinine colourimetric assay kit from Cayman chemical 
company. The assay was performed according to the manufacturer’s 
instructions. Briefly, all the reagents were equilibrated to room temperature. 
Creatinine reaction buffer was prepared by mixing creatinine sodium borate, 
creatinine surfactant and creatinine 1 M sodium hydroxide in 1:3:2 ratio. 
Creatinine standard (0-5.0 mg/dL) was prepared as per the manufacturer’s 
protocol. 15 µL of standard and sample (plasma) in duplicate was added to a 96 
well plate. This was followed by the addition of 100 µL of creatinine reaction 
buffer. Next, 100 µL of creatinine colour reagent was added to each. The 
absorbance was measured on a microplate spectrophotometer at a wavelength 
of 490 nm at 1 min and 7 min, respectively. The change in optimal density (Δ 
OD) was calculated from equation 3.3. Adjusted Δ O.D. was obtained by 
subtracting the average of Δ OD of control (zero concentration (0 mg/dL) of 
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creatinine standard) from the standards and test samples. The creatinine 
concentration in mg/dL was calculated from equation 3.4 
𝛥𝛥 𝑂𝑂𝑂𝑂 =  𝐴𝐴490 (7𝑚𝑚𝑚𝑚𝑚𝑚)  −  𝐴𝐴490 (1𝑚𝑚𝑚𝑚𝑚𝑚) 
Equation 3.3 Calculation of change in optimal density 
where, 𝛥𝛥 𝑂𝑂𝑂𝑂 is change in optimal density, 𝐴𝐴 is absorbance. 
𝑪𝑪𝒑𝒑 =
𝑨𝑨𝒅𝒅𝑨𝑨𝑨𝑨𝑼𝑼𝒂𝒂𝒑𝒑𝒅𝒅 𝑼𝑼𝒂𝒂𝒎𝒎𝒑𝒑𝒍𝒍𝒑𝒑 𝜟𝜟 𝑶𝑶𝑫𝑫 − (𝒂𝒂 − 𝒂𝒂𝒊𝒊𝒂𝒂𝒑𝒑𝒑𝒑𝒂𝒂𝒑𝒑𝒑𝒑𝒂𝒂)
𝑼𝑼𝒍𝒍𝒇𝒇𝒑𝒑𝒑𝒑
 ×  𝑼𝑼𝒂𝒂𝒎𝒎𝒑𝒑𝒍𝒍𝒑𝒑 𝒅𝒅𝒂𝒂𝒍𝒍𝑨𝑨𝒂𝒂𝒂𝒂𝒇𝒇𝒊𝒊 
Equation 3.4 Calculation of serum creatinine 
where, 𝐶𝐶𝐶𝐶 is creatinine in mg/dL. 
3.3.2.7. Histology 
Histology was performed to investigate cellular change in the liver of mice 
that exhibited increased ALT activity. The frozen livers were sliced at a thickness 
of 15 µm using a cryostat microtome (CM 1959, LEICA Biosystems) maintained 
at -20°C. The liver sections were placed on poly-L-lysine-coated microscope 
slides and then dried under a fan overnight. The dried sections were then stored 
at -20°C until required. The sections were thawed for 30 min at room 
temperature and washed in isotonic PBS two times for 5 min each. This was 
followed by rinsing of sections with distilled water for 10 sec and staining with 
heamotoxylin QS (H-3404) for 10 sec. Next, the sections were rinsed in tap water 
until a blueish colour was obtained. The sections were washed in dH2O and 
rinsed in 95% ethanol for 10 sec. The sections were then counterstained with 
eosin for 15 sec. The excess of eosin was removed by rinsing in 95% ethanol. 
Next, the sections were dehydrated in increasing concentration of ethanol (70%, 
95%, 100%) for 2 min. Lastly, the sections were soaked in xylene two times for 5 
min each and mounted in DPX mounting solution. Finally, the sections were 
examined, and representative pictures were captured using the Nikon RM229 
microscope.
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3.3.2.8. Microsome preparation 
Hepatic microsomes were prepared from treated mice as previously 
described by Guengerich (Guengerich, 2014). Briefly, the liver was removed and 
placed in individual beakers containing 1.15% potassium chloride (KCl) on ice. 
The liver was washed with 1.15% KCl, trimmed and debris was removed. This 
was followed by homogenisation of the liver with 2 mL of buffer A pH 7.4 (0.1 
M Tris, 0.1 M KCl, 1 mM EDTA, 20 µM BHT). Homogenisation was carried out 
with a Teflon-glass homogeniser using 5-6 vertical passes. The homogenate was 
then centrifuged at 10,000 rpm for 20 min. The supernatant was transferred into 
new tubes and was centrifuged at 35,000 rpm for 1 h. The supernatant obtained 
was discarded and an equal volume of buffer B pH 7.4 (0.1 M potassium 
pyrophosphate, 1 mM EDTA, 20 µM BHT) was added into the same centrifuge 
tube containing pellets. The pellets were dislodged with the use of a pipette and 
then homogenised with 4 passes of the Teflon-glass homogeniser. The 
homogenate was centrifuged at 35,000 rpm for 1 h. Again, the supernatant was 
discarded and 1 mL of buffer C pH 7.4 (10 mM Tris-HCl, 1 mM EDTA, 20% 
glycerol) was added to the pellet and again homogenised. Note that 
dithiothreitol (DTT) was added to each buffer (Buffer A, B, C) before use. The 
final homogenate was transferred to Eppendorf tubes and was stored in -80oC. 
The BCA assay was performed as described in Section 2.3.2.3 of Chapter 2 to 
determine the protein concentration of the microsomes.  
3.3.2.9. Erythromycin N-demethylation 
Erythromycin N-demethylation assay was performed to determine the 
catalytic activity of CYP3A as described by Kitada et al. (Kitada et al., 1988). The 
reaction mixture containing 1 mg of microsomal protein and 0.45 ml of 
erythromycin buffer (0.1 M phosphate buffer pH 7.4, 0.1 mM EDTA and 0.4 mM 
erythromycin) was prepared and incubated for 2 min at 37oC in a shaking water 
bath. The reaction was initiated by addition of 0.05 mL of 50 mM NADPH. After 
30 min, 0.33 mL of 15% zinc sulphate was added and was incubated for 5 min at 
room temperature. Next, 0.33 mL of saturated barium hydroxide was added to 
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each sample, mixed gently, and was further incubated for 5 min. The samples 
were then centrifuged for 10 min at 2000 rpm. 0.83 ml of supernatant was 
pipetted into new glass test tubes followed by addition of 0.33 mL of Nash 
reagent (30% ammonium acetate and 0.4% acetylacetone). The samples were 
then incubated for 30 min at 60oC, centrifuged and absorbance of the supernatant 
was measured on a visible spectrophotometer at the wavelength of 415 nm. The 
catalytic activity of CYP3A was expressed as nmol/mg/min. 
3.3.2.10.  Western blotting 
Western blotting was performed as described in the Section 2.3.2.3 of 
Chapter 2. Briefly, 1 µg/ µL of proteins sample were prepared and heated in 4×-
Laemmli sample buffer at 95oC for 5 min. 10 µL was then subjected to SDS-PAGE 
and analysed by Western blotting. The concentration of the primary antibody 
used was - CYP3A (1: 1000) and GAPDH (1: 3000). 
3.3.2.11. Statistical analysis 
Tumour volume was analysed using a two-way ANOVA mixed effect 
coupled with a Tukey post-hoc test, with day of treatment as a repeated-
measures factor and drug treatment as an independent factor. All other data that 
were independent of the time were analysed using a one-way ANOVA coupled 
with Bonferroni post-hoc test. Data are presented as the mean ± SEM. p < 0.05 
was the minimal requirement for a statistically significant difference. Data were 
tested for normality using the Kolmogorov-Smirnov test, and non-normal data 
was log-transformed before further analysis using Graphpad prism V8. 




3.4.1. Efficacy of the combination treatment in xenograft model of ALK-
positive non-small cell lung cancer 
In a previous study, the combination of crizotinib and selumetinib 
significantly decreased the proliferation of ALK-positive NSCLC cells. To 
determine whether the in vitro efficacy is translated to in vivo, the efficacy of the 
crizotinib, selumetinib and their combination was further investigated in a 
xenograft model of ALK-positive NSCLC. Nu/J mice bearing H3122 xenografts 
were treated with crizotinib (25 mg/kg), selumetinib (25 mg/kg) and their 
combination orally once daily for 14 days. Mice were monitored daily for their 
weight loss and survival. There were slight decreases in the bodyweight of the 
mice in all four groups (Table 3.1), but no statistically significant difference in 
body weight between the treatment groups and the vehicle control was observed 
(p > 0.05, one-way ANOVA). Similarly, there were no significant differences in 
organ weight (expressed as % of body weight) among the treatment groups 
compared to the vehicle control (p > 0.05, one-way ANOVA) (Table 3.1) 
Crizotinib, selumetinib and their combination treatment significantly 
decreased tumour volume by 52%, 59% and 76% compared to the vehicle control. 
Furthermore, combination treatment significantly decreased tumour volume by 
50% and 42%, respectively, compared to the crizotinib (p < 0.05, two-way 
ANOVA) and the selumetinib (p < 0.05, two-way ANOVA) single drug 
treatments. Of particular note, unexpectedly mice treated with selumetinib alone 
decreased tumour growth greater than crizotinib alone (although statistically not 
significant) (Figure 3.1A). However, there was no significant difference in 
tumour weight among the treatment groups (Figure 3.1B). Moreover, the 
correlation between tumour volume and tumour weight was examined. high 
correlation (r = 0.9903) was found, suggesting unbiased measurement (Figure 
3.1C). 
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Table 3.1 Body weight and organ weight of Nu/J mice 








-0.2 ± 0.29 -0.45 ± 0.38 -0.4 ± 0.34 -0.03 ± 0.47 
Organ Weight (% of Body Weight) 
Liver 6.05 ± 0.41 5.8 ± 0.21 6.2 ± 0.3 6.5 ± 0.14 
Spleen 0.41 ± 0.07 0.49 ± 0.03 0.47 ± 0.03 0.49 ± 0.02 
Lungs 1.09 ± 0.09 1.17 ± 0.05 1.16 ± 0.07 1.12 ± 0.07 
Heart 0.49 ± 0.08 0.57 ± 0.02 0.57 ± 0.02 0.6 ± 0.01 
Kidneys 1.73 ± 0.3 1.97 ± 0.03 2.07 ± 0.05 2.05 ± 0.07 
Testes 0.8 ± 0.13 0.89 ± 0.05 0.9 ± 0.07 0.85 ± 0.04 
Brain 1.19 ± 0.06  1.23 ± 0.06 1.18 ± 0.07 1.26 ± 0.1 
Statistical significance was determined by one-way ANOVA with Bonferroni post-hoc test. All data are 
presented as mean ± SEM from n = 7. Multiple comparisons among treatment groups and vehicle did not 
show a significant difference in both body and organ weight (p > 0.05, one-way ANOVA) 
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Figure 3.1 Effect of crizotinib, selumetinib and their combination on tumour growth 
in a xenograft model of ALK-positive NSCLC. (A) Tumour volume (mm3) of male 
Nu/J mice bearing H3122 xenograft during treatment with a vehicle (olive oil), 
crizotinib (25 mg/kg), selumetinib (25 mg/kg) and their combination orally once daily 
for 14 days. Significance was determined by mixed-model two-way ANOVA with 
Tukey post-hoc tests. Data are presented as mean ± SEM, from n=7. Statistical 
differences between the growth curves as a whole are indicated as *p<0.05 for crizotinib 
vs. combination and, #p < 0.05 for selumetinib vs. combination, (B) Tumour weight in 
grams. Significance was determined by one-way ANOVA with Bonferroni post-hoc test. 
Data are presented as mean ± SEM from n=7. (C) Correlation between tumour volume 
and tumour weight. 
Chapter 3: Toxicity and efficacy of crizotinib and selumetinib combination treatment 
117  
 
3.4.2. Effect of the crizotinib, selumetinib and their combination on 
proliferation, apoptosis, and angiogenesis. 
To determine the mechanism of tumour growth suppression by crizotinib, 
selumetinib and their combination, immunohistochemistry of tumour sections 
was performed. Nu/J mice bearing H3122 xenografts were treated with 
crizotinib (25 mg/kg), selumetinib (25 mg/kg) and their combination orally once 
daily for 14 days. Tumours were excised, sectioned and immunolabelling with 
respective antibodies was performed. Ki67 is a marker of proliferating cells, and 
60-70% of cells in tumours from all treatment groups were Ki67 positive with no 
significant difference among the treatment groups and vehicle control (Fig. 3.2B, 
p > 0.05, one-way ANOVA). Because selumetinib alone suppressed tumour 
growth more than the ALK inhibitor crizotinib, it was hypothesised that a 
possible mechanism that could explain this could be inhibition of angiogenesis 
by interference with ERK signalling (Murphy et al., 2006). 
Immunohistochemistry for CD105, an endothelial cell marker was carried out. 
However, all tumours from all treatment groups were well vascularised as 
visualised with CD105 staining, with no statistically significant difference in 
MVD among the treatment groups and vehicle control (Fig. 3.3B, p > 0.05, one-
way ANOVA).  
It was then hypothesised that the frequency of apoptotic cells would be 
greatest in the treatment groups with the greatest tumour suppression (i.e., 
selumetinib alone and crizotinib plus selumetinib combination). However, 
histological staining for apoptosis using TUNEL unexpectedly revealed that the 
highest frequency of apoptotic cells was in tumours from crizotinib treated mice. 
By contrast, tumours from mice treated for 14 days with selumetinib either alone 
or in combination with crizotinib did not show a significantly different 
frequency of apoptotic cells compared with the vehicle control mice (Fig. 3.4B, p 
> 0.05, one-way ANOVA). 
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Figure 3.2 Effect of crizotinib, selumetinib and their combination on markers of cell 
proliferation. (A) Representative IHC staining of Ki67, (B) Quantification of Ki67 
positive using nuclear image algorithm. The H3122 xenograft mice were orally gavaged 
daily with vehicle (25%DMSO/olive oil), crizotinib (25 mg/kg), selumetinib (25 mg/kg) 
and their combination for 14 days. Tumours were resected and analysed by IHC. 
Significance was determined by one-way ANOVA with Bonferroni post-hoc tests. All 
data are presented as mean ± SEM from n=5. Multiple comparisons among the treatment 
groups and vehicle did not show a significant difference in Ki67 staining (p > 0.05). Scale 
bar: 100 µm. 
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Figure 3.3 Effect of crizotinib, selumetinib and their combination on the marker of 
angiogenesis. (A) Representative IHC staining of CD105, (B) Quantification of CD105 
positive endothelial cells using microvessel algorithm. The H3122 xenograft mice were 
orally gavaged daily with vehicle (25%DMSO/olive oil), crizotinib (25 mg/kg), 
selumetinib (25 mg/kg) and their combination for 14 days. Tumours were resected and 
analysed by IHC. Significance was determined by one-way ANOVA with Bonferroni 
post-hoc tests. All data are presented as mean ± SEM from n=5. Multiple comparisons 
among the treatment groups and vehicle did not show a significant difference in CD105 
staining (p > 0.05). Scale bar: 100 µm. 
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Figure 3.4 Effect of crizotinib, selumetinib and their combination on markers of 
apoptosis. (A) Representative IHC staining of TUNEL, (B) Quantification of TUNEL 
positive cells using IHC nuclear image algorithm. The H3122 xenograft mice were orally 
gavaged daily with vehicle (25%DMSO/olive oil), crizotinib (25 mg/kg), selumetinib 
(25 mg/kg) and their combination for 14 days. Tumours were resected and analysed by 
IHC. Significance was determined by one-way ANOVA with Bonferroni post-hoc tests. 
All data are presented as mean ± SEM from n=5. *p<0.05 for crizotinib vs. combination 
Scale bar: 100 µm.  
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3.4.3. Pre-clinical toxicity of the combination of crizotinib and selumetinib. 
To ensure that the crizotinib, selumetinib, and their combination are safe, 
Balb/c mice were treated with vehicle (DMSO/olive oil), crizotinib (5 mg/kg or 
25 mg/kg), selumetinib (25 mg/kg) and their respective combination orally once 
daily for 14 days. Mice were monitored daily for weight loss and survival. 
Change in body weight was not significantly different between the treatment 
groups (p > 0.05, one-way ANOVA) (Table 3.2 and Table 3.3). Furthermore, there 
was no significant difference in organ weight (expressed as % of body weight) 
between the treatment groups and vehicle control for all major organs (Table 3.2 
and Table 3.3). 
Next, to determine the effect of drugs on kidney and liver function, ALT 
activity and creatinine levels were examined. ALT activity in all treatment 
groups was not significantly different from vehicle control (p > 0.05, one-way 
ANOVA). However, in group 1, one mouse each from the vehicle, crizotinib, and 
combination groups had ALT activity greater than 80 U/L (i.e., 122, 296, and 104 
U/L, respectively, Figure 3.5A). Similarly, in group 2, one mouse each from the 
vehicle and crizotinib treated groups had ALT activity values greater than 80 
U/L (i.e., 126 and 89 U/L, respectively, Figure 3.5B). Therefore, the 
histopathology of the liver section was explored by performing H and E staining. 
No histopathological differences in liver sections between treatment groups and 
vehicle control were observed. Necrotic cells or lesions were not found in the 
liver section from the vehicle or drug treatment groups (Figure 3.6). Moreover, 
there was no significant difference in creatinine level (a kidney function marker) 
between any of the treatment groups, as all mice had plasma creatinine values 
in the normal range (< 2 mg/dl) (Figure 3.7). 
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Table 3.2 Body weight and organ weight of Balb/c mice (Group 1) 







change (g)  
0.37 ± 0.65 0.03 ± 0.93 0.55 ± 0.73 0.1 ± 0.65 
Organ Weight (% of Body Weight) 
Liver 5.26 ± 0.84 5.58 ± 1.01 4.92 ± 0.76 5.16 ± 0.97 
Spleen 0.32 ± 0.06 0.39 ± 0.12 0.28 ± 0.02 0.26 ± 0.03 
Lungs 0.87 ± 0.20 1.41 ± 0.55 0.87 ± 0.32 0.98 ± 0.25 
Heart 0.58 ± 0.11 0.71 ± 0.13 0.55 ± 0.04 0.52 ± 0.05 
Kidneys 1.96 ± 0.16 1.94 ± 0.25 1.89 ± 0.09 1.86 ± 0.15 
Testes 0.755 ± 0.13 0.73 ± 0.07 0.93 ± 0.25 0.69 ± 0.04 
Statistical significance was determined by one-way ANOVA with Bonferroni post-hoc test. All data are 
presented as mean ± SEM from n = 7. Multiple comparisons among treatment groups and vehicle did not 
show a significant difference in both body and organ weight (p > 0.05, one-way ANOVA) 
 
Table 3.3 Body weight and organ weight of Balb/c mice (Group2) 







change (g)  
-1.23 ± 0.35 -0.28 ± 0.41 0.55 ± 0.73 0.8 ± 0.23 
Organ Weight (% of Body Weight) 
Liver 5.60 ± 0.22 5.22 ± 0.22 4.92 ± 0.76 5.33 ± 0.20 
Spleen 0.27 ± 0.01 0.28 ± 0.02 0.28 ± 0.02 0.29 ± 0.01 
Lungs 1.15 ± 0.14 0.99 ± 0.15 0.87 ± 0.32 0.89 ± 0.08 
Heart 0.61 ± 0.08 0.57 ± 0.06 0.55 ± 0.04 0.55 ± 0.03 
Kidneys 2.02 ± 0.04 2.02 ± 0.09 1.89 ± 0.09 1.92 ± 0.03 
Testes 0.70 ± 0.14 0.65 ± 0.05 0.93 ± 0.25 0.69 ± 0.01 
Statistical significance was determined by one-way ANOVA with Bonferroni post-hoc test. All data are 
presented as mean ± SEM from n = 7. Multiple comparisons among treatment groups and vehicle did not 
show a significant difference in both body and organ weight (p > 0.05, one-way ANOVA) 
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Figure 3.5 Effect of crizotinib, selumetinib, and their combination on liver function 
in Balb/c mice. Mice were treated with the (A) vehicle (10%DMSO/ 90%olive oil), 
crizotinib (5 mg/kg), selumetinib (25 mg/kg) and their combination, (B) vehicle 
(25%DMSO/ 75%olive oil), crizotinib (25 mg/kg), selumetinib (25 mg/kg) and their 
combination, orally once daily for 14 days. Plasma was separated and ALT assay was 
performed. Significance was determined by one-way-ANOVA with Bonferroni post-hoc 
test. All data are presented as mean ± SEM, n=6. None were significantly different. 
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Figure 3.6 Histology of Liver sections. Mice were treated with the (A) vehicle 
(10%DMSO/ 90%olive oil), crizotinib (5 mg/kg), selumetinib (25 mg/kg) and their 
combination, (B) vehicle (25%DMSO/ 75%olive oil), crizotinib (25 mg/kg), selumetinib 
(25 mg/kg) and their combination, orally once daily for 14 days. The liver was excised, 
and H and E staining was performed. Morphological change in livers sections with 
elevated ALT was analysed. The picture was taken at 10×. Scale bar: 100 µm.
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Figure 3.7 Effect of crizotinib, selumetinib, and their combination on kidney function 
in Balb/c mice. Mice were treated with the (A) vehicle (10%DMSO/ 90%olive oil), 
crizotinib (5 mg/kg), selumetinib (25 mg/kg) and their combination, (B) vehicle 
(25%DMSO/ 75%olive oil), crizotinib (25 mg/kg), selumetinib (25 mg/kg) and their 
combination, orally once daily for 14 days. Plasma was separated and creatinine assay 
was performed. Significance was determined by one-way-ANOVA with Bonferroni 
post-hoc test. All data are presented as mean ± SEM, n=6. None were significantly 
different
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3.4.4. Effect of the combination treatment on CYP3A activity 
To determine whether crizotinib and selumetinib alone or in combination 
could alter the activity of their major metabolising enzyme CYP3A was 
investigated. Balb/c mice were treated with the vehicle (DMSO/olive oil), 
crizotinib (5 mg/kg or 25 mg/kg), selumetinib (25 mg/kg), and their respective 
combination orally once daily for 14 days. The liver was excised, microsomes 
were prepared, and the CYP3A assay was performed. There was no significant 
change in CYP3A catalytic activity in single or combination treatment of 
crizotinib and selumetinib compared to the vehicle control. Used as a positive 
control to check on assay validity, dexamethasone, a CYP3A inducer, 
significantly increased CYP3A catalytic activity compared to the vehicle control 
(p < 0.05, one-way ANOVA) (Figure 3.8A and 3.8D). Furthermore, Western 
blotting of microsomal protein showed no change in polypeptide levels of 
hepatic CYP3A by crizotinib, selumetinib and their combination (Figure 3.8C 
and 3.8F). Again, a significant increase in CYP3A protein by dexamethasone 
compared to vehicle control was observed (Figure 3.8C and 3.8F) (p < 0.05, one-
way ANOVA). These results suggest that neither crizotinib (5 mg/kg or 25 
mg/kg) nor selumetinib (25 mg/kg) nor a combination of the two alter the 
metabolism of either drug.
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Figure 3.8 Effect of crizotinib, selumetinib and their combination on CYP3A enzyme. 
(A) CYP3A catalytic activity, (B) Representative Western blots of CYP3A, (C) 
Densitometry of Western blots of CYP3A of Balb/c mice orally gavaged with vehicle 
(10%DMSO/olive oil), crizotinib (5 mg/kg), selumetinib (25 mg/kg) and their 
combination once daily for 14 days. (D) CYP3A catalytic activity, (E) Representative 
Western blots of CYP3A, (F) Densitometry of Western blots of CYP3A of Balb/c mice 
orally gavaged with vehicle (25% DMSO/olive oil), crizotinib (25 mg/kg), selumetinib 
(25 mg/kg) and their combination once daily for 14 days. The liver was harvested and 
microsomes were prepared. V: vehicle, C: crizotinib, S: selumetinib, C+S: combination, 
D: dexamethasone. Significance was determined by one-way-ANOVA with Bonferroni 
post-hoc test. All data are presented as mean ± SEM. Ψ p < 0.05 significantly different 
compared to vehicle control, crizotinib, selumetinib and the combination.  




The efficacy of crizotinib and selumetinib combination treatment and their 
underlying molecular mechanism of tumour suppression was investigated in a 
xenograft model of ALK-positive NSCLC. Furthermore, the toxicity of both the 
singular and combination treatment was examined. Lastly, the effect of 
crizotinib, selumetinib and their combination on the catalytic activity of hepatic 
CYP3A was determined. The combination showed superior efficacy with 
substantial tumour suppression compared to single drug treatment, but 
unexpectedly, selumetinib alone was almost as effective as the two drugs 
combined. Both the singular and combination treatment elicited no significant 
toxicity. Moreover, the two drugs had no effect on CYP3A activity and thus were 
unlikely to alter each other’s metabolism. 
The combination treatment significantly reduced tumour volume 
compared to all other treatments. This finding was consistent with the effect of 
drugs in in vitro study, where the combination of crizotinib and selumetinib 
synergistically inhibit the proliferation of ALK-positive NSCLC cells. The 
combination almost abolished the RAS/MAPK signalling resulting in a marked 
decrease in cell proliferation and increase in apoptosis compared to the single 
drug treatment. Interestingly, selumetinib alone reduced tumour growth to 
almost the same degree as the drug combination. Nevertheless, the unexpected 
efficacy of selumetinib as a monotherapy in vivo does not support the hypothesis 
that dual MEK/ALK inhibition in ALK-positive cancer would add benefit 
beyond what could be achieved by a sufficient dose of a MEK inhibitor alone. 
This conclusion is supported by toxicology results where 25 mg/kg/day 
selumetinib did not elevate any of the measures of toxicity. Thus, results 
comparable to combination drug treatment may be achieved by a MEK inhibitor 
alone at a tolerable dose. 
The results here are in contrast to in vitro experiments using H3122 cells, 
where selumetinib alone was 30-fold less potent at reducing cell viability than 
crizotinib alone. The reasons for the difference between these in vitro and in vivo 
results are unclear. The bioavailability of crizotinib (43%) (Kwon & Meagher, 
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2012) is only slightly less than that of selumetinib (62%) (Dymond et al., 2016); 
an insufficient difference to explain the contrast between the results obtained in 
in vitro previously and in vivo. The possible differences in drug metabolism may 
explain the difference in the results. Crizotinib is a primary substrate of CYP3A, 
and according to in vitro studies causes moderate CYP3A protein inhibition and 
induces mRNA expression (Johnson et al., 2015; Mao et al., 2013; Tan et al., 2010). 
CYP3A is also the major enzyme responsible for selumetinib metabolism 
(Dymond et al., 2016). It was hypothesised that CYP3A activity could be greater 
in mice treated with crizotinib, reducing crizotinib exposure compared to 
selumetinib administered alone. Nevertheless, no differences were detected in 
hepatic CYP3A activity and their polypeptide levels among crizotinib, 
selumetinib, and their combination compared to the vehicle control. 
Furthermore, immunohistochemistry was performed in attempts to 
determine the reasons for the unexpected efficacy of selumetinib as a 
monotherapy in this study. Both selumetinib and crizotinib are known to have 
anti-tumour activity by increasing apoptosis and decreasing cell proliferation 
and angiogenesis (Cozzo et al., 2016; Dai et al., 2017; Takahashi et al., 2012). It 
was first hypothesised that selumetinib may have had an anti-angiogenic effect 
through suppression of ERK activation (Murphy et al., 2006). Contrary to this 
hypothesis, both single and combination treatments did not reduce MVD in 
tumours taken from mice at day 14 compared to the vehicle control as measured 
by CD105 immunolabelling (Figure 3.3B). It was then hypothesised that the 
selumetinib treated tumours would show an increased frequency of apoptosis. 
Contrary to this hypothesis apoptosis was upregulated only in the crizotinib 
group compared to the vehicle control (Fig. 3.4B).  Finally, it was hypothesised 
that tumour suppression was due to a cytostatic effect of selumetinib, but in 
contradiction to this, there were no differences in proliferating cell frequency as 
measured by Ki67 immunolabelling (Fig. 3.2B).  
In vitro study had demonstrated that crizotinib, selumetinib and their 
combination significantly increased G1 phase arrest using flow cytometry. 
However, Ki67 is present in G1, S, G2 and the mitotic phase, and only absent in 
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the G0 phase of the cell cycle (Bruno & Darzynkiewicz, 1992; Guillaud et al., 
1989). Therefore, Ki67 labelling may not accurately reflect the response to 
treatment, as it would not differentiate between cells in G1 arrest and other cells. 
Moreover, the predictive value of Ki67 labelling index for response to 
chemotherapy remain controversial. In breast cancer clinical trials, the Ki67 
labelling was reported to be an independent prognostic factor but it was not 
related to improved treatment response (International Breast Cancer Study, 
2002; Viale et al., 2008; Yerushalmi et al., 2010). Additionally, in an animal study 
using a triple negative breast cancer xenograft model, an univariate statistical 
analysis showed that Ki67 labelling in tumour sections from control and treated 
mice were comparable, where significant tumour suppression was achieved 
(Martey et al., 2017). However, a multivariate analysis showed that Ki67 played 
an important role as a component of a biological network of 16 molecular targets 
that as a whole predicted treatment outcome with a 95% success rate (Martey et 
al., 2019). Thus, it is likely that Ki67 also plays a crucial role as a part of a larger 
protein network in the suppression of H3122 xenograft tumours. Multivariate 
analysis of different molecular targets of the combination treatment can help to 
identify the biological networks and interaction between signalling proteins that 
are crucial in suppression of tumour growth.  
Furthermore, suppression of ERK activation is also known to stimulate T-
cells activation in some cancers (Ebert et al., 2016). It is highly unlikely that this 
could account for the results, as the xenograft model employed athymic mice. 
Further studies are needed to ascertain the translatability of these findings to 
humans. 
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The development of an appropriate animal model is crucial for 
translational cancer research to be successful. Mouse models of cancer not only 
provide an opportunity to learn about cancer molecular biology in the dynamic 
physiological system, but also facilitates the investigation of novel anti-cancer 
therapy (Cheon & Orsulic, 2011; Zhang, Moore, et al., 2011). Prior to clinical 
trials, extensive preclinical studies are conducted to examine the preliminary 
pharmacokinetics, toxicity and efficacy of anti-cancer drugs (Mak et al., 2014). It 
is the purpose of this chapter to report on attempts to develop a new and 
improved mouse model of ALK positive lung cancer. 
4.1.1. Mouse models in cancer research 
Mouse models in cancer research can be categorised into xenograft, 
genetically engineered, syngeneic, and chemical induced model (Cekanova & 
Rathore, 2014; Cook et al., 2012; Kellar et al., 2015). Each model has its own 
advantages and limitations. 
4.1.1.1.  Xenograft models  
In xenograft cancer models, cancer cells of either human or animal origin 
are transplanted either subcutaneously under the flank (ectopic) or directly into 
the organ of tumour origin (orthotopically) in immunocompromised athymic 
nude mice or severely compromised immunodeficient SCID mice (Bibby, 2004; 
Liu et al., 2012; Morton & Houghton, 2007; Ruggeri et al., 2014). Athymic nude 
mice are deficient in T lymphocytes whereas, SCIDs mice are deficient in both B 
and T lymphocytes making them a suitable host for transplantation of human 
cancer cells (Bosma & Carroll, 1991; Flanagan, 1966). On the other hand, in 
immunocompetent mice the human cancer cells are likely to be rejected by the 
host immune system (Kellar et al., 2015). The use of human cancer cells in 
xenograft models facilitate the accurate representation of the complexities of 
human tumour (Kellar et al., 2015). Moreover, orthotopic cancer models closely 
mimic the microenvironment of human tumours and thus, provide a clinically 
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relevant system for evaluating novel drug therapies (Kellar et al., 2015; Onn et 
al., 2003). The main drawback of xenograft cancer models is the use of 
immunocompromised mice that may not represent natural responses of cancers 
in humans (Cekanova & Rathore, 2014). 
4.1.1.2.  Genetically engineered mouse models 
Genetically engineered mouse (GEM) models are generated by the 
manipulation of the mouse germline. They are developed either by activating 
oncogenes or suppressing tumour suppressor genes via different approaches 
such as transgenic, gene-targeting such as knockouts, knockins, conditional and 
inducible, RNA interference or chromosomal engineering (Cheon & Orsulic, 
2011; Zhang, Moore, et al., 2011). Transgenic mice are generated by 
microinjection of DNA into the pronuclei of fertilised zygotes where the 
transgene sequences are integrated into the mouse genome (Cekanova & 
Rathore, 2014). This model can be applied to study the role of genetic 
abnormalities in tumour initiation and progression (Kellar et al., 2015). The major 
limitation of transgenic models is the inability to control the level and pattern of 
transgene expression (Cheon & Orsulic, 2011). 
4.1.1.3.  Syngeneic mouse models 
Syngeneic mouse model is developed by injecting immunologically 
compatible cancer cells into immunocompetent mice. The Lewis lung carcinoma 
(LCC) model is currently the only reproducible syngeneic model for lung cancer. 
As these models are fully immunocompetent, they provide actual immune and 
toxicity responses to cancer therapy and tumour growth (Kellar et al., 2015; 
Olson et al., 2018). However, the main limitation of the syngeneic model is that 
its therapeutic efficacy is poorly translated in humans. This is most likely due to 
inherent differences in human and mouse cancer biology (Cook et al., 2012; 
Kellar et al., 2015). 
4.1.1.4. Chemically induced mouse models 
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Chemically induced mouse models are generated by exposure to 
carcinogens such as N-ethyl-N-nitrosourea, N-butyl-N-(4-hydroxybutyl) 
nitrosamine, N-ethyl-N-nitrosourea, azoxymethane, benzopyrene, urethane 31 
and asbestos fibres  (Cekanova & Rathore, 2014). This method uses the inbred 
mouse strains such as A/J or SWR that are susceptible to tumorigenesis (Kellar 
et al., 2015). 
4.1.2. Mouse models in lung cancer 
Lung cancer is the leading cause of cancer death worldwide (Ferlay et al., 
2015). This gives rise to the need for the development of a clinically relevant 
animal model of lung cancer that can facilitate the development of novel 
therapeutic strategies. Different mouse models of lung cancer have been 
developed using different technique (Kellar et al., 2015). 
The mouse model of lung cancer is developed by grafting the lung cancer 
cells of mouse origin onto a host mouse or induced in tissue by genetic 
modification or exposure of carcinogens (Henry et al., 1981; Kellar et al., 2015; 
Soda et al., 2008). The major disadvantages of these models are that they produce 
tumours of mouse origin that do not recapitulates human cancer (Kellar et al., 
2015). On the other hand, the human lung cancer cells are grafted either in the 
flank (ectopic) or directly into the lungs (orthotopic) of immunocompromised 
mice, such as SCID or nude mice (Kellar et al., 2015). The ectopic xenograft model 
of lung cancer is convenient to develop and has been extensively used, but the 
model does not mimic the organ environment in which the tumour naturally 
grows (Liu et al., 2012; Richmond & Su, 2008). However, the orthotopic model of 
lung cancer closely mimic the tumour microenvironment and are clinically 
relevant (Kang et al., 2006; Liu et al., 2012; Onn et al., 2003). 
Orthotopic lung cancer models can be developed by several different 
methods. The cells may be directly injected into the lung either by intrathoracic 
implantation via puncture (Liu et al., 2012) or the cells may be introduced into 
the airways by intratracheal (Kang et al., 2006) or intrabronchial injection 
(McLemore et al., 1987; Nakajima et al., 2014). Intrathoracic implantation, by 
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direct puncturing through the intercostal space to lung parenchyma, avoids 
thoracotomy or intubation, but increases the risk of intrathoracic haemorrhage 
and haemoptysis (Liu et al., 2012). The intrapulmonary implantation of lung 
cancer cells generates a site-specific tumour. However, the disadvantages of this 
method are the requirement of endotracheal intubation and thoracotomy 
(McLemore et al., 1987; Wang et al., 1997). Nonsurgical bronchial implantation 
enables the development of a tumour in a lung without causing pneumothorax, 
bleeding, pleural dissemination, or effusion, but the risk of death during cancer 
cell inoculation was increased (Nakajima et al., 2014).  
Due to the various problems in existing lung cancer models, an orthotopic 
model of lung cancer was attempted by engraftment via vascular delivery and 
pulmonary entrapment. This method has been successfully used to create lung 
tumour nodules in the lungs of immunocompetent mice using Lewis lung 
carcinoma cells (Zhao et al., 2012) and breast cancer lung metastasis (Rashid et 
al., 2013)  but has not been used to study non-small cell lung cancer using human 
lung adenocarcinoma cells in immunocompromised mice.  
4.2.  Aim and objectives 
The aim was to establish an orthotopic lung cancer model via tail vein 
injection of human lung adenocarcinoma cells. The specific objectives were (1) to 
characterise the tumour nodules from an orthotopic lung cancer model, (2) to 
detect the human cancer cells in the lung sections from the orthotopic lung cancer 
mouse model and, (3) to determine the presence of EML4-ALK fusion in the lung 
sections of mice injected with H3122 cells 
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4.3. Methods and Materials 
4.3.1. Materials 
4.3.1.1. Chemical reagents 
Crizotinib and selumetinib were purchased from LC laboratories (Woburn, 
MA, USA). RPMI, BSA, FBS, and penicillin/streptomycin were purchased from 
Life Technologies (Auckland, New Zealand). 3, 3’-diamino benzadine (DAB) 
substrate kit and streptavidin-horseradish peroxidase were purchased from BD 
Biosciences (San Diego, CA, USA). Haematoxylin quick stain (QS) (modified 
Mayer’s formula), avidin-biotin blocking kit were purchased from Vector 
Laboratories (Burlingame, CA, USA). Acetone, acetylacetone, hydrogen 
peroxide (30%) and methanol were obtained from Merck (Billerica, MA, USA). 
Citric acid, DMSO, ethylenediaminetetraacetic acid (EDTA), eosin Y solution 
alcohol, glycerol, PBS, poly-L-lysine, trizma hydrochloride (Tris-HCL), and 
xylene (DPX) mounting medium were purchased from Sigma Aldrich (St Louis, 
MO, USA). Xylene was purchased from Bio-lab (Auckland, New Zealand). Dako 
pen was purchased from Dako (Glostrup, Denmark) 
4.3.1.2. Antibodies 
Antibodies against ALK, p-ALK were purchased from Cell Signaling 
Technology (Danvers, MA, USA). Ki67 antibody was obtained from Abcam 
(Cambridge, UK). Polyclonal goat anti-rabbit immunoglobulin/biotinylated 
were purchased from Dako (Glostrup, Denmark). HRP-conjugated goat anti-
rabbit was obtained from Calbiochem (San Diego, CA, US). 
4.3.2. Methods 
4.3.2.1.  Cell culture 
Cell culture was carried out as described in Section 2.3.2.1 of Chapter 2. 
Briefly, A549 cells and H3122 cells were maintained in RPMI supplemented with 
penicillin (100 U/mL), streptomycin (100 μg/mL) and 2% and 5% of FBS, 
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respectively. Cells were grown in a humidified incubator at 37oC, 5% CO2 and 
95% O2. 
4.3.2.2. Animal housing and care 
Male immunocompromised SCID mice were purchased from Animal 
Resources Centre, Australia (Canning Vale, Australia). SCID mice were housed 
in pathogen-free condition with sterile woodchip bedding supplied with sterile 
food (Reliance rodent diet, Dunedin, NZ) and water. Mice were kept in a room 
maintained at a temperature of 21-24°C with relative humidity at 30 ± 5% on a 
scheduled 12 h light/dark cycle. All the animal experiments were performed 
after approval by University of Otago (AEC #9/17). 
4.3.2.3.  Tail vein injection 
Immunocompromised male SCID mice (n=48) weighing 20-30 g were 
divided into two identical experiments that comprised of 24 mice each. In each 
experiment, cell suspension of H3122 cell (1×106 cells/ml) and A549 cell (1×106 
cells/ml) in isotonic PBS was prepared. Mice were restrained, the tail was 
warmed for 3-5 min to dilate the veins, and then 100 µL of cell suspension 
containing either 1×105 H3122 cells or 1×105 A549 cells was injected into the 
lateral vein of the tail by the use of insulin syringes (needle bevel up) (12.7mm × 
29G needle). Mice were weighed daily and monitored for respiratory distress, 
mobility, and signs of pain daily for up to 8 weeks. A weight loss of more than 
20% was considered to be unacceptable and would lead to early euthanisation of 
the mouse. At the end of 3rd, 5th, and 8th week in each experiment, 4 mice from 
each group (i.e., 8 mice across the two repeats of the experiment) were 
euthanised by CO2 inhalation and perfused with isotonic PBS followed by 10% 
formalin. Major organs such as lungs, liver, kidney, spleen, brain, heart, testes 
were excised, weighed, and washed with isotonic PBS. The organs were then 
kept in 10% formalin for 48 hours at 4oC. On the following day, the organs were 
washed with isotonic PBS and were kept in 30% starch solution for 24 hours at 
4oC. Finally, organs were embedded in OCT and were frozen immediately in 
liquid nitrogen. The frozen organs were stored in -20oC. Lungs were quickly 
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photographed prior to fixation and compared with the lungs taken from SCID 
mice that were not injected with lung cancer cells, from another experiment. 
Figure 4.1 Schematic diagram of the study design of development of orthotopic lung 
cancer mouse model. Two identical experiments with total of (n = 48) mice was carried 
out as described in the Section 4.3.2.3 
4.3.2.4.  Histology 
The frozen lungs were sliced at a thickness of 6-µm using cryostat 
maintained at -20°C. The lung sections were placed on poly-L-lysine-coated 
microscope slides and then air-dried overnight. The sections were then stored at 
-20°C until required.  
Lung sections were thawed for 30 min at room temperature followed by 
washing in isotonic PBS two times for 5 min each. Next, sections were fixed by 
incubating in the mixture of an equal volume of acetone and methanol for 10 min 
at room temperature. This was followed by washing the section in distilled water 
(dH2O) for 10 sec. Heamotoxylin QS (H-3404) was added to each section and 
incubated for 25 sec. Then, the sections were rinsed in tap water until the blueish 
colour was obtained. The sections were washed in dH2O and dipped in 95% 
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ethanol for 15 sec. Eosin was then added and incubated for 45 sec. The excess of 
eosin was removed by rinsing in 95% of ethanol. Next, the sections were 
dehydrated in increasing concentration of ethanol (70%, 95% and 100%ethanol) 
for 2 min each. Lastly, the sections were soaked in xylene for 5 min for two times 
and mountant in DPX mounting solution. Coverslip mounted sections were then 
examined by two examiners blinded to the treatment groups using a Nikon 
RM229 microscope.  
4.3.2.5. Immunohistochemistry 
Ki67 
Lung sections of 6-µm thickness were sliced. The sections were thawed for 
30 min at room temperature and washed in isotonic PBS for two times 5 min 
each. Then, the sections were fixed in acetone for 10 min at room temperature. 
The excess of acetone was aspirated and then treated with 0.3 % H2O2 in 
methanol for 20 min. The sections were air-dried, and the circle was drawn 
around the section with DAKO pen. Sections were washed with isotonic PBS 
three times for 2 min each. Antigen retrieval was performed by boiling (at 95oC 
in water bath) the section in a citrated buffer (10mM citric acid, 0.05% Tween-20) 
pH 6 for 20-30 min followed by cooling in the same solution for 30 min. Then, 
the sections were washed with isotonic PBS two times for 5 min each and 
incubated in range of blocking solution (1.5%-5% goat serum, 0.2%-5% BSA) for 
1 h at room temperature in a humidified chamber. Avidin-biotin blocking was 
performed for the sections treated with biotinylated secondary antibodies.  The 
sections were rinsed with isotonic PBS for 5 min and incubated in primary 
antibody (Monoclonal mouse anti-human antigen Ki67) at a 1:100 dilution in 
0.2% BSA for overnight in a humidified chamber at 4oC. 
On the following day, the primary antibody was aspirated, and sections 
were washed with isotonic PBS four times for 5 min each. The sections were then 
incubated for up to 2 h with either HRP-conjugated secondary anti-rabbit 
secondary antibody or up to 45 min with biotinylated secondary antibody (1:100 
dilution in 0.2% BSA) was added at room temperature. The streptavidin was 
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applied for 30 min at room temperature (only for sections incubated with 
biotinylated secondary antibody). and a signal was detected using DAB. The 
sections were counterstained with haematoxylin QS. The sections were 
dehydrated in increasing concentration of ethanol (70%, 95% and 100%) for 2 min 
each, soaked in xylene and then mountant with DPX mounting solution. Finally, 
the sections were examined using the Nikon RM229 microscope. 
p-ALK 
Frozen sections sliced at a thickness of 6-µm were thawed for 30 min 
followed by washing in isotonic PBS twice for 5 min each. The sections were then 
fixed in acetone for 10 min and incubated with 3% H2O2 in methanol for 20 min. 
Antigen retrieval was carried out by boiling (at 95oC in water bath) in EDTA 
buffer (1mM EDTA and 0.05% Tween 20) pH 9 for 30 min and then cooling the 
sections in same buffer solution for 30 min at room temperature. The sections 
were incubated in range of blocking solution (1.5%-5% goat serum, 0.2%-1% 
BSA) for 1 h in a humidified chamber at room temperature. Avidin-biotin 
blocking was performed for the sections treated with biotinylated secondary 
antibodies. This was followed by incubation with p-ALK antibody (1:100 in 0.2% 
of BSA) for 48 hrs in a humidified chamber at 4oC. 
Next, the sections were washed with isotonic PBS four times for 5 min and 
were incubated for up to 2 h with either HRP-conjugated secondary anti-rabbit 
secondary antibodies or up to 45 min with biotinylated secondary antibody 
(1:100 dilution in 0.2% BSA) was added at room temperature. The streptavidin 
was applied for 30 min at room temperature (only for sections incubated with 
biotinylated secondary antibody) and a signal was detected using DAB. The 
sections were counterstained with haematoxylin QS, dehydrated and mounted. 
Finally, the sections were examined using the Nikon RM229 microscope. 
4.3.2.6.  Statistical analysis 
Comparison of weight gain over time between H3122 and A549 cells 
injected mice was analysed using linear regression. Comparison of body weight 
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change within a group (3rd, 5th, and 8th week) of mice injected with H3122 and 
A549 was analysed using one-way ANOVA with Bonferroni post-hoc test. 
Organ weight at necropsy was analysed using one-way ANOVA with 
Bonferroni post-hoc test. GraphPad prism V7 was used to carry out all statistical 
analyses. 




4.4.1. Body weight and Organ weight 
Mice were weighed daily and monitored for mobility, respiratory distress, 
and signs of pain to determine whether the tail vein injection of human lung 
adenocarcinoma cells affected mouse health. Mice injected with H3122 cells had 
slightly higher baseline body weight compared to those injected with A549 cells 
by 1.8 g (Figure 4.2, F value = 884.5, degree of freedom in the numerator (DFn) = 
1, degree of freedom in the denominator (DFd) = 111, p < 0.0001, linear 
regression). This difference in weight was maintained throughout the study and 
there was no significant difference in the rate of weight gained between them 
(Figure 4.2, 0.068 g/day for mice injected with A549 cells and 0.075g/day for 
mice injected with H3122 cells, F value = 2.549, DFn = 1, DFd = 110, p = 0.1133, 
linear regression). After 50 days of injecting the cells, mice started to show signs 
of distress evident as hunched posture, immobility, rough coats, and laboured 
breathing. At this point mice injected with A549 cells began to lose weight at the 
rate of 0.08 g/day. However, this was not significant (F value = 1.52. DFn = 1, 
DFd = 6, p = 0.2638, linear regression). On the 8th week, one of the mice had 
protruding eyes and was euthanised. Following this, remaining mice were also 
euthanised within a day.  
The change in body weight after the 3rd, 5th and 8th week of mice injected 
with H3122 and A549 cells are presented in Table 4.1 and Table 4.2, respectively. 
In H3122 injected mice, the change in body weight was significantly higher in 
mice euthanised at 8th week compared to those in 3rd week. However, in A549 
injected mice, the change in body weight was significantly higher in mice 
euthanised at 8th week compared to those in both 3rd and 5th week.  
Furthermore, there were no significant differences in organ weight 
(expressed as % of body weight) between any of the groups (3rd, 5th and 8th week) 
(p > 0.05, one-way ANOVA) as shown in Table 4.1 and Table 4.2. On visual 
examination of the lungs, indistinguishable or minimally apparent white patches 
were observed after 3rd weeks necropsy mice. By the 5th week, numerous 
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superficial white patches started to appear that further spread widely by week 8 
(Figure 4.3 and Figure 4.4). However, no abnormalities were observed in lungs 
of SCID mice from another experiment that was not injected with lung cancer 
cells. 
Figure 4.2 Body weight of SCIDS mice injected with H3122 or A549 cells over 8 weeks. 
SCIDS mice were injected with cell suspension containing either 1 ×105 H3122 cells or 1 
×105 A549 cells in the lateral vein of the tail. Mice were then euthanised at 3rd, 5th, and 
8th week. All data are presented as mean ± SEM. Significance was determined by linear 
regression analysis.  
 
Table 4.1 Body weight and organ weight of SCID mice injected with H3122 cells 
 3rd week 5th week 8th week 
Body weight 
change (g) 1.54 ± 0.51 
3.01 ± 0.53 3.40 ± 0.58* 
Organ weight (% of body weight) 
Liver  7.32 ± 0.52  7.67 ± 0.53 7.46 ± 0.35 
Spleen 0.19 ± 0.02 0.19 ± 0.01 0.23 ± 0.01 
Lungs 1.33 ± 0.09 1.61 ± 0.09 1.47 ± 0.12 
Heart 0.74 ± 0.03 0.90 ± 0.04 0.81 ± 0.03 
Kidneys 2.36 ± 0.12 2.44 ± 0.16 2.36 ± 0.07 
Testes 0.62 ± 0.03 0.61 ± 0.03 0.57 ± 0.02 
Brain 1.41 ± 0.06  1.23 ± 0.05 1.21 ± 0.04 
Statistical significance was determined by one-way ANOVA with Bonferroni post-hoc test. All data are 
presented as mean ± SEM from n = 8. * Significantly increase compared to body weight change in 3rd week
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Table 4.2 Body weight and organ weight of SCID mice injected with A549 cells 
 3rd week 5th week 8th week 
Body weight 
change (g) 2.34 ± 0.23 
2.07 ± 0.41 3.75 ± 0.28* 
Organ weight (% of body weight) 
Liver 6.79 ± 0.49 7.40± 0.47 8.30 ± 0.18 
Spleen 0.20 ± 0.01 0.22 ± 0.04 0.22 ± 0.01 
Lungs 1.18 ± 0.09 1.56 ± 0.09 1.46 ± 0.07 
Heart 0.71 ± 0.02 0.88 ± 0.03 0.74 ± 0.02 
Kidneys 2.26 ± 0.10 2.39 ± 0.11 2.48 ± 0.09 
Testes 0.52 ± 0.04 0.64 ± 0.02 0.60 ± 0.03 
Brain 1.29 ± 0.06  1.33 ± 0.06 1.27 ± 0.05 
Statistical significance was determined by one-way ANOVA with Bonferroni post-hoc test. All data are 
presented as mean ± SEM from n = 8. * Significantly increase compared to body weight change in 3rd week 
and 5th week. 
4.4.2. Histology and immunohistochemistry of lung sections 
To characterise the tumour nodules in the lungs of mice injected with 
H3122 and A549 human lung adenocarcinoma cells, H and E staining was 
performed. Histology of the lungs did not show tumour cell nodules with 
distinct edges (Figure 4.3 and Figure 4.4). At the 3rd week, lung sections of mice 
injected with H3122 and A549 cells showed a sparse network of bronchioles, 
alveolar ducts, and sacs with infrequent areas where cells were aggregated in the 
parenchyma (Figure 4.3A and Figure 4.4A). By week 5, these areas spread widely 
and further spread through by week 8. A larger size of Figure 4.3 and Figure 4.4 
are given in Appendix 1.3. and Appendix 1.4., respectively. 
Immunohistochemistry was performed to examine the presence of cancer 
cells in the lung sections of H3122 and A549 cells injected mice. However, the 
areas of cellular density found in the lung sections could not be confirmed as 
cancer cells as no positive staining for tumour cell markers was observed. The 
primary antibody for human specific cell marker (Ki67) staining was not 
distinguishable from that for non-specific labelling in lung sections of mice 
injected with either cell line. Furthermore, no specific staining with either ALK 
or p-ALK antibodies was observed in mice injected with H3122 cells. Here, the 
section incubated with secondary antibody showed high amounts of non-
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specific staining. Despite the use of a range of antigen retrieval techniques and 
different secondary antibodies (both directly conjugated to HRP, and 
biotinylated), specific labelling of the primary antibody was not detected in lung 
sections of mice injected with lung cancer cells compared to those not injected 
with lung cancer cells. 
Figure 4.3 Gross appearance and histology of lungs of SCID mice after 3rd , 5th and 8th 
week of injection with H3122 cells via the tail vein. Mice were injected with 1×105 
H3122 cells into lateral vein of the tail. Mice were then euthanised after 3rd, 5th and 8th 
week of injection. Lungs were excised, sectioned and H and E staining was performed. 
Lungs of mice at (A) 3rd, (B) 5th, (C) 8th weeks after cell injection. White patches on lungs 
appeared by week 5. H and E staining of lung sections of mice at (D) 3rd, (E) 5th, (F) 8th 
week after cells injection using a 10× objective. Squares and arrow indicate areas of high 
cell density. (G-I) Area shown in insets from panel (D-F) respectively, using 20× 
objective. (J-L) Area shown in insets from images (D-F), respectively, using 40× 
objective. Scale bars: D-I 100 µM and J-L 50 µM. 
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Figure 4.4  Gross appearance and histology of lungs of SCID mice after 3rd, 5th and 8th 
week of injection with A549 cells via the tail vein. Mice were injected with 1×105 A549 
cells into the lateral vein of the tail. Mice were then euthanised after 3rd, 5th and 8th week 
of injection. Lungs were excised, sectioned and H and E staining was performed. Lungs 
of mice at (A) 3rd, (B) 5th, (C) 8th weeks after cell injection. White patches on lungs 
appeared by week 5. H and E staining of lung sections of mice at (D) 3rd, (E) 5th, (F) 8th 
week after cells injection using a 10× objective. Squares and arrow indicate areas of high 
cell density. (G-I) Area shown in insets from panel (D-F) respectively, using 20× 
objective. (J-L) Area shown in insets from images (D-F), respectively, using 40× 
objective. Scale bars: D-I 100 µM and J-L 50 µM.




While it was intended to establish an orthotopic model of lung cancer via 
tail vein injection of human lung adenocarcinoma cells (H3122 and A549), the 
development of an orthotopic lung cancer model was not successful. Though 
some aggregation of cells were observed, discrete tumour nodules were not 
detected in the histology of the lung sections. Furthermore, no specific positive 
staining to human cancer markers such as Ki67 and ALK/p-ALK were detected 
in the lung sections.  
The mice injected with human lung adenocarcinoma cells gained body 
weight during the period of the experiment compared to the baseline body 
weight though poor animal condition was observed 7-8 week following 
injection. At each necropsy, no gross physical changes were observed in the 
major organs. This was evident from no marked differences in their weight. 
Furthermore, there was a lack of visually identifiable abnormalities on the major 
organs, except on the lungs. However, further studies are warranted to confirm 
the infiltration of cancer cells into the major organs. 
By the 5th week of necropsy, gross appearance of lungs showed the 
presence of numerous superficial white spots. Although, histological differences 
were observed, individual cancer cells could not be identified using 
immunohistochemistry. There may be two possible reasons for this. First, cancer 
cells may have been present but not detected by immunolabelling methods. This 
could potentially be due to over-fixation of lungs with formalin. Testing this 
hypothesis would require a repeat of the experiment, testing a range of fixation 
methods or other visualisation methods (such as fluorescently labelling cells). 
The second possible reason may be that the cancer cells have failed to engraft in 
the lung parenchyma, such that cellular aggregations in haematoxylin and eosin 
stained sections were either artefacts or pathological features secondary to 
embolism. However, this is difficult to reconcile with the time-dependent 
appearance of superficial lesions on the lungs, loss of body condition, and 
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increasing density of cells in lung histology, most apparent 8 weeks after 
injection of human lung adenocarcinoma cells. 
Tail vein injection method for the development of animal cancer model is 
known to cause thromboembolism (Rashid et al., 2013) that can in turn cause 
localised ischaemia and tissue hypoxia (Evans et al., 2017). Thromboembolism is 
a significant cause of death in human lung cancer, following the development of 
tumour nodules (Chew et al., 2008). In the Chew et al.  study, a sign of ischaemia 
was observed in mouse lungs at the beginning of week 5 after injection followed 
by a sudden decline in the health of the mice at 7-8 weeks. However, the use of 
tail vein injection method for the development of orthotopic lung cancer model 
did not result in visible tumour nodules. Additionally, cancer cells could not be 
detected. Therefore, the lung cancer model described here requires further 
development before it could be reliably used in preclinical drug development 
studies. 
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5.1. Synopsis of thesis 
ALK-positive NSCLC most commonly expresses the EML4-ALK fusion 
protein and it is associated with patients of relatively young age and with a non-
smoking history (Hallberg & Palmer, 2011; Shaw et al., 2009; Soda et al., 2007; 
Toyokawa & Seto, 2014b). Crizotinib is the first generation ALK-TKI with proven 
superiority over standard platinum-based chemotherapy (Solomon, Mok, et al., 
2014). Despite impressive initial responses to crizotinib in over 60% of patients, 
resistance inevitably develops within a year or two of therapy (Choi et al., 2010; 
Solomon, Mok, et al., 2014). The aim of this thesis was to develop combination 
therapy that targets the primary oncoprotein and its major effector aimed at 
overcoming existing resistance and ultimately at delaying the emergence of 
resistance. The results of the experiments described in this thesis showed that 
the combination of the ALK inhibitor crizotinib with MEK inhibitor selumetinib 
significantly improved efficacy in both in vitro and in vivo studies. Unexpectedly 
however, selumetinib alone reduced tumour growth to almost the same degree 
as the combination treatment in xenograft model of ALK-positive NSCLC. 
Moreover, both the singular and combination of crizotinib and selumetinib was 
safe and elicited no alteration in each other’s primary metabolizing enzyme, 
CYP3A. These findings support the clinical investigation of crizotinib and 
selumtinib combination therapy, but also suggest that much of the benefit of the 
combination may potentially be achieved using MEK inhibitor as a 
monotherapy. 
5.2.  Key findings of thesis 
5.2.1. Combination treatment in ALK-positive NSCLC 
The identification of an ALK-rearrangement oncogene as a therapeutic 
target and the development of potent ALK tyrosine kinase inhibitors (TKIs) has 
revolutionised treatment for ALK-positive patients (Camidge & Doebele, 2012). 
But despite initial responses, complete and lasting response to ALK-TKI 
monotherapy is rare to non-existent, as patients typically relapse within a year 
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of therapy (Sullivan & Planchard, 2015; Ziogas et al., 2018). This has been 
extended by sequential treatment with second or third generation ALK 
inhibitors such as ceritinib, alectinib or loratinib but only by several years 
(Gadgeel et al., 2014; Lin et al., 2017; Shaw, Friboulet, et al., 2016; Shaw et al., 
2019; Ziogas et al., 2018). The median OS for ALK-positive NSCLC patients 
receiving crizotinib followed by a next generation ALK TKIs is 7 years (Pacheco 
et al., 2019). Therefore, overcoming ALK inhibitor resistance is an area of major 
research effort. Another promising strategy that can overcome and delay the 
emergence of resistance is combination therapy (Bozic et al., 2013; Crystal et al., 
2014; Lovly & Pao, 2012; Zhou & Cox, 2015). Bozic et al. have concluded on 
theoretical grounds that the upfront combination of two drugs may be highly 
effective compared to sequential therapy in delaying the onset of drug resistance 
(Bozic et al., 2013). Their model predicted that failure of sequential treatment is 
high even in the absence of cross-resistance mutations, while simultaneous 
combination therapy has a potential to cure even in the presence of cross-
resistance mutations (Bozic et al., 2013). This is because tumours are genetically 
diverse and are thus likely to contain a small population of cells that may confer 
resistant to any given drug. Therefore, the use of a single drug is highly unlikely 
to eradicate a tumour as these cells will survive and multiply resulting in 
treatment failure. Therefore, combining two or more drugs may increase the 
chance of improving survival and potentially even cure (Bozic et al., 2013).  
Several potential combinations of ALK-TKIs with secondary TKIs for 
EGFR, IGFR, MEK1/2, STAT3 and SRC, HSP90 inhibitor, and immunotherapy 
have been investigated in a preclinical model and clinical trial of ALK-positive 
NSCLC (ClinicalTrials.gov National Library of Medicine (US), 2019a, 2019b; 
Courtin et al., 2016; Crystal et al., 2014; Cuyas et al., 2016; Hrustanovic et al., 2015; 
Lovly et al., 2014; Tanizaki, Okamoto, Takezawa, et al., 2012; Yamaguchi et al., 
2014). Clinical studies are recruiting to test the efficacy of the combination of 
ceritinib with trametinib (ClinicalTrials.gov National Library of Medicine (US), 
2019b) and alectinib with bevacizumab (ClinicalTrials.gov National Library of 
Medicine (US), 2019a) in ALK-positive NSCLC patients. Furthermore, Crystal et 
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al. (Crystal et al., 2014) reported that the combination of ceritinib and MEK 
inhibitor synergistically inhibit the proliferation of tumour cells in ALK-driven 
patient-derived in vitro and in vivo resistant model of ceritinib. They also 
demonstrated that a combination of crizotinib and SRC inhibitor effectively 
inhibited the proliferation of tumour cells in patient-derived in vitro and in vivo 
resistant models of crizotinib (Crystal et al., 2014). Similarly, combination of 
crizotinib with either EGFR or IGFR inhibitors showed synergistic inhibition in 
cell viability of ALK-positive NSCLC cells (Lovly et al., 2014; Wilson et al., 2017; 
Yamaguchi et al., 2014). 
Hrustanovic et al. have identified RAS/MAPK pathway as a major 
downstream effector of EML4-ALK harbouring lung adenocarcinoma 
(Hrustanovic et al., 2015). Moreover, they showed that upfront dual inhibition of 
ALK and MEK enhanced the magnitude and duration of initial response in both 
in vitro and in vivo models of ALK-positive NSCLC (Hrustanovic et al., 2015). 
Building on the work of Hrustanovic et al. this thesis focused on MAPK 
pathway, targeting MEK, which is an early mediator upstream of ERK but 
downstream of ALK and other RTKs such as EGFR, IGFR, MET, KIT. Here, the 
combination of ALK inhibitor, crizotinib, and MEK inhibitor, selumetinib, 
significantly suppressed the proliferation of tumour cells in in vitro and in vivo 
model of ALK-positive NSCLC that complements and corroborates the finding 
of Hrustanovic et al. 
However, there are some important differences between the result from 
this thesis and those of Hrustanovic et al. This can be explained firstly by a dose 
of trametinib and selumetinib used in an efficacy study of the combination 
treatment in xenograft model of ALK-positive NSCLC. Both trametinib and 
selumetinib are potent as MEK inhibitors (Wu & Park, 2015). Hrustanovic et al. 
have used the submaximal dose (1 mg/kg/day) of trametinib (Hrustanovic et 
al., 2015) whereas, in this study maximal dose (25 mg/kg/day) of selumetinib 
was used. Interestingly, selumetinib alone demonstrated unexpected efficacy in 
tumour suppression, unlike trametinib that had no marked effect as 
monotherapy in a xenograft model of H3122 cells.  
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Next, the combined effect of crizotinib and selumetinib was even greater in 
crizotinib resistant ALK-positive NSCLC cells, where even a low concentration 
of both drugs was sufficient to cause the significant suppression of cell 
proliferation. Clinical studies have suggested that targeting the resistance 
mechanism after the emergence of resistance may not be optimally efficacious 
(Johnson, Flaherty, et al., 2014). Johnson et al. showed that a combination of 
BRAF and MEK inhibitor after the emergence of resistance to BRAF inhibitor 
added no marked benefit to the patient with BRAF inhibitor-resistant melanoma 
(Johnson, Flaherty, et al., 2014). However, the dual inhibition of BRAF and MEK 
in the first line setting had a higher response rate and overall survival compared 
to BRAF inhibitors in patients with metastatic melanoma (Robert et al., 2015). 
Unlike for these results, the combination of crizotinib and selumetinib was 
highly effective in both crizotinib naïve and crizotinib resistant H3122 cells. 
Thus, the combination is likely to be beneficial even to patients with acquired 
resistance to crizotinib. However, specific studies are needed to ascertain the 
translation of these findings to human.  
The precise mechanism of resistance in CR-H3122 cells has not been 
determined. In a previous study, Wilson et al. showed the upregulation of 
phosphorylation of SRC and ALK in CR-H3122 cells (Wilson et al., 2017). In a 
separate study, the sequencing of the ALK kinase domain in both H3122 and CR-
H3122 did not reveal any differences (Appendix 1, Table A1.1). Thus, it was 
hypothesised that either ALK copy number is increased or ALK activation is 
dysregulated. Further studies are needed to understand the mechanism of 
resistance in CR-H3122 cells. 
Taken together, the results presented in this thesis are consistent with the 
work of Bozic et al. (Bozic & Nowak, 2016; Bozic et al., 2013) who concluded that 
simultaneous combination therapy can be more effective than sequential 
combination therapy in delaying the emergence of mutations or combinations of 
mutations that confer resistance to both drugs (Bozic et al., 2013). Thus, an 
upfront combination of the two drugs could suppress the accumulation of 
mutations and ultimately extend the time to relapse. 
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5.2.2. Mechanism of tumour suppression 
5.2.2.1. Effect on apoptosis 
Apoptosis plays a vital role in maintaining tissue homeostasis and is 
responsible for eliminating unwanted, damaged cells (Baig et al., 2016; Hassan 
et al., 2014; Jin & El-Deiry, 2005). Dysregulation of the apoptotic pathway is a key 
characteristic of cancer that not only facilitates tumour growth and survival but 
also renders resistance to therapy (Hassan et al., 2014; Igney & Krammer, 2002). 
Thus, a key strategy for the treatment of cancer is the use of a drug that can 
induce apoptosis in cancer cells. Here, it was hypothesised that the combination 
of crizotinib and selumetinib would combine to increase apoptosis in crizotinib 
naïve and crizotinib resistant ALK-positive NSCLC cells. 
Crizotinib has been reported to exhibit anti-tumour activity by induction of 
apoptosis in concentration dependent manner in both Karpas299 and SU-DHL-
1 ALCL cells (Christensen et al., 2007). The authors reported a 3 to 4-fold increase 
in the number of apoptotic cells after treatment with 100 nmol/L crizotinib for 
24 h (Christensen et al., 2007). Moreover, crizotinib was found to increase the 
percentage of apoptotic cells in dose dependent manner in both ovarian cancer 
cells (A2780 and SKOV3) (Huang et al., 2017) and pancreatic cancer cells (PANC-
1) (Yan et al., 2014). Similarly, treatment with selumetinib resulted in 
concentration dependent apoptosis in diffuse large B-cell lymphoma (SUDHL4, 
SUDHL6 and OCI-LY19) cells (Bhalla et al., 2011). Selumetinib induced > 70% 
apoptosis in SUDHL4 and > 40% apoptosis in SUDHL6 cells with 200 nM for 48 
h, whereas approximately 60% apoptosis in OCI-LY19 cells with 300 nM for 48 h 
(Bhalla et al., 2011). In breast cancer (MDA-MB-231 and HCC-1937) cells, 
selumetinib was found to increase the number of apoptotic cells in a 
concentration dependent manner (Zhou et al., 2016). In the present study, as 
hypothesised, the combination of crizotinib and selumetinib increased apoptosis 
compared to either of single drug treatment in both crizotinib naïve and 
crizotinib resistant ALK-positive NSCLC cells. This was mediated by 
upregulation of Bim, followed by an increase in the level of cleaved caspase-3 
and cleaved PARP. 
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Bim is a BH3 only proapoptotic protein, belongs to the B-cell lymphoma 2 
(Bcl-2) family. In response to cell stress, Bim binds to the anti-apoptotic/pro-
survival Bcl-2 proteins through its BH3 domain, sequestering them or directly 
activating proapoptotic effectors BAX and BAK that in turn trigger 
permeabilisation of mitochondria. Apoptogenic factors such as cytochrome c get 
released from mitochondria which then activate the caspases. The activated 
caspase causes cleavage of multiple cellular proteins such as PARP which induce 
apoptosis (Bouillet & Strasser, 2002; Campbell & Tait, 2018; Chen et al., 2005; 
Degterev et al., 2003; O'Connor et al., 1998; Sionov et al., 2015; Strasser et al., 
2000). Both crizotinib and selumetinib single drug treatment have been reported 
to induce apoptosis by upregulating the expression of Bim in various cancer cells 
including NSCLC cells (Bhalla et al., 2011; Tanizaki et al., 2011). In MET 
amplification-positive NSCLC (EBC-1 and H1993) cells, crizotinib was found to 
elicit apoptosis by increasing the expression of Bim. Transfection with siRNA 
specific to Bim mRNA was found to markedly suppress the upregulation of Bim 
by crizotinib that in turn resulted in a reduction of crizotinib induced apoptosis 
(Tanizaki et al., 2011). Crizotinib was also reported to upregulate Bim expression 
and induce apoptosis in FIG-ROS1-positive glioblastoma (U118) cells (Das et al., 
2015). Furthermore, a clinical study by Zhang et al. has shown that the Bim 
deletion polymorphism in ALK-positive NSCLC patients was related with poor 
clinical response to crizotinib with shorter PFS (182 days vs. 377 days) and poor 
ORR (44.4% vs. 81.7%) compared to those without it (Zhang et al., 2017). 
Similarly, selumetinib was reported to induce apoptosis by upregulating the 
expression of Bim in NSCLC (Calu-6, H2347 and H3122) cells. Knockdown of 
Bim by SiRNA was found to markedly decrease the overexpression of Bim by 
selumetinib that in turn inhibited selumetinib induced apoptosis (Meng, Fang, 
et al., 2010). In B-cell lymphoma cells, treatment with selumetinib increased the 
expression of Bim (Bhalla et al., 2011). Thus, Bim is the critical effector for both 
crizotinib and selumetinib single drug treatment. 
Furthermore, the apoptotic effect of crizotinib, selumetinib and their 
combination was further examined in this project using a xenograft model of 
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ALK-positive NSCLC. The TUNEL assays were performed to detect apoptotic 
cells in tumour sections. This assay is based on labelling of DNA breaks where 
terminal deoxynucleotidyl transferase (TdT) catalyse the attachment of deoxy-
nucleotide binds to 3’-OH ends of DNA double stranded break (Gavrieli et al., 
1992). Unexpectedly, apoptosis was upregulated only in the crizotinib treated 
group compared to vehicle control (although the difference was not significant). 
Neither selumetinib nor the combination exhibited greater apoptotic effect 
compared to crizotinib alone or vehicle control. These findings are in contrast to 
in vitro results where crizotinib and selumetinib individually elicited apoptosis 
and their combination synergistically increased apoptosis in H3122 and CR-
H3122 cells. This may be explained in part by the cytostatic effect of selumetinib. 
Some investigators have reported that MEK inhibitors - including selumetinib - 
have had a mainly cytostatic effect in a preclinical model of acute myelogenous 
leukaemia. Inhibition of MEK alone was not sufficient to trigger cell death in 
these cell lines (Zhang et al., 2014). Moreover, selumetinib was found to have a 
cytostatic effect in in vitro and in vivo model of melanoma. Selumetinib alone (10 
or 30 mg/kg BID) significantly suppressed the tumour growth by decreasing 
proliferation but did not induce apoptosis in in vivo model of melanoma. 
However, a combination of selumetinib (30 mg/kg) with docetaxel (15 mg/kg) 
increased its cytotoxic effects that resulted in tumour regression (Haass et al., 
2008). 
5.2.2.2. Effect on proliferation 
The fundamental characteristic of cancer cells is their ability to proliferate 
uncontrollably (Hanahan & Weinberg, 2000, 2011). Unlike normal cells, cancer 
cells lose their ability to control cell division leading to aberrant cell proliferation 
and growth (Farber, 1995; Feitelson et al., 2015; Golias et al., 2004). This is 
manifested by alteration in activity or expression of proteins involved in cell 
cycle progression (Feitelson et al., 2015). Since cell proliferation depends on the 
rate of cell division and the fraction of cells undergoing cell division (Andreeff 
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et al., 2000), it is crucial to investigate the effect of an anti-cancer drug on the cell 
cycle progression.  
In this study, crizotinib, selumetinib and their combination resulted in G1 
cell cycle arrest in both crizotinib naïve and crizotinib resistant ALK-positive 
NSCLC cells. Interestingly, the combination treatment compared to selumetinib 
significantly induced G1 phase arrest only at 24 h in crizotinib naïve H3122 cells 
and at 48 h in crizotinib resistant CR-H3122 cells. The G1 phase arrest was 
mediated by downregulation of cyclin D1 expression and overexpression of p27 
protein that in turn prevent the transition of G1 to S phase. In relation to this, 
cyclin D1-CDK4/6 and cyclin E-CDK2 complexes have been reported to be 
essential for G1 progression and G1/S phase transition, respectively. 
Additionally, p27 - a cyclin dependent kinase inhibitor – has been found to 
inhibit the activity of CDK2 and CDK2-cyclin complexes (Lees, 1995; Nigg, 1995; 
Vermeulen et al., 2003). In these studies, the combination of crizotinib and 
selumetinib synergistically enhanced p27 and reduced cyclin D1 expression that 
further increased G1 phase arrest and suppressed the S phase. These findings 
were consistent with the previous studies where both crizotinib and selumetinib 
single drug treatment resulted in G1 cell cycle arrest. Crizotinib has also been 
previously found to increase the number of cells in G1 phase and decrease the 
number of cells in S phase in concentration dependent manner in Karpas299 and 
SU-DHL-1 ALCL cells (Christensen et al., 2007). A similar result was 
demonstrated by Xu et al. where the treatment of 40 nM crizotinib for 72 h 
significantly increased the percentage of cells at G1 phase by 30% and 8% in both 
Karpas299 and SU-DHL-1 cells, respectively (Xu, Kim, et al., 2018). In pleural 
mesothelioma (H2593) cells, treatment of 1 µM crizotinib for 48 h increased the 
proportion of cells in G1 phase compared to control (Kanteti et al., 2016). 
Similarly, selumetinib was reported to significantly increase the percentage of 
cells in G1 phase and decrease the percentage of cells in S phase in concentration 
dependent manner in breast cancer (MDA-MB-231 and HCC-1937) cells (Zhou 
et al., 2016). In colorectal cancer (COLO205, HCT116, HT-29) and melanoma 
Chapter 5: Discussion 
158  
 
(A375 and MelJuso) cells, treatment with 1 µM selumetinib for 48 h resulted in 
G1 cell cycle arrest (Sale & Cook, 2013). 
Furthermore, the observed anti-proliferative effect of single and combined 
treatment with crizotinib and selumetinib in the in vitro study in this project was 
further explored in an in vivo study. Here, Ki67, a nuclear protein associated with 
cell proliferation (Gerdes et al., 1983), was measured in order to evaluate the anti-
proliferative effect of crizotinib, selumetinib and their combination treatment on 
ALK-positive NSCLC xenografts. Unexpectedly, no change in Ki67 staining was 
found among treatment groups compared to vehicle control. This finding was in 
contrast with the finding of in vitro studies using H3122 and CR-H3122 cells. 
Though Ki67 is generally used as a cell proliferation marker to predict the 
effectiveness of anti-cancer therapy in the suppression of tumour growth, it is 
crucial to note that the predictive value of Ki67 as an indicator of benefit of 
chemotherapy remains controversial. In the IBCSG VIII study, premenopausal 
patients were randomly allocated to receive either six 28-day courses of a 
combination of chemotherapy (cyclophosphamide, methotrexate, and 5-
fluorouracil (CMF)) alone or 24 monthly subcutaneous implants of goserelin 
alone or sequential treatment of six 28 days of CMF followed by 18 monthly 
goserelin implants. The sequential treatment of CMF and goserelin improved 
disease-free survival (DFS) (5-year DFS 88% vs. 84% vs. 73%) compared to CMF 
or goserelin alone (International Breast Cancer Study et al., 2003). In IBCSG IX 
study, postmenopausal patients were randomly allocated to receive either three 
28 days course of CMF followed by tamoxifen orally for 57 months or tamoxifen 
alone for 60 months. The sequential treatment of CMF and tamoxifen 
significantly improved DFS (5 years DFS 84% vs. 69%) and overall survival (89% 
vs 81%) compared to tamoxifen alone (International Breast Cancer Study, 2002). 
However, in both clinical trials, no significant interaction between Ki67 labelling 
and DFS was found (Viale et al., 2008; Yerushalmi et al., 2010). Therefore, Ki67 
labelling was not predictive of a better response to chemotherapy in these clinical 
studies. 
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5.2.2.3. Effect on angiogenesis 
Angiogenesis, a physiological process of formation of new blood vessels 
from pre-existing vessels, plays an important role in cancer progression and 
metastasis (Hanahan & Weinberg, 2011; Lugano et al., 2020; Nishida et al., 2006; 
Tonini et al., 2003; Weis & Cheresh, 2011). Neovasculature formed by the process 
of angiogenesis is required for proper nourishment (i.e., oxygen and nutrient 
supply) and elimination of metabolic waste from tumour sites (Hanahan & 
Weinberg, 2011). Thus, inhibiting the tumour related angiogenesis has become a 
key tactic to suppress tumour progression in cancer therapy. Both crizotinib and 
selumetinib individually have been reported to exhibit their anti-tumour activity 
by inhibiting angiogenesis in various cancers (Cozzo et al., 2016; Takahashi et al., 
2012; Yan et al., 2014; Zou et al., 2007). Thus, in this study it was hypothesised 
that the singular and combined treatment of crizotinib and selumetinib would 
reduce the angiogenesis in a xenograft model of ALK-positive NSCLC. The level 
of angiogenesis in tumour section was quantified by MVD was measured by 
immunolabelling of CD105. CD105, an auxiliary receptor of transforming factor 
beta (TGF-β) - predominately upregulated in proliferating endothelial cells 
(Burrows et al., 1995; Nassiri et al., 2011). It is highly specific to tumour 
neovascularisation (Miyata et al., 2013; Nassiri et al., 2011) compared to other 
pan-endothelial markers such as CD31 and CD34 that is expressed in pre-
existing vasculature, macrophages and, lymphatic endothelial cell (Fina et al., 
1990; Lindenmayer & Miettinen, 1995; Miyata et al., 2013). In this study, contrary 
to the hypothesis, no change in MVD was found in both single and combination 
treatment group compared to vehicle control. There are at least three possible 
reasons that may explain this finding. First possible reason may be deregulation 
of coordination of angiogenesis with continued tumour cell proliferation that 
causes hypoxia (Tonini et al., 2003). Since there was a rapid increase in tumour 
size in the vehicle control group (117 mm3 to 944 mm3 in 14 days), the rapidly 
proliferating tumour cells may outgrow the capacity of the host vasculature 
(Tonini et al., 2003) and decreases neovascularisation. This ultimately reduces 
the CD105 expression. Second reason may be overexpression of CD105 may not 
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always represent an increase in rate of angiogenesis  (Ollauri-Ibanez et al., 2020). 
The persistent high level of CD105 did not enhance angiogenesis by stimulating 
sprouting or vascularisation but rather caused alteration in structure of 
vasculature that prevented blood vessels from maturing and stabilising. That in 
turn facilitated invasion and metastasis of tumour cells (Ollauri-Ibanez et al., 
2020). Third reason may be that the singular and combination of crizotinib and 
selumetinib may not have any effect on angiogenesis in ALK-positive NSCLC. 
Furthermore, in a clinical study involving cervical squamous cell cancer patients 
treated with radical radiotherapy with/without chemotherapy, no correlation 
was found between the tumour CD105 expression and survival among the 
patients. This indicates that the CD105 may have poor predictive value as an 
indicator of treatment outcome (Metcalfe et al., 2018). Further studies are 
warranted to confirm this result. 
5.2.2.4. Effect on signalling pathways downstream of ALK 
Studies have shown that RAS/MAPK, AKT/mTOR and, JAK/STAT 
pathways are key pathways downstream of ALK that are responsible for the 
cancer cell survival and proliferation (Chiarle et al., 2008; Hallberg & Palmer, 
2013; Lin et al., 2017; Palmer et al., 2009; Solomon, Wilner, et al., 2014). Among 
these three pathways, RAS/MAPK pathway has been reported to be a major 
effector of EML4-ALK that is responsible for tumour survival (Hrustanovic et al., 
2015). Hrustanovic et al. demonstrated that HELP domain of EML4 drives the 
activation of RAS/MAPK by engaging all three major RAS isoforms. Resistance 
to ALK inhibition was observed when MAPK pathway was reactivated either by 
downregulation of phosphatase DUSP6 or genomic amplification of KRAS-
wildtype (Hrustanovic et al., 2015). Thus, in this study, it was hypothesised that 
the combination treatment targeting primary oncoprotein, ALK and its critical 
effector, RAS/MAPK pathway would combat resistance, potentially improving 
therapeutic efficacy. 
Crizotinib inhibits the activity of ALK in various cancers expressing ALK 
fusion oncoproteins (Christensen et al., 2007; Hrustanovic et al., 2015; 
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McDermott et al., 2008; Yan et al., 2014; Zou et al., 2007). Christensen et al. 
showed that crizotinib strongly inhibited tyrosine phosphorylation of NPM-
ALK which in turn inhibited the phosphorylation of PLCγ, STAT3, AKT and 
ERK in dose dependent manner, in both in vitro and in vivo models of anaplastic 
large cell lymphoma (ALCL) (Christensen et al., 2007). Similarly, crizotinib was 
reported to potently suppress AKT and ERK signalling in anaplastic large cell 
lymphoma (SU-DHL-1 and Karpas-299), neuroblastoma (NB-1) and in the H3122 
cell line (McDermott et al., 2008). On the other hand, selumetinib, a MEK 
inhibitor, has been reported to suppress tumour growth by predominantly 
inhibiting the phosphorylation of ERK in various cancers, including NSCLC 
(Adjei et al., 2008; Davies et al., 2007; Garon et al., 2010; Holt, Logie, Odedra, et 
al., 2012; Huynh et al., 2007; Meng, Dai, et al., 2010; Yeh et al., 2007). Screening of 
tumour cell lines has demonstrated that cells harbouring RAS or RAF mutations 
with predominantly activated RAS/MAPK signalling pathway have increased 
sensitivity to selumetinib (Davies et al., 2007; Garon et al., 2010; Haass et al., 
2008). In this study, the combination of ALK inhibitor, crizotinib, and MEK 
inhibitor, selumetinib, demonstrated superior anti-tumour activity by 
synergistic inhibition of the major downstream RAS/MAPK signalling in both 
crizotinib naïve and crizotinib resistant ALK-positive NSCLC cells. 
5.2.2.5. Role of RAS/MAPK pathway 
RAS/MAPK signalling pathway plays a key role in regulating 
physiological process such as cell proliferation, apoptosis and, angiogenesis (Lu 
& Xu, 2006; Molina & Adjei, 2006; Morrison, 2012; Zhang & Liu, 2002). 
Upregulation of RAS/MAPK pathway promotes proliferation and angiogenesis 
as well as inhibiting apoptosis in various types of cancer (Dhillon et al., 2007; 
Guo et al., 2020; Lu & Xu, 2006). Various studies have shown the involvement of 
RAS/MAPK pathway in regulation of G1 cell cycle proteins and progression of 
cell cycle (Bhatt et al., 2005; Chambard et al., 2007; Terada et al., 1999; Villanueva 
et al., 2007; Weber et al., 1997). Phosphorylation and activation of ERK facilitates 
the migration of ERK to the nucleus where it phosphorylates transcription 
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factors such that in turn upregulates cyclin D1 and downregulates p27 (Bhatt et 
al., 2005; Chambard et al., 2007; Lavoie et al., 1996; Torii et al., 2006). In this study, 
the synergistic downregulation of ERK phosphorylation by combination 
treatment of crizotinib and selumetinib led to G1 phase arrest through 
overexpression of p27 and suppression of cyclin D1 expression. Thus, 
RAS/MAPK signalling is crucial for G1 phase progression and entry to the S 
phase of cell cycle in both H3122 and CR-H3122 cell line. 
Furthermore, the RAS/MAPK pathway has been reported to regulate 
apoptosis by downregulation of the proapoptotic protein Bim (Ewings et al., 
2007; Gillings et al., 2009). ERK activation downregulates Bim by both 
transcriptional and posttranslational modification (Gillings et al., 2009). ERK 
phosphorylates FOXO3A and promotes the proteasomal degradation of 
FOXO3A (Yang et al., 2008) that is involved in transcription of Bim (Gilley et al., 
2003). On the other hand, ERK directly phosphorylates Bim and facilitates its 
proteasomal degradation (Ley et al., 2003; Luciano et al., 2003; Marani et al., 
2004). This decreases the expression of Bim protein and thereby inhibits 
apoptosis. In this study, the combination of crizotinib and selumetinib markedly 
reduced the phosphorylation of ERK that in turn increased the expression of 
Bim, resulting in increased apoptosis. Other studies have shown that 
AKT/mTOR pathway is also involved in the regulation of Bim via sequestering 
the activity of FOX3A (Fu & Tindall, 2008). However, Bland et al. have shown 
that the crizotinib (0.25 µM) had no effect on the AKT/mTOR pathway as no 
change in phosphorylation of mTOR was observed in H3122 cells (Bland et al., 
2019). These finding further suggests that the upregulation of Bim by the 
combination treatment in this project may be solely due to the decrease in 
phosphorylation of ERK.  
5.2.3. Safety profile and drug interaction 
Drug safety is one of the key elements in the development of new therapy 
(Alshammari, 2016), so prior investigation of safety profile is important from an 
early stage of drug development. Other studies have shown that both crizotinib 
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and selumetinib single drug treatments induce adverse events that range from 
grade 1-2 to grade 3-4 (Adjei et al., 2008; Banerji et al., 2010; Camidge et al., 2012; 
Catalanotti et al., 2013). Crizotinib has been reported to cause adverse events 
such as gastrointestinal upset, visual disturbance, elevation in ALT and AST 
level, neutropenia (Camidge et al., 2012). On the other hand, selumetinib is 
known to cause side effects that includes diarrhoea, nausea, acneiform, pleural 
effusion (Adjei et al., 2008; Banerji et al., 2010; Catalanotti et al., 2013). Thus, in 
the present study, the possibility of synergistic toxicity that may be induced by 
the combination of crizotinib with selumetinib was investigated. Combination of 
crizotinib (5 mg/kg and 25 mg/kg) and selumetinib (25 mg/kg) was well 
tolerated in mice, with insignificant weight loss and no adverse effect on kidney 
and liver function. Though some mice from the vehicle control and crizotinib 
groups showed higher values of ALT (> 80 U/L), there was no histopathological 
differences in liver morphology with other mice. These findings suggest that oral 
administration of crizotinib and selumetinib at the dose of 25 mg/kg once daily 
for 14 days is nontoxic in mice and may increase the quality of life by maintaining 
efficacy with less risk of adverse events. Further studies are warranted to 
translate this finding to humans- (Nair et al., 2018). 
The narrow therapeutic index and the inherent toxicity of anticancer drugs 
raise the importance of drug interaction in cancer treatment (Scripture & Figg, 
2006). Drug interactions can change the pharmacokinetics or pharmacodynamics 
of given treatment altering its efficacy and toxicity. Co-administration of drugs 
that inhibit or induce CYP enzymes or that compete for metabolism by same CYP 
enzyme have a greater chance of interaction (Scripture & Figg, 2006). It has been 
reported that crizotinib, a primary substrate of CYP3A, is a moderate inhibitor 
and weak inducer of CYP3A (Johnson et al., 2015; Mao et al., 2013; Tan et al., 
2010). Co-administration of crizotinib (250 mg BID for 28 days) with midazolam 
(2 mg OD) increased midazolam area under the plasma concentration-time curve 
by 3.7-fold confirming crizotinib to be a moderate CYP3A inhibitor (Tan et al., 
2010). On the other hand, Mao et al. evaluated crizotinib CYP3A4 induction 
potency in cryopreserved human hepatocytes and found that crizotinib induced 
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CYP3A4 mRNA expression in a concentration dependent manner (Mao et al., 
2013). Similarly, CYP3A4 is the major enzyme responsible for selumetinib 
oxidative metabolism (Dymond et al., 2016). Selumetinib AUC was increased 
with co-administration of a CYP3A4 inhibitor such as itraconazole while the 
AUC was decreased with a CYP3A4 inducer such as rifampicin (Dymond et al., 
2017). In this study, the effect of single and combination treatment of crizotinib 
and selumetinib on catalytic activity of CYP3A enzyme was investigated. 
Contrary to previous studies, oral administration of either 5 mg/kg or 25 mg/kg 
crizotinib once daily for 14 days did not alter liver CYP3A activity compared to 
the vehicle control. These findings suggest that crizotinib at the given dose 
regimen neither inhibited nor induced the CYP3A enzyme in mice. Moreover, 
the combination of crizotinib (5 mg/kg and 25 mg/kg) and selumetinib (25 
mg/kg) had no effect on CYP3A catalytic activity and thus were unlikely to alter 
each other’s metabolism.  
5.2.4. Orthotopic lung cancer model 
Development of an appropriate mouse model is crucial for screening new 
drug candidates for the treatment of lung cancer. Therefore, the development of 
a mouse model is an indispensable part of the lung cancer drug development 
process. The goal of this investigation was to develop an orthotopic lung cancer 
model via tail vein injection of two human lung adenocarcinoma (A549, H3122) 
cell lines that could recapitulate human lung cancer for preclinical assessment of 
novel anti-cancer drugs. Tail vein injection techniques have been successfully 
used previously in the development of breast cancer lung metastasis model 
(Rashid et al., 2013) and other lung cancer models (Zhao et al., 2012). Rashid et 
al. injected breast cancer (4T1-luc2) cell line (1 × 106 cells in 100 µL PBS) into the 
median tail vein of Balb/c mice that instantly generated diffusely distributed cell 
implantation throughout the lungs (Rashid et al., 2013). Also, tail vein injection 
of red fluorescent protein (RFP)- labelled Lewis lung carcinoma cells (2 × 106 cells 
in 100 µL PBS) in female C57 immunocompetent mice resulted in tumour 
colonies in the lung by day 5 (Zhao et al., 2012). In this study, the tail vein 
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injection of H3122 and A549 cells in SCID mice resulted in some aggregation of 
cells with no discrete tumour nodules, consistent with the dispersed cancer cell 
pattern obtained by Rashid et al. (Rashid et al., 2013). However, immunolabeling 
of human cancer marker failed to detect any cancer cells in the lung sections.  
The pathological changes in the lungs of mice after tail vein injection of 
tumour cells were consistent with thromboembolism. Area of white patches was 
observed on the lungs that correspond to areas of hypoxia prominent at the 
beginning 5 weeks after injection. Studies have shown that tail vein injection may 
lead to sudden death following thromboembolic event (Rashid et al., 2013). In 
addition to this, tail vein injection has been criticised for lack of more steady 
progression of tumour burden in a breast cancer lung metastasis model (Rashid 
et al., 2013). Therefore, an attempt to establish orthotopic lung cancer model in 
this study remains inconclusive and requires further studies to confirm the 
presence of human lung adenocarcinoma cells in the lungs of the mice. 
5.3. Clinical implications  
NSCLC patients harbouring ALK rearrangement are highly sensitive to 
ALK-TKIs and thus are the preferred choice of therapy in these patients (Lin et 
al., 2017; Ziogas et al., 2018). In clinical settings, despite great initial response, 
patients on ALK-TKI monotherapy or sequential treatment with next generation 
ALK-TKIs unavoidably develop resistance within several years of therapy (Choi 
et al., 2010; Lin et al., 2017; Ziogas et al., 2018). Thus, complete, and lasting 
response to ALK-TKIs is extremely rare. Upfront combination treatment could 
be a promising alternative strategy that can improve initial response as well as 
overcome resistance resulting in long-term disease control.  
In this study, the combination of ALK inhibitor, crizotinib and MEK 
inhibitor, selumetinib significantly decreased the growth of tumour in both in 
vitro and in vivo model of ALK-positive NSCLC compared to monotherapy. This 
finding indicates that the combination of crizotinib and selumetinib has the 
potential to prevent the emergence of resistance with a higher and more robust 
Chapter 5: Discussion 
166  
 
response in ALK-positive NSCLC patients and thereby could improve the ORR, 
OS and PFS. 
Interestingly, inhibition of MEK alone was almost as effective as the 
combination treatment to suppress the tumour growth in xenograft model of 
ALK-positive NSCLC. Therefore, MEK inhibitor as a monotherapy can also be a 
prospective candidate for treatment of ALK-positive NSCLC. Furthermore, the 
combination showed a greater effect in reducing cell viability of crizotinib 
resistant ALK-positive NSCLC cells even at the low dose of individual drugs. So, 
the combination treatment could effectively overcome the acquired crizotinib 
resistance even at the lower doses of the two drugs and thus could be a potential 
alternative treatment for patients progressed on crizotinib. 
Moreover, the combination of crizotinib and selumetinib, each at the dose 
of 25 mg/kg, did not show any interactions and was safe. Thus, the combination 
treatment is likely to attain optimum efficacy while exhibiting no or minor 
treatment related adverse event. This could ultimately improve the quality of 
life. Currently, several clinical trials of combination therapy using ALK 
inhibitors with other drugs such as MEK inhibitors, angiogenesis inhibitors etc. 
are being conducted (ClinicalTrials.gov National Library of Medicine (US), 
2019a, 2019b, 2020). The outcome from these studies may inform further about 
the safety and efficacy of the combination therapy in clinical scenarios. 
5.4. Limitations and future studies  
This study evaluated the effect of crizotinib and selumetinib combination 
treatment using only one ALK-positive (H3122) cell line harbouring variant 1. 
Though H3122 cells are the most commonly used cell line and are clinically 
relevant to human treatment (Cha et al., 2016; Sabir et al., 2017; Yoshida et al., 
3383) this study has not explored, compared and confirmed the effect of the 
combination treatment on other ALK-positive cell lines such as STE-1 cells – also 
harbouring variant 1 - and H2228 cells harbouring variant 3. Secondly, the CR-
H3122 cell line was generated in the Ashton lab by addition of increasing 
concentrations of crizotinib in H3122 cells and was maintained in 0.8 µM of 
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crizotinib prior to experiment. Though the CR-H3122 cells were highly resistant 
to crizotinib, the precise mechanism of resistance in CR-H3122 cells is still 
unclear. Thus, future studies need to explore the mechanism of CR-H3122 cells 
by carrying out whole genome sequencing as well as genome microarray 
analyses to detect the expression of other genes that could be altered by a bypass 
mechanism. Thirdly, immunolabelling was performed to determine the 
mechanism of tumour suppression by crizotinib, selumetinib and their 
combination. However, it was not possible to draw any specific conclusion from 
the data obtained. Here, only one tumour marker was used to examine the effect 
of treatment on proliferation or apoptosis or angiogenesis. The use of at least two 
different methods would be helpful to confirm the result. For example Flow 
cytometry or IHC of bromodeoxyuridine (BrdU)  that measures the fraction of 
cells involved in chromosomal DNA synthesis (Barnes & Gillett, 1995; Beresford 
et al., 2006) could be used together with Ki67 immunolabeling, IHC of VEGF 
(Maae et al., 2011), a potent angiogenic factor, could be used together with CD105 
and analysis of cleaved caspase-3 (western blotting or IHC or flow cytometry) 
(Crowley & Waterhouse, 2016; Martey et al., 2017) together with the TUNEL 
assays.  
Although tail vein injection of H3122 and A549 cells into SCID mice was carried 
out to develop an orthotopic lung cancer model, IHC for Ki67 or ALK was unable 
to detect human cancer cells in the lung section of the mice. One possible 
explanation for this as that fixation of lungs by formalin may have masked 
antigen exposure. This problem might be overcome in future  by the use of 
fluorescently tagged human adenocarcinoma cell line (Zhao et al., 2012) or 
overexpression of luciferase gene (Rashid et al., 2013) that will facilitate the 
detection of cancer cells either by live imaging via in vivo imaging technology or 
fluorescence microscopy and flow cytometry of lung samples. Also, the 
confirmation of the white patches resembling hypoxia in the lung of mice as the 
hypoxic lesion was not made. Thus, in future studies, the hypoxic lesions could 
be confirmed using tetrazolium chloride (Linsell & Ashton, 2014) staining in 
fresh lung sections. 
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In vitro derived resistant cells are established by exposing specific targeted 
therapy to sensitive cells until resistance emerges. Though these cell lines may 
give an idea regarding potential resistance mechanism, they could never be 
applied for treatment decisions for individual patients (Crystal et al., 2014). On 
the contrary, resistant cells obtained directly from patients progressed on specific 
targeted therapy can provide information on genetic alteration occurred 
clinically resulting in the drug resistance. This could be helpful in choosing 
appropriate therapy to combat resistance (Crystal et al., 2014). Therefore, in 
future studies, the effect of crizotinib and selumetinib should be explored in both 
in vitro and in vivo patient derived resistant model of ALK-positive NSCLC. 
Lastly, this study identifies, Bim, PARP and CDK as druggable target and 
thus showed the possibility of triple drug therapy. Bozic et al. have reported that 
the triple therapy is essential for those patients with large tumour burden (Bozic 
et al., 2013). Therefore, the use of BH3 mimetic Bcl2 inhibitor or PARP inhibitor 
or CDK inhibitor together with crizotinib and selumetinib may be even more 
effective in suppressing ALK+ tumour growth. 
5.5. Conclusion 
In this study, the combination of crizotinib and selumetinib synergistically 
inhibited the cell viability of both crizotinib naïve and crizotinib resistant ALK-
positive NSCLC cells. The suppression of cell proliferation was mediated by 
downregulation of RAS/MAPK signalling pathway that led to a decrease in cell 
cycle progression and increase in apoptosis. The combination treatment 
synergistically increased the expression of cyclin D1 and downregulated p27 
expression resulting in G1 cell cycle arrest. Furthermore, the upregulation of Bim 
facilitated the increase in intrinsic apoptosis of H3122 and CR-H3122 cells. 
Moreover, the in vitro effect of the combination treatment was successfully 
translated in a xenograft model of ALK-positive NSCLC where the combination 
showed significant suppression of tumour growth. Unexpectedly, selumetinib 
alone markedly suppressed tumour growth raising the possibility that MEK 
inhibitor alone may be almost as effective as the combination therapy. Both 
Chapter 5: Discussion 
169  
 
singular and combination of crizotinib and selumetinib were non-toxic and did 
not interact with each other’s major metabolizing enzyme, CYP3A. Thus, these 
findings led support to the clinical investigation of dual ALK/MEK inhibition 
therapy as a strategy to delay or overcome drug resistance in ALK-positive 
NSCLC and suggest the possibility of drug therapies with three or more targets. 
 
Figure 5.1 Schematic diagram illustrating the mechanism behind marked 
inhibition of tumour cell proliferation in ALK-positive NSCLC by the 
combination of crizotinib and selumetinib. 
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A1.1. ALK kinase domain sequences of crizotinib naïve and 
crizotinib resistant ALK-positive NSCLC 
Table A1.1 ALK kinase domain sequences of H3122 and CR-H3122 cell lines. The 
kinase domain of ALK was amplified from H3122 and CR-H3122 cDNA using PCR 
primers (Table A1.2). After gel purification the PCR products were sequenced using 
Sanger sequencing. The sequences of exons 22-25 (NM_004304), corresponding to the 
kinase domain are indicated in bold. 
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Table A1.2 Primer sequences used for amplification and sequencing of ALK kinase 
domain. 
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A1.2. Raw image of full blots used for western blots 
Figure A1.1 Raw image of Western blots for ALK, pALK, ERK, pERK and β-tubulin 
in H3122 cells
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Figure A1.2 Raw image of Western blots for CyclinD1, p27 and β-tubulin in H3122 
cells 
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Figure A1.3 : Raw image of Western blots for Bim after 24 and 48 h of drug treatment 
in H3122 cells 
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Figure A1.4 Raw image of Western blots for cleaved Caspase-3 after 24 and 48 h of 
drug treatment in H3122 cells 
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Figure A1.5 Raw image of Western blots for cleaved PARP after 24 and 48 h of drug 
treatment in H3122 cells 
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Figure A1.6 Raw image of Western blots for ALK, pALK, ERK, pERK and β-tubulin 
in CRH3122 cells 
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Figure A1.7 Raw image of Western blots for CyclinD1, p27 and β-tubulin in CRH3122 
cells 
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Figure A1.8 Raw image of Western blots for Bim, cleaved Caspase-3, cleaved PARP 
and β-tubulin after 24 h of drug treatment in CRH3122 cells 
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Figure A1.9 Raw image of western blotting for CYP3A and GAPDH. 
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A1.3. Histology of lung section injected with H3122 cells 
 




Figure A1.10 Gross appearance and histology of lungs of SCID mice after 3rd , 5th and 8th week of injection with H3122 cells via the tail vein. 
Mice were injected with 1×105 H3122 cells into lateral vein of the tail. Mice were then euthanised after 3rd, 5th and 8th week of injection. Lungs 
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were excised, sectioned and H and E staining was performed. Lungs of mice at (A) 3rd, (B) 5th, (C) 8th weeks after cell injection. White patches on 
lungs appeared by week 5. H and E staining of lung sections of mice at (D) 3rd, (E) 5th, (F) 8th week after cells injection using a 10× objective. 
Squares and arrow indicate areas of high cell density. (G-I) Area shown in insets from panel (D-F) respectively, using 20× objective. (J-L) Area 
shown in insets from images (D-F), respectively, using 40× objective. Scale bars: D-I 100 µM and J-L 50 µM. 
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A1.4. Histology of lung section of A549 injected mice 
 




Figure A1.11  Gross appearance and histology of lungs of SCID mice after 3rd, 5th and 8th week of injection with A549 cells via the tail vein. 
Mice were injected with 1×105 A549 cells into the lateral vein of the tail. Mice were then euthanised after 3rd, 5th and 8th week of injection. Lungs 
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were excised, sectioned and H and E staining was performed. Lungs of mice at (A) 3rd, (B) 5th, (C) 8th weeks after cell injection. White patches on 
lungs appeared by week 5. H and E staining of lung sections of mice at (D) 3rd, (E) 5th, (F) 8th week after cells injection using a 10× objective. 
Squares and arrow indicate areas of high cell density. (G-I) Area shown in insets from panel (D-F) respectively, using 20× objective. (J-L) Area 
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